49562-28-9 | propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate

Packsize	Purity	Availability	Price	Discounted Price
250mg	95%	in stock	$18.00	$12.00
1g	95%	in stock	$18.00	$13.00
5g	95%	in stock	$25.00	$17.00
25g	95%	in stock	$37.00	$26.00
100g	95%	in stock	$105.00	$74.00
500g	95%	in stock	$386.00	$270.00

Description

• Catalog Number: AI51088
• Chemical Name: propan-2-yl 2-{4-[(4-chlorophenyl)carbonyl]phenoxy}-2-methylpropanoate
• CAS Number: 49562-28-9
• Molecular Formula: C20H21ClO4
• Molecular Weight: 360.8313
• MDL Number: MFCD00133314
• SMILES: CC(OC(=O)C(Oc1ccc(cc1)C(=O)c1ccc(cc1)Cl)(C)C)C

Computed Properties

• Complexity: 458
• Covalently-Bonded Unit Count: 1
• Heavy Atom Count: 25
• Hydrogen Bond Acceptor Count: 4
• Rotatable Bond Count: 7
• XLogP3: 5.2

Literature

• Expression of cytochrome P450 epoxygenases and soluble epoxide hydrolase is regulated by hypolipidemic drugs in dose-dependent manner.

  Toxicology and applied pharmacology 20180915

• Fenofibrate induced PPAR alpha expression was attenuated by oestrogen receptor alpha overexpression in Hep3B cells.

  Environmental toxicology 20180201

• Zoledronate dysregulates fatty acid metabolism in renal tubular epithelial cells to induce nephrotoxicity.

  Archives of toxicology 20180101

• Effects of tetramethylpyrazine from Chinese black vinegar on antioxidant and hypolipidemia activities in HepG2 cells.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20171101

• Inferring transcription factor activity from microarray data reveals novel targets for toxicological investigations.

  Toxicology 20170815

• Association of Liver Injury From Specific Drugs, or Groups of Drugs, With Polymorphisms in HLA and Other Genes in a Genome-Wide Association Study.

  Gastroenterology 20170401

• Discriminating between adaptive and carcinogenic liver hypertrophy in rat studies using logistic ridge regression analysis of toxicogenomic data: The mode of action and predictive models.

  Toxicology and applied pharmacology 20170301

• Pyrazinamide induced hepatic injury in rats through inhibiting the PPARα pathway.

  Journal of applied toxicology : JAT 20161201

• Both cholestatic and steatotic drugs trigger extensive alterations in the mRNA level of biliary transporters in rat hepatocytes: Application to develop new predictive biomarkers for early drug development.

  Toxicology letters 20161130

• In vitro metabolism of fenofibric acid by carbonyl reducing enzymes.

  Chemico-biological interactions 20161025

• AMPK-dependent signaling modulates the suppression of invasion and migration by fenofibrate in CAL 27 oral cancer cells through NF-κB pathway.

  Environmental toxicology 20160701

• Effects of short-chain acyl-CoA dehydrogenase on cardiomyocyte apoptosis.

  Journal of cellular and molecular medicine 20160701

• Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression.

  World journal of gastroenterology 20160314

• Transcriptome analyses demonstrate that Peroxisome Proliferator-Activated Receptor α (PPARα) activity of an ultraviolet absorber, 2-(2'-hydroxy-3',5'-di-tert-butylphenyl)benzotriazole, as possible mechanism of their toxicity and the gender differences.

  The Journal of toxicological sciences 20160101

• Transcriptomic analysis of untreated and drug-treated differentiated HepaRG cells over a 2-week period.

  Toxicology in vitro : an international journal published in association with BIBRA 20151225

• Transcriptomics hit the target: Monitoring of ligand-activated and stress response pathways for chemical testing.

  Toxicology in vitro : an international journal published in association with BIBRA 20151225

• Systems pharmacological analysis of drugs inducing stevens-johnson syndrome and toxic epidermal necrolysis.

  Chemical research in toxicology 20150518

• Identification of modulators of the nuclear receptor peroxisome proliferator-activated receptor α (PPARα) in a mouse liver gene expression compendium.

  PloS one 20150101

• Identification of chemical modulators of the constitutive activated receptor (CAR) in a gene expression compendium.

  Nuclear receptor signaling 20150101

• PPARα-dependent exacerbation of experimental colitis by the hypolipidemic drug fenofibrate.

  American journal of physiology. Gastrointestinal and liver physiology 20140901

• Fish oil and fenofibrate prevented phosphorylation-dependent hepatic sortilin 1 degradation in Western diet-fed mice.

  The Journal of biological chemistry 20140808

• Hugan Qingzhi medication ameliorates hepatic steatosis by activating AMPK and PPARα pathways in L02 cells and HepG2 cells.

  Journal of ethnopharmacology 20140528

• PPAR agonists reduce steatosis in oleic acid-overloaded HepaRG cells.

  Toxicology and applied pharmacology 20140401

• Inflammatory myopathy associated with statins: report of three cases.

  Modern rheumatology 20140301

• Genomic models of short-term exposure accurately predict long-term chemical carcinogenicity and identify putative mechanisms of action.

  PloS one 20140101

• Early identification of clinically relevant drug interactions with the human bile salt export pump (BSEP/ABCB11).

  Toxicological sciences : an official journal of the Society of Toxicology 20131201

• A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.

  Toxicological sciences : an official journal of the Society of Toxicology 20131101

• Fenofibrate suppresses melanogenesis in B16-F10 melanoma cells via activation of the p38 mitogen-activated protein kinase pathway.

  Chemico-biological interactions 20131005

• FDA-approved drugs and other compounds tested as inhibitors of human glutathione transferase P1-1.

  Chemico-biological interactions 20130905

• A systems biology approach to the hepatic role of the oxysterol receptor LXR in the regulation of lipogenesis highlights a cross-talk with PPARα.

  Biochimie 20130301

• Wy14643 improves vascular function in the aorta of the spontaneously hypertensive rat mainly by activating peroxisome proliferator-activated receptors alpha.

  European journal of pharmacology 20121205

• Novel starch-based PVA thermoplastic capsules for hydrophilic lipid-based formulations.

  Journal of pharmaceutical sciences 20121201

• Comparison of the effects of n-3 long chain polyunsaturated fatty acids and fenofibrate on markers of inflammation and vascular function, and on the serum lipoprotein profile in overweight and obese subjects.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20121101

• Improved dissolution rate and bioavailability of fenofibrate pellets prepared by wet-milled-drug layering.

  Drug development and industrial pharmacy 20121101

• Meta-analysis of safety of the coadministration of statin with fenofibrate in patients with combined hyperlipidemia.

  The American journal of cardiology 20121101

• Interaction between SNPs in the RXRA and near ANGPTL3 gene region inhibits apoB reduction after statin-fenofibric acid therapy in individuals with mixed dyslipidemia.

  Journal of lipid research 20121101

• Lipidomic profiling reveals protective function of fatty acid oxidation in cocaine-induced hepatotoxicity.

  Journal of lipid research 20121101

• Effect of fenofibrate and atorvastatin on VLDL apoE metabolism in men with the metabolic syndrome.

  Journal of lipid research 20121101

• Effects of 90-day hypolipidemic treatment on insulin resistance, adipokines and proinflammatory cytokines in patients with mixed hyperlipidemia and impaired fasting glucose.

  International journal of clinical pharmacology and therapeutics 20121101

• Management of hyperglycemia, dyslipidemia, and albuminuria in patients with diabetes and CKD: a systematic review for a KDOQI clinical practice guideline.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20121101

• What is more valuable: fenofibrate patents or fenofibrate clinical outcomes?

  Archives of internal medicine 20121022

• Poly(2-ethyl-2-oxazoline) as matrix excipient for drug formulation by hot melt extrusion and injection molding.

  Macromolecular rapid communications 20121015

• Synthesis of highly water-soluble fibrate derivatives via BGLation.

  Bioorganic & medicinal chemistry letters 20121015

• Development of solid self-emulsifying drug delivery system (SEDDS) I: use of poloxamer 188 as both solidifying and emulsifying agent for lipids.

  Pharmaceutical research 20121001

• The combined strategy with PPARα agonism and AT₁ receptor antagonism is not superior relative to their individual treatment approach in preventing the induction of nephropathy in the diabetic rat.

  Pharmacological research 20121001

• Genome-wide association study indicates variants associated with insulin signaling and inflammation mediate lipoprotein responses to fenofibrate.

  Pharmacogenetics and genomics 20121001

• False-positive amphetamine/ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (CEDIA) and ecstasy (MDMA/3,4-methylenedioxymethamphetamine) (DRI) test results with fenofibrate.

  Therapeutic drug monitoring 20121001

• Antiangiogenic metronomic therapy for children with recurrent embryonal brain tumors.

  Pediatric blood & cancer 20120901

• The safety and effectiveness of statins as treatment for HIV-dyslipidemia: the evidence so far and the future challenges.

  Expert opinion on pharmacotherapy 20120901

• Effect of fenofibrate treatment for hyperlipidaemia on serum creatinine and cystatin C.

  Annals of clinical biochemistry 20120901

• Fenofibrate triggers apoptosis of glioblastoma cells in vitro: new insights for therapy.

  Cell cycle (Georgetown, Tex.) 20120901

• Effect of rosuvastatin monotherapy or in combination with fenofibrate or ω-3 fatty acids on lipoprotein subfraction profile in patients with mixed dyslipidaemia and metabolic syndrome.

  International journal of clinical practice 20120901

• Use of fibrates in clinical practice: Queensland Lipid Group consensus recommendations.

  International journal of evidence-based healthcare 20120901

• Beyond low-density lipoprotein cholesterol: why, who and when.

  Singapore medical journal 20120901

• Role of fenofibrate in restoring angiogenesis in diabetic and control hind limb ischemic rats.

  General physiology and biophysics 20120901

• Building multivariate systems biology models.

  Analytical chemistry 20120821

• Evaluation of the antifibrotic effect of fenofibrate and rosiglitazone on bleomycin-induced pulmonary fibrosis in rats.

  European journal of pharmacology 20120815

• Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway.

  Biochemical pharmacology 20120815

• Restoration of adipose function in obese glucose-tolerant men following pioglitazone treatment is associated with CCAAT enhancer-binding protein β up-regulation.

  Clinical science (London, England : 1979) 20120801

• Study design, rationale, and baseline characteristics: evaluation of fenofibric acid on carotid intima-media thickness in patients with type IIb dyslipidemia with residual risk in addition to atorvastatin therapy (FIRST) trial.

  Cardiovascular drugs and therapy 20120801

• Fenofibrate increases high-density lipoprotein and sphingosine 1 phosphate concentrations limiting abdominal aortic aneurysm progression in a mouse model.

  The American journal of pathology 20120801

• Nano-pulverization of poorly water soluble compounds with low melting points by a rotation/revolution pulverizer.

  Die Pharmazie 20120801

• Radioiodinated dechloro-4-iodofenofibrate: a hydrophobic model drug for molecular imaging studies.

  International journal of pharmaceutics 20120715

• Fenofibrate-induced nuclear translocation of FoxO3A triggers Bim-mediated apoptosis in glioblastoma cells in vitro.

  Cell cycle (Georgetown, Tex.) 20120715

• Comparative efficacy and safety of fenofibrate/pravastatin plus ezetimibe triple therapy and simvastatin/ezetimibe dual therapy in type 2 diabetic patients with mixed hyperlipidaemia and cardiovascular disease.

  Diabetes & vascular disease research 20120701

• Peroxisome proliferator-activated receptor alpha induction of uncoupling protein 2 protects against acetaminophen-induced liver toxicity.

  Hepatology (Baltimore, Md.) 20120701

• Improved insulin sensitivity after treatment with PPARγ and PPARα ligands is mediated by genetically modulated transcripts.

  Pharmacogenetics and genomics 20120701

• Antioxidant SMe1EC2 may attenuate the disbalance of sodium homeostasis in the organism induced by higher intake of cholesterol.

  Molecular and cellular biochemistry 20120701

• The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal): evaluation of impacts on fish liver, by histopathology, stereology, vitellogenin and CYP1A immunohistochemistry, after sub-acute exposures of the zebrafish model.

  Environmental toxicology and pharmacology 20120701

• Triglycerides: a case for treatment?

  Current opinion in cardiology 20120701

• Fenofibrate - a potential systemic treatment for diabetic retinopathy?

  American journal of ophthalmology 20120701

• [Effects of ursolic acid in ameliorating insulin resistance in liver of KKAy mice via peroxisome proliferator-activated receptors α and γ].

  Zhong xi yi jie he xue bao = Journal of Chinese integrative medicine 20120701

• Application of mixtures of polymeric carriers for dissolution enhancement of fenofibrate using hot-melt extrusion.

  International journal of pharmaceutics 20120615

• The peroxisome proliferator-activated receptor α agonist fenofibrate decreases airway reactivity to methacholine and increases endothelial nitric oxide synthase phosphorylation in mouse lung.

  Fundamental & clinical pharmacology 20120601

• Beneficial effects of fenofibrate in retinal pigment epithelium by the modulation of stress and survival signaling under diabetic conditions.

  Journal of cellular physiology 20120601

• High-fat diet-induced renal cell apoptosis and oxidative stress in spontaneously hypertensive rat are ameliorated by fenofibrate through the PPARα-FoxO3a-PGC-1α pathway.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20120601

• Role of the PPAR-α agonist fenofibrate in severe pediatric burn.

  Burns : journal of the International Society for Burn Injuries 20120601

• Solid lipid nanoparticles: continuous and potential large-scale nanoprecipitation production in static mixers.

  Colloids and surfaces. B, Biointerfaces 20120601

• In vitro antimalarial activity and drug interactions of fenofibric acid.

  Antimicrobial agents and chemotherapy 20120601

• Improvement of myocardial lipid accumulation and prevention of PGC-1α induction by fenofibrate.

  Molecular medicine reports 20120601

• Fenofibrate-associated changes in renal function and relationship to clinical outcomes among individuals with type 2 diabetes: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) experience.

  Diabetologia 20120601

• Comparative molecular profiling of the PPARα/γ activator aleglitazar: PPAR selectivity, activity and interaction with cofactors.

  ChemMedChem 20120601

• Design of lipid-based formulations for oral administration of poorly water-soluble drug fenofibrate: effects of digestion.

  AAPS PharmSciTech 20120601

• Fibrates: therapeutic potential for diabetic nephropathy?

  European journal of internal medicine 20120601

• A review of time courses and predictors of lipid changes with fenofibric acid-statin combination.

  Cardiovascular drugs and therapy 20120601

• The natural carotenoid astaxanthin, a PPAR-α agonist and PPAR-γ antagonist, reduces hepatic lipid accumulation by rewiring the transcriptome in lipid-loaded hepatocytes.

  Molecular nutrition & food research 20120601

• Effect of fenofibrate on the secretion of endothelium-derived contracting factors in hypertensive rats.

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20120601

• Reduction of Food Intake by Fenofibrate is Associated with Cholecystokinin Release in Long-Evans Tokushima Rats.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20120601

• Flavone-based novel antidiabetic and antidyslipidemic agents.

  Journal of medicinal chemistry 20120524

• Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.

  Journal of medicinal chemistry 20120524

• Fenofibrate, an anti-dyslipidemia drug, elicits the dilation of isolated porcine retinal arterioles: role of nitric oxide and AMP-activated protein kinase.

  Investigative ophthalmology & visual science 20120514

• Evidence of pharmaceutical innovation and therapeutic enthusiasm: strategies for patent extension.

  Archives of internal medicine 20120514

• Avoidance of generic competition by Abbott Laboratories' fenofibrate franchise.

  Archives of internal medicine 20120514

• Severe hypertriglyceridaemia. Treatment with plasmapheresis.

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20120514

• PPARα activation improves endothelial dysfunction and reduces fibrosis and portal pressure in cirrhotic rats.

  Journal of hepatology 20120501

• Risk assessment of premature drug release during wet granulation of ordered mesoporous silica loaded with poorly soluble compounds itraconazole, fenofibrate, naproxen, and ibuprofen.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20120501

• Development of a multiparametric cell-based protocol to screen and classify the hepatotoxicity potential of drugs.

  Toxicological sciences : an official journal of the Society of Toxicology 20120501

• Rare PPARA variants and extreme response to fenofibrate in the Genetics of Lipid-Lowering Drugs and Diet Network Study.

  Pharmacogenetics and genomics 20120501

• β (CCL2) and α (CXCL10) chemokine modulations by cytokines and peroxisome proliferator-activated receptor-α agonists in Graves' ophthalmopathy.

  The Journal of endocrinology 20120501

• Glycemic control over 5 years in 4,900 people with type 2 diabetes: real-world diabetes therapy in a clinical trial cohort.

  Diabetes care 20120501

• Reversibility of fenofibrate therapy-induced renal function impairment in ACCORD type 2 diabetic participants.

  Diabetes care 20120501

• Pravastatin and fenofibrate in combination (Pravafenix(®)) for the treatment of high-risk patients with mixed hyperlipidemia.

  Expert review of cardiovascular therapy 20120501

• Novel missense variants in LCAT and APOB genes in an Italian kindred with familial lecithin:cholesterol acyltransferase deficiency and hypobetalipoproteinemia.

  Journal of clinical lipidology 20120501

• Cardiovascular primary prevention: how high should we set the bar?

  Archives of internal medicine 20120423

• New fibrate use and acute renal outcomes in elderly adults: a population-based study.

  Annals of internal medicine 20120417

• Development of a sensitive liquid chromatography/tandem mass spectrometry method for the determination of fenofibric acid in rat plasma.

  Biomedical chromatography : BMC 20120401

• Early life-stage toxicity of eight pharmaceuticals to the fathead minnow, Pimephales promelas.

  Archives of environmental contamination and toxicology 20120401

• Novel phenoxyalkylcarboxylic acid derivatives as hypolipidaemic agents.

  Journal of enzyme inhibition and medicinal chemistry 20120401

• Biomolecular chemistry of isopropyl fibrates.

  Journal of pharmaceutical sciences 20120401

• A randomized, double-blind, placebo-controlled study of the safety and tolerance of regadenoson in subjects with stage 3 or 4 chronic kidney disease.

  Journal of nuclear cardiology : official publication of the American Society of Nuclear Cardiology 20120401

• One-year efficacy and safety of rosuvastatin + fenofibric acid combination therapy in patients with mixed dyslipidemia: evaluation of dose response.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20120401

• Modulatory effect of fenofibrate on endothelial production of neutrophil chemokines IL-8 and ENA-78.

  Cardiovascular drugs and therapy 20120401

• Are PPAR alpha agonists a rational therapeutic strategy for preventing abnormalities of the diabetic kidney?

  Pharmacological research 20120401

• The PPARα agonists fenofibrate and CP-778875 cause increased β-oxidation, leading to oxidative injury in skeletal and cardiac muscle in the rat.

  Toxicologic pathology 20120401

• Sodium butyrate stimulates expression of fibroblast growth factor 21 in liver by inhibition of histone deacetylase 3.

  Diabetes 20120401

• Apolipoprotein B-48 as a determinant of endothelial function in obese subjects with type 2 diabetes mellitus: effect of fenofibrate treatment.

  Atherosclerosis 20120401

• Safety of a fixed-dose combination of fenofibrate/pravastatin 160 mg/40 mg in patients with mixed hyperlipidaemia: a pooled analysis from a database of clinical trials.

  Clinical drug investigation 20120401

• Fenofibric acid for hyperlipidemia.

  Expert opinion on pharmacotherapy 20120401

• Efficacy of fenofibrate in Chinese patients with primary biliary cirrhosis partially responding to ursodeoxycholic acid therapy.

  Journal of digestive diseases 20120401

• Influence of lipid imbalance on butyrylcholinesterase activity and biotransformation efficiency.

  Die Pharmazie 20120401

• Controlled delivery of nanosuspensions from osmotic pumps: zero order and non-zero order kinetics.

  Journal of controlled release : official journal of the Controlled Release Society 20120328

• Indole-based fibrates as potential hypolipidemic and antiobesity agents.

  Journal of medicinal chemistry 20120322

• FAT SIGNALS--lipases and lipolysis in lipid metabolism and signaling.

  Cell metabolism 20120307

• Modification of crystallization behavior in drug/polyethylene glycol solid dispersions.

  Molecular pharmaceutics 20120305

• The effect of CYP7A1 polymorphisms on lipid responses to fenofibrate.

  Journal of cardiovascular pharmacology 20120301

• Plasma mannose-binding lectin is stimulated by PPARα in humans.

  American journal of physiology. Endocrinology and metabolism 20120301

• A genome-wide association study of inflammatory biomarker changes in response to fenofibrate treatment in the Genetics of Lipid Lowering Drug and Diet Network.

  Pharmacogenetics and genomics 20120301

• LPL gene variants affect apoC-III response to combination therapy of statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

  Journal of lipid research 20120301

• Non-lipid effects of rosuvastatin-fenofibrate combination therapy in high-risk Asian patients with mixed hyperlipidemia.

  Atherosclerosis 20120301

• The work-up for mixed hyperlipidemia: a case study.

  The Journal of family practice 20120301

• Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  American heart journal 20120301

• Acitretin- and tumor necrosis factor inhibitor-resistant acrodermatitis continua of hallopeau responsive to the interleukin 1 receptor antagonist anakinra.

  Archives of dermatology 20120301

• Intronic cis-regulatory modules mediate tissue-specific and microbial control of angptl4/fiaf transcription.

  PLoS genetics 20120301

• Fenofibrate, a peroxisome proliferator-activated receptor alpha, improves myocardial capillary density in diabetic rats.

  JPMA. The Journal of the Pakistan Medical Association 20120301

• Preparation and characterization of hydroxypropyl methyl cellulose films containing stable BCS Class II drug nanoparticles for pharmaceutical applications.

  International journal of pharmaceutics 20120227

• Relationship between paraoxonase and homocysteine: crossroads of oxidative diseases.

  Archives of medical science : AMS 20120227

• Peroxisome proliferator-activated receptor-α agonists modulate CXCL9 and CXCL11 chemokines in Graves' ophthalmopathy fibroblasts and preadipocytes.

  Molecular and cellular endocrinology 20120226

• Diabetes: Should we use fibrates in patients with diabetes and mild CKD?

  Nature reviews. Nephrology 20120221

• Soluplus® as an effective absorption enhancer of poorly soluble drugs in vitro and in vivo.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20120214

• Comparison of high-resolution ultrasonic resonator technology and Raman spectroscopy as novel process analytical tools for drug quantification in self-emulsifying drug delivery systems.

  Journal of pharmaceutical and biomedical analysis 20120205

• In vitro and in silico strategies to identify OATP1B1 inhibitors and predict clinical drug-drug interactions.

  Pharmaceutical research 20120201

• Prevention and treatment of diabetic retinopathy: evidence from large, randomized trials. The emerging role of fenofibrate.

  Reviews on recent clinical trials 20120201

• The effect of bexarotene on atorvastatin pharmacokinetics: results from a phase I trial of bexarotene plus chemotherapy in patients with advanced non-small cell lung cancer.

  Cancer chemotherapy and pharmacology 20120201

• Combination treatment with pioglitazone and fenofibrate attenuates pioglitazone-mediated acceleration of bone loss in ovariectomized rats.

  The Journal of endocrinology 20120201

• High free fatty acids level related with cardiac dysfunction in obese rats.

  Diabetes research and clinical practice 20120201

• Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges.

  Current atherosclerosis reports 20120201

• Significant differential effects of omega-3 fatty acids and fenofibrate in patients with hypertriglyceridemia.

  Atherosclerosis 20120201

• PPARα activation inhibits endothelin-1-induced cardiomyocyte hypertrophy by prevention of NFATc4 binding to GATA-4.

  Archives of biochemistry and biophysics 20120201

• Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.

  Diabetes care 20120201

• Do persons with diabetes benefit from combination statin and fibrate therapy?

  Current cardiology reports 20120201

• Use of fenofibrate during the first trimester of unplanned pregnancy in a patient with hypertriglyceridemia.

  The Annals of pharmacotherapy 20120201

• The cardiovascular effects of peroxisome proliferator-activated receptor agonists.

  The American journal of medicine 20120201

• Various oscillation patterns of serum fibroblast growth factor 21 concentrations in healthy volunteers.

  Diabetes & metabolism journal 20120201

• The Association between Apolipoprotein A-II and Metabolic Syndrome in Korean Adults: A Comparison Study of Apolipoprotein A-I and Apolipoprotein B.

  Diabetes & metabolism journal 20120201

• Investigation of a fenofibrate-hydroxypropyl-beta-cyclodextrin system prepared by a co-grinding method.

  Die Pharmazie 20120201

• Severe neutropenia in a renal transplant patient suggesting an interaction between mycophenolate and fenofibrate.

  Current drug safety 20120201

• Synthesis, characterization and biological evaluation of ureidofibrate-like derivatives endowed with peroxisome proliferator-activated receptor activity.

  Journal of medicinal chemistry 20120112

• Transcription factor GATA-6 recruits PPARα to cooperatively activate Glut4 gene expression.

  Journal of molecular biology 20120106

• Peroxisome proliferator-activated receptor-α activation attenuates 3-nitropropionic acid induced behavioral and biochemical alterations in rats: possible neuroprotective mechanisms.

  European journal of pharmacology 20120105

• The changes in plasma retinol-binding protein 4 levels are associated with those of the apolipoprotein B-containing lipoproteins during dietary and drug treatment.

  Angiology 20120101

• Hypolipidemic activity of Symplocos cochinchinensis S. Moore leaves in hyperlipidemic rats.

  Journal of natural medicines 20120101

• Xenobiotic metabolomics: major impact on the metabolome.

  Annual review of pharmacology and toxicology 20120101

• Hypertriglyceridemia, Metabolic Syndrome, and Cardiovascular Disease in HIV-Infected Patients: Effects of Antiretroviral Therapy and Adipose Tissue Distribution.

  International journal of vascular medicine 20120101

• Alterations in lipid metabolism mediate inflammation, fibrosis, and proliferation in a mouse model of chronic cholestatic liver injury.

  Gastroenterology 20120101

• Antiatherogenic and Anti-Ischemic Properties of Traditional Chinese Medicine Xinkeshu via Endothelial Protecting Function.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• The chylomicron: relationship to atherosclerosis.

  International journal of vascular medicine 20120101

• Fenofibrate-induced rhabdomyolysis in a patient with chronic renal failure due to nephrotic syndrome: a rare case report.

  Clinical biochemistry 20120101

• Clinical implications of the ACCORD trial.

  The Journal of clinical endocrinology and metabolism 20120101

• Microwave-assisted synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-Amino-6-(4-substituted phenyl)-pyrimidin-4-yl)-phenoxy)-2-methyl propanoic acid derivatives.

  Archiv der Pharmazie 20120101

• Current State-of-Art and New Trends on Lipid Nanoparticles (SLN and NLC) for Oral Drug Delivery.

  Journal of drug delivery 20120101

• Nuclear receptors in nonalcoholic Fatty liver disease.

  Journal of lipids 20120101

• AVE8134, a novel potent PPARα agonist, improves lipid profile and glucose metabolism in dyslipidemic mice and type 2 diabetic rats.

  Acta pharmacologica Sinica 20120101

• Differential induction of stearoyl-CoA desaturase 1 and 2 genes by fibrates in the liver of rats.

  Biological & pharmaceutical bulletin 20120101

• Presenilin is the molecular target of acidic γ-secretase modulators in living cells.

  PloS one 20120101

• β-conglycinin combined with fenofibrate or rosuvastatin have exerted distinct hypocholesterolemic effects in rats.

  Lipids in health and disease 20120101

• 55-week treatment of mice with the unani and ayurvedic medicine pomegranate flower ameliorates ageing-associated insulin resistance and skin abnormalities.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Vinegar-Baked Radix Bupleuri Regulates Lipid Disorders via a Pathway Dependent on Peroxisome-Proliferator-Activated Receptor-α in High-Fat-Diet-Induced Obese Rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• Lipid disorders in elderly hypertensive patients.

  International journal of hypertension 20120101

• Evaluation of the incidence and risk factors for development of fenofibrate-associated nephrotoxicity.

  Journal of clinical lipidology 20120101

• Metabolic syndrome in the Mediterranean region: Current status.

  Indian journal of endocrinology and metabolism 20120101

• Hypertriglyceridemia-induced recurrent acute pancreatitis: A case-based review.

  Indian journal of endocrinology and metabolism 20120101

• Relaxation of rat thoracic aorta by fibrate drugs correlates with their potency to disturb intracellular calcium of VSMCs.

  Vascular pharmacology 20120101

• Mangiferin decreases plasma free fatty acids through promoting its catabolism in liver by activation of AMPK.

  PloS one 20120101

• PPARs in Regulation of Paraoxonases: Control of Oxidative Stress and Inflammation Pathways.

  PPAR research 20120101

• Honey supplementation in spontaneously hypertensive rats elicits antihypertensive effect via amelioration of renal oxidative stress.

  Oxidative medicine and cellular longevity 20120101

• Is the gut microbiota a new factor contributing to obesity and its metabolic disorders?

  Journal of obesity 20120101

• Changes in Lipids and Lipoproteins after Selective LDL Apheresis (7-Year Experience).

  Cholesterol 20120101

• Quality and safety of medication use in primary care: consensus validation of a new set of explicit medication assessment criteria and prioritisation of topics for improvement.

  BMC clinical pharmacology 20120101

• Stress-induced cardiomyopathy after negative pressure pulmonary edema during emergence from anesthesia -A case report-.

  Korean journal of anesthesiology 20120101

• Self-rated health and mortality in individuals with diabetes mellitus: prospective cohort study.

  BMJ open 20120101

• 5, 8, 11, 14-eicosatetraynoic acid suppresses CCL2/MCP-1 expression in IFN-γ-stimulated astrocytes by increasing MAPK phosphatase-1 mRNA stability.

  Journal of neuroinflammation 20120101

• Preliminary evidence for an association between LRP-1 genotype and body mass index in humans.

  PloS one 20120101

• Potent PPARα activator derived from tomato juice, 13-oxo-9,11-octadecadienoic acid, decreases plasma and hepatic triglyceride in obese diabetic mice.

  PloS one 20120101

• Effects of bezafibrate on lipid and glucose metabolism in dyslipidemic patients with diabetes: the J-BENEFIT study.

  Cardiovascular diabetology 20120101

• Rosuvastatin: a review of the pharmacology and clinical effectiveness in cardiovascular disease.

  Clinical Medicine Insights. Cardiology 20120101

• The renoprotective actions of peroxisome proliferator-activated receptors agonists in diabetes.

  PPAR research 20120101

• Regulation of reverse cholesterol transport - a comprehensive appraisal of available animal studies.

  Nutrition & metabolism 20120101

• Interplaying factors that effect multiple sclerosis causation and sustenance.

  ISRN neurology 20120101

• The association of hypertriglyceridemia with cardiovascular events and pancreatitis: a systematic review and meta-analysis.

  BMC endocrine disorders 20120101

• Fenofibrate down-regulates renal OCT2-mediated organic cation transport via PPARα-independent pathways.

  Drug metabolism and pharmacokinetics 20120101

• Emerging pharmacotherapies for diabetic macular edema.

  Experimental diabetes research 20120101

• Myricetin Increases Hepatic Peroxisome Proliferator-Activated Receptor α Protein Expression and Decreases Plasma Lipids and Adiposity in Rats.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• New insights into the role of peroxisome proliferator-activated receptors in regulating the inflammatory response after tissue injury.

  PPAR research 20120101

• Is there a role for hypolipidaemic drug therapy in the prevention or treatment of microvascular complications of diabetes?

  The open cardiovascular medicine journal 20120101

• The promoter of Rv0560c is induced by salicylate and structurally-related compounds in Mycobacterium tuberculosis.

  PloS one 20120101

• JC virus T-antigen regulates glucose metabolic pathways in brain tumor cells.

  PloS one 20120101

• Comparative transcriptional network modeling of three PPAR-α/γ co-agonists reveals distinct metabolic gene signatures in primary human hepatocytes.

  PloS one 20120101

• Fenofibrate reduces mortality and precludes neurological deficits in survivors in murine model of Japanese encephalitis viral infection.

  PloS one 20120101

• Cardiovascular events in patients received combined fibrate/statin treatment versus statin monotherapy: Acute Coronary Syndrome Israeli Surveys data.

  PloS one 20120101

• Pathobiochemical changes in diabetic skeletal muscle as revealed by mass-spectrometry-based proteomics.

  Journal of nutrition and metabolism 20120101

• Fenofibrate enhances the in vitro differentiation of foxp3(+) regulatory T cells in mice.

  PPAR research 20120101

• Nitric oxide manipulation: a therapeutic target for peripheral arterial disease?

  Cardiology research and practice 20120101

• Anti-inflammatory effect of simvastatin in an experimental model of spinal cord trauma: involvement of PPAR-α.

  Journal of neuroinflammation 20120101

• Metronomic chemotherapy with the COMBAT regimen in advanced pediatric malignancies: a multicenter experience.

  Oncology 20120101

• Regulation of hepatic paraoxonase-1 expression.

  Journal of lipids 20120101

• Effects of PPARs agonists on cardiac metabolism in littermate and cardiomyocyte-specific PPAR-γ-knockout (CM-PGKO) mice.

  PloS one 20120101

• Treatment of chronic hemodialysis patients with low-dose fenofibrate effectively reduces plasma lipids and affects plasma redox status.

  Lipids in health and disease 20120101

• Inflammation and oxidative stress in obesity-related glomerulopathy.

  International journal of nephrology 20120101

• Liquid chromatography-tandem mass spectrometry analysis of perfluorooctane sulfonate and perfluorooctanoic Acid in fish fillet samples.

  Journal of analytical methods in chemistry 20120101

• Lipid-regulating effect of traditional chinese medicine: mechanisms of actions.

  Evidence-based complementary and alternative medicine : eCAM 20120101

• AS601245, an Anti-Inflammatory JNK Inhibitor, and Clofibrate Have a Synergistic Effect in Inducing Cell Responses and in Affecting the Gene Expression Profile in CaCo-2 Colon Cancer Cells.

  PPAR research 20120101

• Red carpeting the newer antidiabetics.

  Journal of pharmacology & pharmacotherapeutics 20120101

• Hepatic Cerebroside Sulfotransferase Is Induced by PPARα Activation in Mice.

  PPAR research 20120101

• Simultaneous determination of atorvastatin calcium, ezetimibe, and fenofibrate in a tablet formulation by HPLC.

  Journal of AOAC International 20120101

• LDL-apheresis: technical and clinical aspects.

  TheScientificWorldJournal 20120101

• PPARs: Interference with Warburg' Effect and Clinical Anticancer Trials.

  PPAR research 20120101

• Fatty Acid Accumulation and Resulting PPARα Activation in Fibroblasts due to Trifunctional Protein Deficiency.

  PPAR research 20120101

• Gold nanoparticles functionalized with peptides for specific affinity aggregation assays of estrogen receptors and their agonists.

  Sensors (Basel, Switzerland) 20120101

• PPARα Activation Protects against Anti-Thy1 Nephritis by Suppressing Glomerular NF-κB Signaling.

  PPAR research 20120101

• Design novel dual agonists for treating type-2 diabetes by targeting peroxisome proliferator-activated receptors with core hopping approach.

  PloS one 20120101

• Postprandial lipemia in pre- and postmenopausal women.

  Journal of natural science, biology, and medicine 20120101

• Pleiotropic protective effects of phytochemicals in Alzheimer's disease.

  Oxidative medicine and cellular longevity 20120101

• Peroxisome proliferator-activated receptorα agonists differentially regulate inhibitor of DNA binding expression in rodents and human cells.

  PPAR research 20120101

• Protection from Metabolic Dysregulation, Obesity, and Atherosclerosis by Citrus Flavonoids: Activation of Hepatic PGC1α-Mediated Fatty Acid Oxidation.

  PPAR research 20120101

• Pan-PPAR Agonist, Bezafibrate, Restores Angiogenesis in Hindlimb Ischemia in Normal and Diabetic Rats.

  International journal of peptides 20120101

• The effects of dietary intervention on HIV dyslipidaemia: a systematic review and meta-analysis.

  PloS one 20120101

• Clustering by plasma lipoprotein profile reveals two distinct subgroups with positive lipid response to fenofibrate therapy.

  PloS one 20120101

• False estimates of elevated creatinine.

  The Permanente journal 20120101

• [Is hypertriglyceridaemia a risk factor for coronary heart disease?].

  Lijecnicki vjesnik 20120101

• Fenofibrate inhibited the differentiation of T helper 17 cells in vitro.

  PPAR research 20120101

• High density lipoprotein is positively correlated with the changes in circulating total adiponectin and high molecular weight adiponectin during dietary and fenofibrate treatment.

  Hormones (Athens, Greece) 20120101

• Delayed-type hypersensitivity to fenofibrate.

  Journal of investigational allergology & clinical immunology 20120101

• Peroxisome Proliferator Activated Receptor-α Agonist Slows the Progression of Hypertension, Attenuates Plasma Interleukin-6 Levels and Renal Inflammatory Markers in Angiotensin II Infused Mice.

  PPAR research 20120101

• Development of a vascularized skin construct using adipose-derived stem cells from debrided burned skin.

  Stem cells international 20120101

• Effects of diet-induced obesity on protein expression in insulin signaling pathways of skeletal muscle in male Wistar rats.

  International journal of general medicine 20120101

• Antihyperglycemic and hypolipidemic effects of α, β-amyrin, a triterpenoid mixture from Protium heptaphyllum in mice.

  Lipids in health and disease 20120101

• A neutral risk on the development of new-onset diabetes mellitus (NODM) in Taiwanese patients with dyslipidaemia treated with fibrates.

  TheScientificWorldJournal 20120101

• Xanthoma of bone: a case report.

  Case reports in endocrinology 20120101

• The PPARα Agonist Fenofibrate Reduces Prepulse Inhibition Disruption in a Neurodevelopmental Model of Schizophrenia.

  Schizophrenia research and treatment 20120101

• Induction of 1-acylglycerophosphocholine acyltransferase genes by fibrates in the liver of rats.

  Biological & pharmaceutical bulletin 20120101

• Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells.

  The Journal of toxicological sciences 20120101

• Conservative management of L-asparaginase-induced hypertriglyceridemia in an adult patient: a case report and review of the literature.

  Onkologie 20120101

• Protective role of fibrates in cardiac ischemia/reperfusion.

  Journal of advanced pharmaceutical technology & research 20120101

• Enhancement of the dissolution rate and bioavailability of fenofibrate by a melt-adsorption method using supercritical carbon dioxide.

  International journal of nanomedicine 20120101

• Variants identified in a GWAS meta-analysis for blood lipids are associated with the lipid response to fenofibrate.

  PloS one 20120101

• Paediatric type III dyslipidaemia: a case of vanishing hyperlipidaemia.

  BMJ case reports 20120101

• IMproving the imPlemEntation of cuRrent guidelines for the mAnagement of major coronary hearT disease rIsk factors by multifactorial interVEntion. The IMPERATIVE renal analysis.

  Archives of medical science : AMS 20111231

• Comparative transcriptomic and metabolomic analysis of fenofibrate and fish oil treatments in mice.

  Physiological genomics 20111205

• [Treatment of gout].

  La Revue de medecine interne 20111201

• Effects of Doxorubicin and Fenofibrate on the activities of NADH oxidase and citrate synthase in mice.

  Basic & clinical pharmacology & toxicology 20111201

• The effects of rosuvastatin alone or in combination with fenofibrate or omega 3 fatty acids on inflammation and oxidative stress in patients with mixed dyslipidemia.

  Expert opinion on pharmacotherapy 20111201

• The peroxisome proliferator-activated receptor-α agonist, BAY PP1, attenuates renal fibrosis in rats.

  Kidney international 20111201

• Soluble CD163 is not increased in visceral fat and steatotic liver and is even suppressed by free fatty acids in vitro.

  Experimental and molecular pathology 20111201

• Aryl hydrocarbon receptor deficiency enhances insulin sensitivity and reduces PPAR-α pathway activity in mice.

  Environmental health perspectives 20111201

• Variants in the APOA5 gene region and the response to combination therapy with statins and fenofibric acid in a randomized clinical trial of individuals with mixed dyslipidemia.

  Atherosclerosis 20111201

• A two-stage approach to the treatment of hyperuricemia in gout: the 'dirty dish' hypothesis.

  Arthritis and rheumatism 20111201

• Adiponectin reduces connective tissue growth factor in human hepatocytes which is already induced in non-fibrotic non-alcoholic steatohepatitis.

  Experimental and molecular pathology 20111201

• Altered fibrin clot properties in patients with retinal vein occlusion.

  Journal of thrombosis and haemostasis : JTH 20111201

• The PPAR alpha agonist gemfibrozil is an ineffective treatment for spinal cord injured mice.

  Experimental neurology 20111201

• Translating clinical findings into knowledge in drug safety evaluation--drug induced liver injury prediction system (DILIps).

  PLoS computational biology 20111201

• [Drug-induced hepatic injury, the challenge for cause investigation].

  Rinsho byori. The Japanese journal of clinical pathology 20111201

• Design of fenofibrate microemulsion for improved bioavailability.

  International journal of pharmaceutics 20111128

• Inhibition of ubiquitin ligase F-box and WD repeat domain-containing 7α (Fbw7α) causes hepatosteatosis through Krüppel-like factor 5 (KLF5)/peroxisome proliferator-activated receptor γ2 (PPARγ2) pathway but not SREBP-1c protein in mice.

  The Journal of biological chemistry 20111125

• The effect of bezafibrate and omega-3 fatty acids on lymphocyte cytokine release and systemic inflammation in patients with isolated hypertriglyceridemia.

  European journal of clinical pharmacology 20111101

• Macrophage cholesterol efflux to plasma and HDL in subjects with low and high homocysteine levels: a FIELD substudy.

  Atherosclerosis 20111101

• Kaempferol regulates the lipid-profile in high-fat diet-fed rats through an increase in hepatic PPARα levels.

  Planta medica 20111101

• Mango modulates body fat and plasma glucose and lipids in mice fed a high-fat diet.

  The British journal of nutrition 20111101

• Fenofibrate, homocysteine, cholesterol efflux and primum non nocere.

  Atherosclerosis 20111101

• A data-driven method for identifying rare variants with heterogeneous trait effects.

  Genetic epidemiology 20111101

• Associations between the use of metformin, sulphonylureas, or diet alone and cardiovascular outcomes in 6005 people with type 2 diabetes in the FIELD study.

  Diabetes research and clinical practice 20111101

• Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg).

  Annals of clinical biochemistry 20111101

• Effects of intensive glucose lowering on brain structure and function in people with type 2 diabetes (ACCORD MIND): a randomised open-label substudy.

  The Lancet. Neurology 20111101

• Fenofibrate-induced decrease of expression of CYP2C11 and CYP2C6 in rat.

  Biopharmaceutics & drug disposition 20111101

• Long-term safety and efficacy of fenofibrate/pravastatin combination therapy in high risk patients with mixed hyperlipidemia not controlled by pravastatin monotherapy.

  Current medical research and opinion 20111101

• A cost-benefit analysis of lipid standardization in the United States.

  Preventing chronic disease 20111101

• Republished review: Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

  Postgraduate medical journal 20111101

• [Multiple cutaneous osteomas of the face in a setting of chronic acne].

  Annales de dermatologie et de venereologie 20111101

• Oxidation by-products and ecotoxicity assessment during the photodegradation of fenofibric acid in aqueous solution with UV and UV/H2O2.

  Journal of hazardous materials 20111030

• Increased expression of Foxj1 after traumatic brain injury.

  Journal of molecular neuroscience : MN 20111001

• CLSM as quantitative method to determine the size of drug crystals in a solid dispersion.

  Pharmaceutical research 20111001

• Management of gout in the older adult.

  The American journal of geriatric pharmacotherapy 20111001

• Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured US population.

  The Annals of pharmacotherapy 20111001

• Fenofibrate: a review of its use in dyslipidaemia.

  Drugs 20111001

• Residual cardiovascular risk in secondary prevention.

  Internal and emergency medicine 20111001

• Safety and impact on cardiovascular events of long-term multifactorial treatment in patients with metabolic syndrome and abnormal liver function tests: a post hoc analysis of the randomised ATTEMPT study.

  Archives of medical science : AMS 20111001

• Improvement of the wettability and dissolution of fenofibrate compacts by plasma treatment.

  International journal of pharmaceutics 20110915

• Investigating the effect of moisture protection on solid-state stability and dissolution of fenofibrate and ketoconazole solid dispersions using PXRD, HSDSC and Raman microscopy.

  Drug development and industrial pharmacy 20110901

• PPARα activation differently affects microparticle content in atherosclerotic lesions and liver of a mouse model of atherosclerosis and NASH.

  Atherosclerosis 20110901

• New approaches to the treatment of diabetic retinopathy.

  Diabetes, obesity & metabolism 20110901

• Fenofibrate increases neuronal vasoconstrictor response in mesenteric arteries from diabetic rats: role of noradrenaline, neuronal nitric oxide and calcitonin gene-related peptide.

  European journal of pharmacology 20110901

• Reactivation of peroxisome proliferator-activated receptor alpha in spontaneously hypertensive rat: age-associated paradoxical effect on the heart.

  Journal of cardiovascular pharmacology 20110901

• A novel nanomatrix system consisted of colloidal silica and pH-sensitive polymethylacrylate improves the oral bioavailability of fenofibrate.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110901

• Comparison of the effects of the n-3 polyunsaturated fatty acid eicosapentaenoic and fenofibrate on the inhibitory effect of arthritis on IGF1.

  The Journal of endocrinology 20110901

• Does microvascular disease predict macrovascular events in type 2 diabetes?

  Atherosclerosis 20110901

• The toxicity potential of pharmaceuticals found in the Douro River estuary (Portugal)--experimental assessment using a zebrafish embryo test.

  Environmental toxicology and pharmacology 20110901

• The diagnosis and treatment of primary biliary cirrhosis.

  The Korean journal of hepatology 20110901

• Synthesis and biological evaluation of orally active hypolipidemic agents.

  Journal of medicinal chemistry 20110825

• NSAID-derived γ-secretase modulation requires an acidic moiety on the carbazole scaffold.

  Bioorganic & medicinal chemistry 20110815

• Fibrates in the treatment of dyslipidemias--time for a reassessment.

  The New England journal of medicine 20110811

• Evaluation of in vivo genotoxic potential of fenofibrate in rats subjected to two-week repeated oral administration.

  Archives of toxicology 20110801

• Fenofibrate administration does not affect muscle triglyceride concentration or insulin sensitivity in humans.

  Metabolism: clinical and experimental 20110801

• PPARs are a unique set of fatty acid regulated transcription factors controlling both lipid metabolism and inflammation.

  Biochimica et biophysica acta 20110801

• Fenofibrate suppresses growth of the human hepatocellular carcinoma cell via PPARα-independent mechanisms.

  European journal of cell biology 20110801

• Hyperlipidaemia and cardiovascular disease: do fibrates have a role?

  Current opinion in lipidology 20110801

• Fenofibrate attenuates contact-stimulated cell motility and gap junctional coupling in DU-145 human prostate cancer cell populations.

  Oncology reports 20110801

• Fenofibrate: a review of its lipid-modifying effects in dyslipidemia and its vascular effects in type 2 diabetes mellitus.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20110801

• Blood lipids and stroke: what more can we do besides reducing low-density lipoprotein cholesterol?

  Current atherosclerosis reports 20110801

• Fenofibric acid reduces fibronectin and collagen type IV overexpression in human retinal pigment epithelial cells grown in conditions mimicking the diabetic milieu: functional implications in retinal permeability.

  Investigative ophthalmology & visual science 20110801

• Profile of serum bile acids in noncholestatic volunteers: gender-related differences in response to fenofibrate.

  Clinical pharmacology and therapeutics 20110801

• Fenofibrate plus simvastatin (fixed-dose combination) for the treatment of dyslipidaemia.

  Expert opinion on pharmacotherapy 20110801

• Short-term fenofibrate treatment reduces elevated plasma Lp-PLA2 mass and sVCAM-1 levels in a subcohort of hypertriglyceridemic GOLDN participants.

  Translational research : the journal of laboratory and clinical medicine 20110801

• Why, when and how should hypertriglyceridemia be treated in the high-risk cardiovascular patient?

  Expert review of cardiovascular therapy 20110801

• Role of Peroxisome Proliferator-Activated Receptor α in Diabetic Nephropathy.

  Diabetes & metabolism journal 20110801

• Managing dyslipidaemia: evolving role of combination therapy.

  Journal of the Indian Medical Association 20110801

• The conflict between in vitro release studies in human biorelevant media and the in vivo exposure in rats of the lipophilic compound fenofibrate.

  International journal of pharmaceutics 20110729

• Fibrate use in the United States and Canada.

  JAMA 20110713

• Fibrate use in the United States and Canada.

  JAMA 20110713

• Trial puts niacin--and cholesterol dogma--in the line of fire.

  Nature medicine 20110707

• Stable reporter cell lines for peroxisome proliferator-activated receptor γ (PPARγ)-mediated modulation of gene expression.

  Analytical biochemistry 20110701

• Comparison of effects of bezafibrate and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 and adipocytokine levels in dyslipidemic subjects with impaired glucose tolerance or type 2 diabetes mellitus: results from a crossover study.

  Atherosclerosis 20110701

• Medical management of diabetic retinopathy: fenofibrate and ACCORD Eye studies.

  Eye (London, England) 20110701

• Regulation of proprotein convertase subtilisin/kexin type 9: therapeutical perspectives.

  Atherosclerosis 20110701

• Peroxisome proliferator-activated receptor-alpha gene level differently affects lipid metabolism and inflammation in apolipoprotein E2 knock-in mice.

  Arteriosclerosis, thrombosis, and vascular biology 20110701

• Peroxisome proliferator-activated receptor α agonists modulate Th1 and Th2 chemokine secretion in normal thyrocytes and Graves' disease.

  Experimental cell research 20110701

• Comparisons of apolipoprotein B levels estimated by immunoassay, nuclear magnetic resonance, vertical auto profile, and non-high-density lipoprotein cholesterol in subjects with hypertriglyceridemia (SAFARI Trial).

  The American journal of cardiology 20110701

• Combination of niacin and fenofibrate with lifestyle changes improves dyslipidemia and hypoadiponectinemia in HIV patients on antiretroviral therapy: results of 'heart positive,' a randomized, controlled trial.

  The Journal of clinical endocrinology and metabolism 20110701

• Non-invited review: prevention of microvascular diabetic complications by fenofibrate: lessons from FIELD and ACCORD.

  Diabetes & vascular disease research 20110701

• Therapy: HIV-associated dyslipidemia: the heart positive study.

  Nature reviews. Endocrinology 20110621

• Effect of the amyloidogenic L75P apolipoprotein A-I variant on HDL subpopulations.

  Clinica chimica acta; international journal of clinical chemistry 20110611

• Surface-active derivative of inulin (Inutec® SP1) is a superior carrier for solid dispersions with a high drug load.

  Journal of pharmaceutical sciences 20110601

• Effects of chronic systemic treatment with peroxisome proliferator-activated receptor α activators on neuroinflammation induced by intracerebral injection of lipopolysaccharide in adult mice.

  Neuroscience research 20110601

• High doses of rosuvastatin are superior to low doses of rosuvastatin plus fenofibrate or n-3 fatty acids in mixed dyslipidemia.

  Lipids 20110601

• Peroxisome proliferator-activated receptor-α is renoprotective in doxorubicin-induced glomerular injury.

  Kidney international 20110601

• Fenofibric acid prevents retinal pigment epithelium disruption induced by interleukin-1β by suppressing AMP-activated protein kinase (AMPK) activation.

  Diabetologia 20110601

• Combination therapy with statin and fibrate in patients with dyslipidemia associated with insulin resistance, metabolic syndrome and type 2 diabetes mellitus.

  Expert opinion on pharmacotherapy 20110601

• Synthesis and antidyslipidemic activity of chalcone fibrates.

  Bioorganic & medicinal chemistry letters 20110601

• Effective kinetics of schisandrin B on serum/hepatic triglyceride and total cholesterol levels in mice with and without the influence of fenofibrate.

  Naunyn-Schmiedeberg's archives of pharmacology 20110601

• Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk of cardiovascular disease: evidence and guidance for management.

  European heart journal 20110601

• Incidence and prevalence of unrecognized myocardial infarction in people with diabetes: a substudy of the Rosiglitazone Evaluated for Cardiac Outcomes and Regulation of Glycemia in Diabetes (RECORD) study.

  Diabetes care 20110601

• Acute renal failure due to fenofibrate monotherapy.

  Anadolu kardiyoloji dergisi : AKD = the Anatolian journal of cardiology 20110601

• Use of metformin in the setting of mild-to-moderate renal insufficiency.

  Diabetes care 20110601

• PPAR-α transcriptional activity is required to combat doxorubicin-induced podocyte injury in mice.

  Kidney international 20110601

• Fenofibrate: altered renal function.

  Prescrire international 20110601

• Single-dose bioequivalence of 105-mg fenofibric acid tablets versus 145-mg fenofibrate tablets under fasting and fed conditions: a report of two phase I, open-label, single-dose, randomized, crossover clinical trials.

  Clinical therapeutics 20110601

• Lipid lowering therapy in type 2 diabetes.

  Wiener medizinische Wochenschrift (1946) 20110601

• Therapeutic target achievement in type 2 diabetic patients after hyperglycemia, hypertension, dyslipidemia management.

  Diabetes & metabolism journal 20110601

• Suppression of endothelin-1-induced cardiac myocyte hypertrophy by PPAR agonists: role of diacylglycerol kinase zeta.

  Cardiovascular research 20110501

• Fenofibrate, a PPAR{alpha} agonist, decreases atrogenes and myostatin expression and improves arthritis-induced skeletal muscle atrophy.

  American journal of physiology. Endocrinology and metabolism 20110501

• Activation of peroxisome proliferator-activated receptor-alpha stimulates both differentiation and fatty acid oxidation in adipocytes.

  Journal of lipid research 20110501

• Pretreatment by low-dose fibrates protects against acute free fatty acid-induced renal tubule toxicity by counteracting PPARα deterioration.

  Toxicology and applied pharmacology 20110501

• Activation of AMP-activated protein kinase prevents lipotoxicity in retinal pericytes.

  Investigative ophthalmology & visual science 20110501

• Solid-phase treatment with the fungus Trametes versicolor substantially reduces pharmaceutical concentrations and toxicity from sewage sludge.

  Bioresource technology 20110501

• Safety review of combination drugs for hyperlipidemia.

  Expert opinion on drug safety 20110501

• Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis.

  Current medical research and opinion 20110501

• Prevention and treatment of diabetic retinopathy: evidence from clinical trials and perspectives.

  Current diabetes reviews 20110501

• The ACCORD (Action to Control Cardiovascular Risk in Diabetes) Lipid trial: what we learn from subgroup analyses.

  Diabetes care 20110501

• Effects of ezetimibe added to ongoing statin therapy on C-reactive protein levels in hypercholesterolemic patients.

  Korean circulation journal 20110501

• Atomistic simulation study of surfactant and polymer interactions on the surface of a fenofibrate crystal.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110418

• Statin or fibrate chronic treatment modifies the proteomic profile of rat skeletal muscle.

  Biochemical pharmacology 20110415

• Inhibition of amyloidogenesis by nonsteroidal anti-inflammatory drugs and their hybrid nitrates.

  Journal of medicinal chemistry 20110414

• Excipient-mediated supersaturation stabilization in human intestinal fluids.

  Molecular pharmaceutics 20110404

• Fenofibrate suppresses microvascular inflammation and apoptosis through adenosine monophosphate-activated protein kinase activation.

  Metabolism: clinical and experimental 20110401

• Proper laboratory notebook practices: protecting your intellectual property.

  Journal of neuroimmune pharmacology : the official journal of the Society on NeuroImmune Pharmacology 20110401

• Fenofibrate exhibits a high potential to suppress the formation of squamous cell carcinoma in an oral-specific 4-nitroquinoline 1-oxide/arecoline mouse model.

  Biochimica et biophysica acta 20110401

• Effects of coadministered ezetimibe plus fenofibrate in mixed dyslipidemic patients with metabolic syndrome.

  Metabolic syndrome and related disorders 20110401

• The ACCORD Study: the devil is in the details.

  Metabolic syndrome and related disorders 20110401

• Fenofibrate, a PPARα agonist, has renoprotective effects in mice by enhancing renal lipolysis.

  Kidney international 20110401

• Effect of simvastatin and fenofibrate on cytokine release and systemic inflammation in type 2 diabetes mellitus with mixed dyslipidemia.

  The American journal of cardiology 20110401

• Effect of preischemic treatment with fenofibrate, a peroxisome proliferator-activated receptor-α ligand, on hepatic ischemia-reperfusion injury in rats.

  Journal of molecular histology 20110401

• Association of gene variants with lipid levels in response to fenofibrate is influenced by metabolic syndrome status.

  Atherosclerosis 20110401

• Prevalence of low high-density lipoprotein cholesterol (HDL-C) as a marker of residual cardiovascular risk among acute coronary syndrome patients from Oman.

  Current medical research and opinion 20110401

• Effect of fenofibrate treatment on the low molecular weight urinary proteome of healthy volunteers.

  Proteomics. Clinical applications 20110401

• Peroxisome proliferator-activated receptor-α agonists protect cortical neurons from inflammatory mediators and improve peroxisomal function.

  The European journal of neuroscience 20110401

• Fenofibrate and statin therapy, compared with placebo and statin, slows the development of retinopathy in type 2 diabetes patients of 10 years duration: the ACCORD study.

  Evidence-based medicine 20110401

• Diabetic retinopathy in 2011: further insights from new epidemiological studies and clinical trials.

  Diabetes care 20110401

• [Biliary diseases - new insights and developments].

  Deutsche medizinische Wochenschrift (1946) 20110401

• Synergistic improvement in insulin resistance with a combination of fenofibrate and rosiglitazone in obese type 2 diabetic mice.

  Archives of pharmacal research 20110401

• The causes and consequences of low levels of high density lipoproteins in patients with diabetes.

  Diabetes & metabolism journal 20110401

• [A dyslipidemia animal model induced by poloxamer 407 in golden hamsters and pilot study on the mechanism].

  Yao xue xue bao = Acta pharmaceutica Sinica 20110401

• Severe hypertriglyceridaemia during treatment with capecitabine.

  British journal of cancer 20110329

• Use of fibrates in the United States and Canada.

  JAMA 20110323

• A novel excipient, 1-perfluorohexyloctane shows limited utility for the oral delivery of poorly water-soluble drugs.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110318

• Efficacy of fenofibric acid plus statins on multiple lipid parameters and its safety in women with mixed dyslipidemia.

  The American journal of cardiology 20110315

• Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.

  Journal of clinical pharmacology 20110301

• Fetal alcohol-induced hyperactivity is reversed by treatment with the PPARα agonist fenofibrate in a rat model.

  Psychopharmacology 20110301

• The correlation between clinical laboratory data and telomeric status of male patients with metabolic disorders and no clinical history of vascular events.

  The aging male : the official journal of the International Society for the Study of the Aging Male 20110301

• Protective effect of berberine on antioxidant enzymes and positive transcription elongation factor b expression in diabetic rat liver.

  Fitoterapia 20110301

• Fibrates and statins in the treatment of diabetic retinopathy.

  Current pharmaceutical biotechnology 20110301

• Fibrate use in diabetes: new concepts.

  Journal of diabetes 20110301

• Fenofibrate, a peroxisome proliferator-activated receptor α agonist, alters triglyceride metabolism in enterocytes of mice.

  Biochimica et biophysica acta 20110301

• Disappearance of angina pectoris by lipid-lowering in type III hyperlipoproteinemia.

  The American journal of cardiology 20110301

• Genetic defects in human pericentrin are associated with severe insulin resistance and diabetes.

  Diabetes 20110301

• Activation of peroxisome proliferator-activated receptor delta inhibits streptozotocin-induced diabetic nephropathy through anti-inflammatory mechanisms in mice.

  Diabetes 20110301

• Triglycerides and atherogenic dyslipidaemia: extending treatment beyond statins in the high-risk cardiovascular patient.

  Heart (British Cardiac Society) 20110301

• Do fibrates truly preserve kidney function?

  Nature reviews. Endocrinology 20110301

• Type 2 diabetes and impaired glucose tolerance in two young adults infected with HIV early in life.

  Diabetes care 20110301

• Does diabetes always confer coronary heart disease risk equivalent to a prior myocardial infarction?: implications for prevention.

  Diabetes care 20110301

• Not a graves' situation.

  The American journal of medicine 20110301

• Combinations of ezetimibe with nonstatin drug regimens affecting lipid metabolism.

  Expert review of cardiovascular therapy 20110301

• Nutritional and metabolic status of HIV-positive patients with lipodystrophy during one year of follow-up.

  Clinics (Sao Paulo, Brazil) 20110301

• Continuous and scalable process for water-redispersible nanoformulation of poorly aqueous soluble APIs by antisolvent precipitation and spray-drying.

  International journal of pharmaceutics 20110214

• Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.

  Planta medica 20110201

• Human NPC1L1 expression is positively regulated by PPARα.

  Pharmaceutical research 20110201

• Effects of fenofibrate on renal function in patients with type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) Study.

  Diabetologia 20110201

• Biorelevant in vitro dissolution testing of products containing micronized or nanosized fenofibrate with a view to predicting plasma profiles.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20110201

• Differential regulation of human apolipoprotein AI and high-density lipoprotein by fenofibrate in hapoAI and hapoAI-CIII-AIV transgenic mice.

  Biochimica et biophysica acta 20110201

• Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective.

  Current opinion in lipidology 20110201

• What combination therapy with a statin, if any, would you recommend?

  Current atherosclerosis reports 20110201

• Differential effects of gemfibrozil and fenofibrate on reverse cholesterol transport from macrophages to feces in vivo.

  Biochimica et biophysica acta 20110201

• Lipids, lipid-lowering therapy and diabetes complications.

  Diabetes & metabolism 20110201

• Effects of fenofibrate on plasma oxidized LDL and 8-isoprostane in a sub-cohort of GOLDN participants.

  Atherosclerosis 20110201

• Geometrical separation method for lipoproteins using bioformulated-fiber matrix electrophoresis: size of high-density lipoprotein does not reflect its density.

  Analytical chemistry 20110201

• Achievement of lipid targets with the combination of rosuvastatin and fenofibric Acid in patients with type 2 diabetes mellitus.

  Cardiovascular drugs and therapy 20110201

• Approach to dyslipidemia, lipodystrophy, and cardiovascular risk in patients with HIV infection.

  Current atherosclerosis reports 20110201

• Comparison of fibrate, ezetimibe, low- and high-dose statin therapy for the dyslipidemia of the metabolic syndrome in a mouse model.

  Angiology 20110201

• Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate.

  Obstetrics and gynecology 20110201

• Serum apolipoprotein AI and B are stronger biomarkers of diabetic retinopathy than traditional lipids.

  Diabetes care 20110201

• Apolipoproteins and diabetic retinopathy.

  Diabetes care 20110201

• Letter by Singh et al regarding article, 'Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the GOLDN study'.

  Circulation. Cardiovascular genetics 20110201

• Efficacy of ezetimibe as monotherapy or combination therapy in hypercholesterolemic patients with and without diabetes.

  The journal of medical investigation : JMI 20110201

• Primary biliary cirrhosis: Fenofibrate plus UDCA promising for incomplete responders to UDCA.

  Nature reviews. Gastroenterology & hepatology 20110201

• Long-term efficacy of adding fenofibric acid to moderate-dose statin therapy in patients with persistent elevated triglycerides.

  Cardiovascular drugs and therapy 20110201

• Effects of medical therapies on retinopathy progression in type 2 diabetes.

  Irish medical journal 20110201

• Detection of trace crystallinity in an amorphous system using Raman microscopy and chemometric analysis.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20110118

• In vitro evaluation of the immunotoxic potential of perfluorinated compounds (PFCs).

  Toxicology and applied pharmacology 20110115

• Synthesis, hypolipidemic and hypoglycemic activity of some novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy)-2-methyl propanoic acid derivatives.

  Bioorganic & medicinal chemistry letters 20110115

• Peroxisome proliferator-activated receptor {alpha} is responsible for the up-regulation of hepatic glucose-6-phosphatase gene expression in fasting and db/db Mice.

  The Journal of biological chemistry 20110114

• Inhibitory effect of fenofibrate on neointima hyperplasia via G(0)/G(1) arrest of cell proliferation.

  European journal of pharmacology 20110110

• Ethanol extract of fructus schisandrae decreases hepatic triglyceride level in mice fed with a high fat/cholesterol diet, with attention to acute toxicity.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Hypolipidemic effects of three purgative decoctions.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Estimated glomerular filtration rate and albuminuria are independent predictors of cardiovascular events and death in type 2 diabetes mellitus: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  Diabetologia 20110101

• Activation of peroxisome proliferator-activated receptor α in megakaryocytes reduces platelet-derived growth factor-BB in platelets.

  Journal of atherosclerosis and thrombosis 20110101

• Effects of fenofibrate therapy on circulating adipocytokines in patients with primary hypertriglyceridemia.

  Atherosclerosis 20110101

• Use of ultra high performance liquid chromatography-tandem mass spectrometry to demonstrate decreased serum statin levels after extracorporeal LDL-cholesterol elimination.

  Journal of biomedicine & biotechnology 20110101

• Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid.

  Alimentary pharmacology & therapeutics 20110101

• Pleiotropic actions of fenofibrate on the heart.

  Pharmacological research 20110101

• Evaluation of anti-atherosclerotic activities of PPAR-α, PPAR-γ, and LXR agonists in hyperlipidemic atherosclerosis-susceptible F(1)B hamsters.

  Atherosclerosis 20110101

• Standards of medical care in diabetes--2011.

  Diabetes care 20110101

• Clinical pearls in general internal medicine.

  Mayo Clinic proceedings 20110101

• Diabetic retinopathy: targeting vasoregression.

  Diabetes 20110101

• Ascorbic acid partly antagonizes resveratrol mediated heme oxygenase-1 but not paraoxonase-1 induction in cultured hepatocytes - role of the redox-regulated transcription factor Nrf2.

  BMC complementary and alternative medicine 20110101

• Study design and rationale of 'Synergistic effect of combination therapy with cilostazol and ProbUcol on plaque stabilization and lesion REgression (SECURE)' study: a double-blind randomised controlled multicenter clinical trial.

  Trials 20110101

• Transforming Growth Factor-β1 as a Common Target Molecule for Development of Cardiovascular Diseases, Renal Insufficiency and Metabolic Syndrome.

  Cardiology research and practice 20110101

• Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis.

  Lipids in health and disease 20110101

• Effects of aleglitazar, a balanced dual peroxisome proliferator-activated receptor α/γ agonist on glycemic and lipid parameters in a primate model of the metabolic syndrome.

  Cardiovascular diabetology 20110101

• Novel adiponectin-resistin (AR) and insulin resistance (IRAR) indexes are useful integrated diagnostic biomarkers for insulin resistance, type 2 diabetes and metabolic syndrome: a case control study.

  Cardiovascular diabetology 20110101

• Rodent models for metabolic syndrome research.

  Journal of biomedicine & biotechnology 20110101

• 'The metabolic syndrome... is dead': these reports are an exaggeration.

  Cardiovascular diabetology 20110101

• Pharmacological and non-pharmacological interventions to influence adipose tissue function.

  Cardiovascular diabetology 20110101

• Genomewide analyses define different modes of transcriptional regulation by peroxisome proliferator-activated receptor-β/δ (PPARβ/δ).

  PloS one 20110101

• Prevalence and progression of visual impairment in patients newly diagnosed with clinical type 2 diabetes: a 6-year follow up study.

  BMC public health 20110101

• Fenofibrate profiled as the fibrate with additional new data, supporting its use with statins in the European Medicines Agency recommendations.

  Cardiovascular journal of Africa 20110101

• Reciprocal relationship between APP positioning relative to the membrane and PS1 conformation.

  Molecular neurodegeneration 20110101

• Megalin/LRP2 expression is induced by peroxisome proliferator-activated receptor -alpha and -gamma: implications for PPARs' roles in renal function.

  PloS one 20110101

• Adiponectin provides cardiovascular protection in metabolic syndrome.

  Cardiology research and practice 20110101

• Targeting vascular NADPH oxidase 1 blocks tumor angiogenesis through a PPARα mediated mechanism.

  PloS one 20110101

• Effects of currently prescribed LDL-C-lowering drugs on PCSK9 and implications for the next generation of LDL-C-lowering agents.

  Lipids in health and disease 20110101

• Can NGOs regulate medicines markets? Social enterprise in wholesaling, and access to essential medicines.

  Globalization and health 20110101

• A Canadian Critical Care Trials Group project in collaboration with the international forum for acute care trialists - Collaborative H1N1 Adjuvant Treatment pilot trial (CHAT): study protocol and design of a randomized controlled trial.

  Trials 20110101

• IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods.

  Die Pharmazie 20110101

• Fixed-dose combination fenofibrate/pravastatin 160/40 mg versus simvastatin 20 mg monotherapy in adults with type 2 diabetes and mixed hyperlipidemia uncontrolled with simvastatin 20 mg: a double-blind, randomized comparative study.

  Clinical therapeutics 20110101

• Lipoprotein(a) Is the Best Single Marker in Assessing Unstable Angina Pectoris.

  Cardiology research and practice 20110101

• Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.

  Cardiovascular diabetology 20110101

• Understanding hypertriglyceridemia in women: clinical impact and management with prescription omega-3-acid ethyl esters.

  International journal of women's health 20110101

• Food protein-stabilized nanoemulsions as potential delivery systems for poorly water-soluble drugs: preparation, in vitro characterization, and pharmacokinetics in rats.

  International journal of nanomedicine 20110101

• Effects of fenofibrate on Semaphorin 6B gene expression in rat skeletal muscle.

  Molecular medicine reports 20110101

• Glycyrrhizic acid attenuates the expression of HMG-CoA reductase mRNA in high fructose diet induced dyslipidemic hamsters.

  Prague medical report 20110101

• The effects of diet-induced obesity on hepatocyte insulin signaling pathways and induction of non-alcoholic liver damage.

  International journal of general medicine 20110101

• Dual acting and pan-PPAR activators as potential anti-diabetic therapies.

  Handbook of experimental pharmacology 20110101

• The role of high-density lipoproteins in reducing the risk of vascular diseases, neurogenerative disorders, and cancer.

  Cholesterol 20110101

• An Increase in Serum Creatinine after Initiation of Fenofibrate in an HIV-Infected Individual: A Case Report and Review of the Literature.

  Journal of the International Association of Physicians in AIDS Care (Chicago, Ill. : 2002) 20110101

• A systems biology approach to dynamic modeling and inter-subject variability of statin pharmacokinetics in human hepatocytes.

  BMC systems biology 20110101

• Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-α agonist treatment.

  Physiological research 20110101

• Long-term use of fenofibrate is associated with increased prevalence of gallstone disease among patients undergoing maintenance hemodialysis.

  Renal failure 20110101

• Traditional chinese medicines in treatment of patients with type 2 diabetes mellitus.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Clinical review: adiponectin biology and its role in inflammation and critical illness.

  Critical care (London, England) 20110101

• Influence of simvastatin, fenofibrate and/or ezetimibe on correlation of low-density lipoprotein and nonhigh-density lipoprotein cholesterol with apolipoprotein B in mixed dyslipidemic patients.

  Journal of clinical lipidology 20110101

• A validated densitometric method for analysis of atorvastatin calcium and metoprolol tartarate as bulk drugs and in combined capsule dosage forms.

  Journal of young pharmacists : JYP 20110101

• Platinum agent-induced hypersensitivity reactions: data mining of the public version of the FDA adverse event reporting system, AERS.

  International journal of medical sciences 20110101

• [Low HDL-cholesterol--an important risk factor for cardiovascular diseases].

  Lijecnicki vjesnik 20110101

• A case of xanthoma disseminatum with spontaneous resolution over 10 years: review of the literature on long-term follow-up.

  Dermatology (Basel, Switzerland) 20110101

• The peroxisome proliferator-activated receptor (PPAR) alpha agonist fenofibrate maintains bone mass, while the PPAR gamma agonist pioglitazone exaggerates bone loss, in ovariectomized rats.

  BMC endocrine disorders 20110101

• Paraoxonase 1 (PON1) polymorphisms, haplotypes and activity in predicting cad risk in North-West Indian Punjabis.

  PloS one 20110101

• Simulation of quality-adjusted survival in chronic diseases: an application in type 2 diabetes.

  Medical decision making : an international journal of the Society for Medical Decision Making 20110101

• HIV and HAART-Associated Dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Malignancy-associated dyslipidemia.

  The open cardiovascular medicine journal 20110101

• Dyslipidaemia of obesity, metabolic syndrome and type 2 diabetes mellitus: the case for residual risk reduction after statin treatment.

  The open cardiovascular medicine journal 20110101

• Myocardial infarction in children: Two interesting cases.

  Annals of pediatric cardiology 20110101

• Antihyperlipidemic effect of Trichilia connaroides in hypercholesterolemic rats and its possible mechanism.

  Journal of pharmacy & bioallied sciences 20110101

• The mechanisms by which lipids coordinately regulate the formation of the protein and lipid domains of the stratum corneum: Role of fatty acids, oxysterols, cholesterol sulfate and ceramides as signaling molecules.

  Dermato-endocrinology 20110101

• Enhanced oral bioavailability of cyclosporine A by liposomes containing a bile salt.

  International journal of nanomedicine 20110101

• Generation of polyclonal antibody with high avidity to rosuvastatin and its use in development of highly sensitive ELISA for determination of rosuvastatin in plasma.

  Chemistry Central journal 20110101

• S-nitrosoglutathione reduces oxidative injury and promotes mechanisms of neurorepair following traumatic brain injury in rats.

  Journal of neuroinflammation 20110101

• Cardiac hypertrophy and fibrosis in the metabolic syndrome: a role for aldosterone and the mineralocorticoid receptor.

  International journal of hypertension 20110101

• Targeting Nuclear Hormone Receptors: PPARα Agonists as Potential Disease-Modifying Drugs for Rheumatoid Arthritis.

  International journal of rheumatology 20110101

• Effects of improving glycemic control with insulin on leptin, adiponectin, ghrelin and neuropeptidey levels in patients with type 2 diabetes mellitus: a pilot study.

  The open cardiovascular medicine journal 20110101

• Profiling circulating and urinary bile acids in patients with biliary obstruction before and after biliary stenting.

  PloS one 20110101

• Aromatase activity and bone loss in men.

  Journal of osteoporosis 20110101

• Treating statin-intolerant patients.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20110101

• Long-term persistance of the pathophysiologic response to severe burn injury.

  PloS one 20110101

• The roles of buyang huanwu decoction in anti-inflammation, antioxidation and regulation of lipid metabolism in rats with myocardial ischemia.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• Scorpion in Combination with Gypsum: Novel Antidiabetic Activities in Streptozotocin-Induced Diabetic Mice by Up-Regulating Pancreatic PPARγ and PDX-1 Expressions.

  Evidence-based complementary and alternative medicine : eCAM 20110101

• A Comparative Study of Mouse Hepatic and Intestinal Gene Expression Profiles under PPARα Knockout by Gene Set Enrichment Analysis.

  PPAR research 20110101

• Liposomes containing glycocholate as potential oral insulin delivery systems: preparation, in vitro characterization, and improved protection against enzymatic degradation.

  International journal of nanomedicine 20110101

• Type 2 diabetes is associated with reduced ATP-binding cassette transporter A1 gene expression, protein and function.

  PloS one 20110101

• Paradoxical regulation of human FGF21 by both fasting and feeding signals: is FGF21 a nutritional adaptation factor?

  PloS one 20110101

• A systems biology strategy for predicting similarities and differences of drug effects: evidence for drug-specific modulation of inflammation in atherosclerosis.

  BMC systems biology 20110101

• Clofibrate relaxes the longitudinal smooth muscle of the mouse distal colon through calcium-mediated desensitisation of contractile machinery.

  Pharmacology 20110101

• Paraoxonase (PON1 and PON3) Polymorphisms: Impact on Liver Expression and Atorvastatin-Lactone Hydrolysis.

  Frontiers in pharmacology 20110101

• Response by sex to statin plus ezetimibe or statin monotherapy: a pooled analysis of 22,231 hyperlipidemic patients.

  Lipids in health and disease 20110101

• Tyrosine kinases in rheumatoid arthritis.

  Journal of inflammation (London, England) 20110101

• Fenofibrate attenuates nicotine-induced vascular endothelial dysfunction in the rat.

  Vascular pharmacology 20110101

• [Possibilities of improvement of prognosis in patients with type 2 diabetes mellitus after coronary interventions].

  Kardiologiia 20110101

• High density lipoprotein structural changes and drug response in lipidomic profiles following the long-term fenofibrate therapy in the FIELD substudy.

  PloS one 20110101

• Incidence of pancreatitis, secondary causes, and treatment of patients referred to a specialty lipid clinic with severe hypertriglyceridemia: a retrospective cohort study.

  Lipids in health and disease 20110101

• Lipid-lowering therapy: who can benefit?

  Vascular health and risk management 20110101

• Consequences of PPAR(α) Invalidation on Glutathione Synthesis: Interactions with Dietary Fatty Acids.

  PPAR research 20110101

• High Sensitivity C - Reactive Protein is Associated with Diastolic Dysfunction in Young African Americans without Clinically Evident Cardiac Disease.

  The open cardiovascular medicine journal 20110101

• Effects and action mechanisms of berberine and Rhizoma coptidis on gut microbes and obesity in high-fat diet-fed C57BL/6J mice.

  PloS one 20110101

• RLIP76, a glutathione-conjugate transporter, plays a major role in the pathogenesis of metabolic syndrome.

  PloS one 20110101

• Soybean glycinin improves HDL-C and suppresses the effects of rosuvastatin on hypercholesterolemic rats.

  Lipids in health and disease 20110101

• Short-term effect of fenofibrate on C-reactive protein: A meta-analysis of randomized controlled trials.

  Diabetology & metabolic syndrome 20110101

• [Perspectives of the use of fenofibrate in patients with type 2 diabetes mellitus: what is new after the ACCORD Study?].

  Kardiologiia 20110101

• Lipid-lowering and antioxidative activities of aqueous extracts of Ocimum sanctum L. leaves in rats fed with a high-cholesterol diet.

  Oxidative medicine and cellular longevity 20110101

• Antioxidant and inflammatory aspects of lipoprotein-associated phospholipase A₂ (Lp-PLA₂): a review.

  Lipids in health and disease 20110101

• Rhabdomyolysis associated with fenofibrate monotherapy in a patient with chronic myelogenous leukemia.

  Case reports in gastroenterology 20110101

• Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement.

  Journal of pharmacy & bioallied sciences 20110101

• Medicinal Chemistry and Actions of Dual and Pan PPAR Modulators.

  The open medicinal chemistry journal 20110101

• Prevalence, Predictors, and Impact of Low High-Density Lipoprotein Cholesterol on in-Hospital Outcomes Among Acute Coronary Syndrome Patients in the Middle East.

  The open cardiovascular medicine journal 20110101

• GW501516, a PPARδ agonist, ameliorates tubulointerstitial inflammation in proteinuric kidney disease via inhibition of TAK1-NFκB pathway in mice.

  PloS one 20110101

• Angiopoietin-like 4 regulates epidermal differentiation.

  PloS one 20110101

• Effects of combination therapy with rosuvastatin and fenofibric acid in patients with mixed dyslipidemia and high-sensitivity C-reactive protein (≥ 2 mg/L). [email protected].

  Journal of clinical lipidology 20110101

• Novel microwell-based spectrophotometric assay for determination of atorvastatin calcium in its pharmaceutical formulations.

  Chemistry Central journal 20110101

• Long-term fenofibrate treatment impaired glucose-stimulated insulin secretion and up-regulated pancreatic NF-kappa B and iNOS expression in monosodium glutamate-induced obese rats: is that a latent disadvantage?

  Journal of translational medicine 20110101

• High-fat meal effect on LDL, HDL, and VLDL particle size and number in the Genetics of Lipid-Lowering Drugs and Diet Network (GOLDN): an interventional study.

  Lipids in health and disease 20110101

• Different impacts of cardiovascular risk factors on oxidative stress.

  International journal of molecular sciences 20110101

• Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure.

  PloS one 20110101

• South Asian Consensus Guidelines for the rational management of diabetes in human immunodeficiency virus/acquired immunodeficiency syndrome.

  Indian journal of endocrinology and metabolism 20110101

• Diagnostic markers based on a computational model of lipoprotein metabolism.

  Journal of clinical bioinformatics 20110101

• Screening for active small molecules in mitochondrial complex I deficient patient's fibroblasts, reveals AICAR as the most beneficial compound.

  PloS one 20110101

• Palmitate-activated macrophages confer insulin resistance to muscle cells by a mechanism involving protein kinase C θ and ε.

  PloS one 20110101

• Stuck at the bench: Potential natural neuroprotective compounds for concussion.

  Surgical neurology international 20110101

• In situ formation of nanocrystals from a self-microemulsifying drug delivery system to enhance oral bioavailability of fenofibrate.

  International journal of nanomedicine 20110101

• Metabolomics of oxidative stress in recent studies of endogenous and exogenously administered intermediate metabolites.

  International journal of molecular sciences 20110101

• Disturbances in body ownership in schizophrenia: evidence from the rubber hand illusion and case study of a spontaneous out-of-body experience.

  PloS one 20110101

• Predicting in vivo anti-hepatofibrotic drug efficacy based on in vitro high-content analysis.

  PloS one 20110101

• Low incidence of paradoxical reductions in HDL-C levels in dyslipidemic patients treated with fenofibrate alone or in combination with ezetimibe or ezetimibe/simvastatin.

  Lipids in health and disease 20110101

• Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.

  Cardiovascular diabetology 20110101

• Toll-like receptor 4 activation in cancer progression and therapy.

  Clinical & developmental immunology 20110101

• Combination therapy with metformin and fenofibrate for insulin resistance in obesity.

  The Journal of international medical research 20110101

• 13-hydroxy linoleic acid increases expression of the cholesterol transporters ABCA1, ABCG1 and SR-BI and stimulates apoA-I-dependent cholesterol efflux in RAW264.7 macrophages.

  Lipids in health and disease 20110101

• Neuroprotective Mechanisms of PPARδ: Modulation of Oxidative Stress and Inflammatory Processes.

  PPAR research 20110101

• Protective effect of lisinopril on hepatic ischemia/reperfusion injury in rats.

  Indian journal of pharmacology 20110101

• Rosiglitazone and fenofibrate additive effects on lipids.

  Cholesterol 20110101

• Nanosuspension: An approach to enhance solubility of drugs.

  Journal of advanced pharmaceutical technology & research 20110101

• N-3 PUFA supplementation triggers PPAR-α activation and PPAR-α/NF-κB interaction: anti-inflammatory implications in liver ischemia-reperfusion injury.

  PloS one 20110101

• A powerful test of parent-of-origin effects for quantitative traits using haplotypes.

  PloS one 20110101

• Atorvastatin and fenofibric acid differentially affect the release of adipokines in the visceral and subcutaneous cultures of adipocytes that were obtained from patients with and without mixed dyslipidemia.

  Pharmacological reports : PR 20110101

• A clustering analysis of lipoprotein diameters in the metabolic syndrome.

  Lipids in health and disease 20110101

• Skeletal effects of the saturated 3-thia Fatty Acid tetradecylthioacetic Acid in rats.

  PPAR research 20110101

• Peroxisome Proliferator-Activated Receptor-α Activation Decreases Mean Arterial Pressure, Plasma Interleukin-6, and COX-2 While Increasing Renal CYP4A Expression in an Acute Model of DOCA-Salt Hypertension.

  PPAR research 20110101

• PPAR-α Agonist Fenofibrate Upregulates Tetrahydrobiopterin Level through Increasing the Expression of Guanosine 5'-Triphosphate Cyclohydrolase-I in Human Umbilical Vein Endothelial Cells.

  PPAR research 20110101

• Involvement of the Retinoid X Receptor Ligand in the Anti-Inflammatory Effect Induced by Peroxisome Proliferator-Activated Receptor γ Agonist In Vivo.

  PPAR research 20110101

• Clinical and functional characterization of URAT1 variants.

  PloS one 20110101

• The peroxisome proliferator-activated receptor: A family of nuclear receptors role in various diseases.

  Journal of advanced pharmaceutical technology & research 20110101

• Association of PPARα Intron 7 Polymorphism with Coronary Artery Disease: A Cross-Sectional Study.

  ISRN cardiology 20110101

• Quantitative estimation of urate transport in nephrons in relation to urinary excretion employing benzbromarone-loading urate clearance tests in cases of hyperuricemia.

  Nephron extra 20110101

• [Current management of gout].

  Acta medica portuguesa 20110101

• Influence of lipid profiles on the risk of hemorrhagic transformation after ischemic stroke: systematic review.

  Cerebrovascular diseases extra 20110101

• Failure to diagnose phaeochromocytoma preoperatively: a case report and review of diagnostic criteria.

  Case reports in anesthesiology 20110101

• [Differentiated approaches to the treatment of chronic pancreatitis patients with metabolic syndrome].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20110101

• Enhanced absorption of the poorly soluble drug fenofibrate by tuning its release rate from ordered mesoporous silica.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20101223

• Fetal bovine serum requirement for pyrrolidine dithiocarbamate-induced apoptotic cell death of MCF-7 breast tumor cells.

  European journal of pharmacology 20101215

• Characterization of the xenobiotic response of Caenorhabditis elegans to the anthelmintic drug albendazole and the identification of novel drug glucoside metabolites.

  The Biochemical journal 20101215

• Using Complementary and Alternative Medicines to Target the Host Response during Severe Influenza.

  Evidence-based complementary and alternative medicine : eCAM 20101201

• Controlled crystallization of the lipophilic drug fenofibrate during freeze-drying: elucidation of the mechanism by in-line Raman spectroscopy.

  The AAPS journal 20101201

• Hypoxia-inducible factor regulates osteoclast-mediated bone resorption: role of angiopoietin-like 4.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20101201

• [Should the treatment of diabetic dyslipidemia be modified after the Action to Control Cardiovascular Risk in Diabetes Lipid study?].

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20101201

• Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.

  Molecular and cellular biochemistry 20101201

• Toxicogenomics and cancer risk assessment: a framework for key event analysis and dose-response assessment for nongenotoxic carcinogens.

  Regulatory toxicology and pharmacology : RTP 20101201

• In vitro evaluation of inhibitory effects of antidiabetic and antihyperlipidemic drugs on human carboxylesterase activities.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• CXCL9 and CXCL11 chemokines modulation by peroxisome proliferator-activated receptor-alpha agonists secretion in Graves' and normal thyrocytes.

  The Journal of clinical endocrinology and metabolism 20101201

• Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.

  Toxicological sciences : an official journal of the Society of Toxicology 20101201

• A predictive ligand-based Bayesian model for human drug-induced liver injury.

  Drug metabolism and disposition: the biological fate of chemicals 20101201

• Heterogeneous postprandial lipoprotein responses in the metabolic syndrome, and response to fenofibrate therapy.

  Cardiovascular drugs and therapy 20101201

• Emergent therapy with therapeutic plasma exchange in acute recurrent pancreatitis due to severe hypertriglyceridemia.

  Transfusion and apheresis science : official journal of the World Apheresis Association : official journal of the European Society for Haemapheresis 20101201

• Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia - a phase 3 study.

  Cardiovascular drugs and therapy 20101201

• Characterisation of fenofibrate dissolution delivered by a self-microemulsifying drug-delivery system.

  The Journal of pharmacy and pharmacology 20101201

• Pharmacoepidemiology safety study of fibrate and statin concomitant therapy.

  The American journal of cardiology 20101201

• [Expression of FXR mRNA, PPAR alpha mRNA and bile acid metabolism related genes in intrahepatic cholestasis of pregnant rats].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20101201

• Long-chain omega-3 polyunsaturated fatty acids may be beneficial for reducing obesity-a review.

  Nutrients 20101201

• Successful drug development despite adverse preclinical findings part 2: examples.

  Journal of toxicologic pathology 20101201

• Retinopathy progression in type 2 diabetes.

  The New England journal of medicine 20101125

• Retinopathy progression in type 2 diabetes.

  The New England journal of medicine 20101125

• Retinopathy progression in type 2 diabetes.

  The New England journal of medicine 20101125

• ACP Journal Club. Intensifying glucose control and adding fenofibrate to simvastatin each reduced progression of retinopathy in type 2 diabetes.

  Annals of internal medicine 20101116

• Catalytic ozonation of fenofibric acid over alumina-supported manganese oxide.

  Journal of hazardous materials 20101115

• Eicosapentaenoic acid improves hepatic steatosis independent of PPARα activation through inhibition of SREBP-1 maturation in mice.

  Biochemical pharmacology 20101115

• Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials.

  Lancet (London, England) 20101113

• Chronic treatment with fibrates elevates superoxide dismutase in adult mouse brain microvessels.

  Brain research 20101104

• [Effects of fenofibrate on the expression of peroxisome proliferator-activated-gamma coactivator-1α in skeletal muscle of rats infused with intralipid].

  Zhonghua yi xue za zhi 20101102

• Fenofibrate but not fenofibric acid inhibits 11beta-hydroxysteroid dehydrogenase 1 in C2C12 myotubes.

  Molecular and cellular biochemistry 20101101

• Influence of peroxisome proliferator-activated receptor-alpha (PPARα) activity on adverse effects associated with amiodarone exposure in mice.

  Pharmacological research 20101101

• Peroxisome proliferator-activated receptor {alpha} agonism prevents renal damage and the oxidative stress and inflammatory processes affecting the brains of stroke-prone rats.

  The Journal of pharmacology and experimental therapeutics 20101101

• The effect of fenofibrate on lymphocyte cytokine release in patients with impaired fasting glucose and impaired glucose tolerance: a preliminary report.

  Atherosclerosis 20101101

• Apolipoprotein B genetic variants modify the response to fenofibrate: a GOLDN study.

  Journal of lipid research 20101101

• Leptin induces hypertrophy through activating the peroxisome proliferator-activated receptor α pathway in cultured neonatal rat cardiomyocytes.

  Clinical and experimental pharmacology & physiology 20101101

• Synthesis and SAR studies of 1,4-benzoxazine MenB inhibitors: novel antibacterial agents against Mycobacterium tuberculosis.

  Bioorganic & medicinal chemistry letters 20101101

• Optimal pharmacologic approach to patients with hypertriglyceridemia and low high-density lipoprotein-cholesterol: randomized comparison of fenofibrate 160 mg and niacin 1500 mg.

  Atherosclerosis 20101101

• Regression to normoglycaemia by fenofibrate in pre-diabetic subjects complicated with hypertriglyceridaemia: a prospective randomized controlled trial.

  Diabetic medicine : a journal of the British Diabetic Association 20101101

• Cardiovascular disease and glycemic treatment.

  Diabetes care 20101101

• Human health risk assessment of pharmaceuticals in water: issues and challenges ahead.

  International journal of environmental research and public health 20101101

• Diabetes & coronary heart disease: current perspectives.

  The Indian journal of medical research 20101101

• Targeting tumor angiogenesis with TSP-1-based compounds: rational design of antiangiogenic mimetics of endogenous inhibitors.

  Oncotarget 20101101

• Combination of fenofibrate and rosiglitazone synergistically ameliorate dyslipidemia and insulin resistance in mice with MSG metabolic syndrome.

  Yao xue xue bao = Acta pharmaceutica Sinica 20101101

• [Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study].

  Nihon rinsho. Japanese journal of clinical medicine 20101101

• The DOCA-Salt Hypertensive Rat as a Model of Cardiovascular Oxidative and Inflammatory Stress.

  Current cardiology reviews 20101101

• Mixed messages on systemic therapies for diabetic retinopathy.

  Lancet (London, England) 20101030

• Spatiotemporal distribution of pharmaceuticals in the Douro River estuary (Portugal).

  The Science of the total environment 20101015

• Unmetabolized fenofibrate, but not fenofibric acid, activates AMPK and inhibits the expression of phosphoenolpyruvate carboxykinase in hepatocytes.

  Life sciences 20101009

• Could the sonographic characterization of carotid plaque improve the surrogacy of intima-media thickness for vascular outcomes?

  International journal of cardiology 20101008

• The effect of fenofibrate on HDL cholesterol and HDL particle concentration in postmenopausal women on tibolone therapy.

  Clinical endocrinology 20101001

• Pleiotropic effects of atorvastatin and fenofibrate in metabolic syndrome and different types of pre-diabetes.

  Diabetes care 20101001

• Fenofibrate promotes ischemia-induced revascularization through the adiponectin-dependent pathway.

  American journal of physiology. Endocrinology and metabolism 20101001

• Apolipoprotein E polymorphisms and postprandial triglyceridemia before and after fenofibrate treatment in the Genetics of Lipid Lowering and Diet Network (GOLDN) Study.

  Circulation. Cardiovascular genetics 20101001

• IVIVC for fenofibrate immediate release tablets using solubility and permeability as in vitro predictors for pharmacokinetics.

  Journal of pharmaceutical sciences 20101001

• Combination of fenofibrate with non-statin drug regimens.

  Current pharmaceutical design 20101001

• Efficacy and safety of fenofibric acid in combination with atorvastatin and ezetimibe in patients with mixed dyslipidemia.

  American heart journal 20101001

• Combination rosuvastatin plus fenofibric acid in a cohort of patients 65 years or older with mixed dyslipidemia: subanalysis of two randomized, controlled studies.

  Clinical cardiology 20101001

• Progression of retinopathy in persons with type 2 diabetes: new data, same conclusions?

  Polskie Archiwum Medycyny Wewnetrznej 20101001

• [Observation on the effect of the catgut implantation treatment for obesity hypertriglyceridemia].

  Zhongguo zhen jiu = Chinese acupuncture & moxibustion 20101001

• The role of a new formulation of fenofibric acid in the treatment of mixed dyslipidemia in type 2 diabetes.

  Drugs of today (Barcelona, Spain : 1998) 20101001

• IVIVR in oral absorption for fenofibrate immediate release tablets using dissolution and dissolution permeation methods.

  Die Pharmazie 20101001

• Efficacy and safety of adding fenofibrate 160 mg in high-risk patients with mixed hyperlipidemia not controlled by pravastatin 40 mg monotherapy.

  The American journal of cardiology 20100915

• Fenofibrate, homocysteine and renal function.

  Current vascular pharmacology 20100901

• Ability of traditional lipid ratios and apolipoprotein ratios to predict cardiovascular risk in people with type 2 diabetes.

  Diabetologia 20100901

• The effects of fenofibric acid alone and with statins on the prevalence of metabolic syndrome and its diagnostic components in patients with mixed dyslipidemia.

  Diabetes care 20100901

• Plasma PCSK9 is increased by fenofibrate and atorvastatin in a non-additive fashion in diabetic patients.

  Atherosclerosis 20100901

• Fibrate therapy in the management of diabetic dyslipidemia: there is no ACCORD to be found.

  Current atherosclerosis reports 20100901

• Fenofibrate concomitantly decreases serum proprotein convertase subtilisin/kexin type 9 and very-low-density lipoprotein particle concentrations in statin-treated type 2 diabetic patients.

  Diabetes, obesity & metabolism 20100901

• The novel role of fenofibrate in preventing nicotine- and sodium arsenite-induced vascular endothelial dysfunction in the rat.

  Cardiovascular toxicology 20100901

• Preparation of fenofibrate immediate-release tablets involving wet grinding for improved bioavailability.

  Drug development and industrial pharmacy 20100901

• [Multirisk approach of the type 2 diabetic patient: controversies surrounding target values after the ACCORD trial].

  Revue medicale suisse 20100901

• [Clinical study of the month. Accord-lipid and accord-eye: towards a new positioning of fenofibrate in the management of type 2 diabetes].

  Revue medicale de Liege 20100901

• Abstracts of the 5(th) Cachexia Conference, Barcelona, Spain, December 5-8, 2009.

  Journal of cachexia, sarcopenia and muscle 20100901

• The frequency and severity of capecitabine-induced hypertriglyceridaemia in routine clinical practice: a prospective study.

  British journal of cancer 20100824

• Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

  Circulation 20100824

• Fenofibrate increases very low density lipoprotein triglyceride production despite reducing plasma triglyceride levels in APOE*3-Leiden.CETP mice.

  The Journal of biological chemistry 20100813

• Combination lipid therapy in type 2 diabetes.

  The New England journal of medicine 20100812

• Combination lipid therapy in type 2 diabetes.

  The New England journal of medicine 20100812

• Combination lipid therapy in type 2 diabetes.

  The New England journal of medicine 20100812

• Comparison of the gastrointestinal absorption and bioavailability of fenofibrate and fenofibric acid in humans.

  Journal of clinical pharmacology 20100801

• Implications of the ACCORD lipid study: perspective from the Residual Risk Reduction Initiative (R(3)i).

  Current medical research and opinion 20100801

• Fenofibrate induces effective apoptosis in mantle cell lymphoma by inhibiting the TNFalpha/NF-kappaB signaling axis.

  Leukemia 20100801

• Management of hypertriglyceridemia in the diabetic patient.

  Current diabetes reports 20100801

• Biorelevant media simulating fed state intestinal fluids: colloid phase characterization and impact on solubilization capacity.

  Journal of pharmaceutical sciences 20100801

• PPARalpha: an emerging therapeutic target in diabetic microvascular damage.

  Nature reviews. Endocrinology 20100801

• Fenofibrate in the treatment of dyslipidemia associated with HIV infection.

  Expert opinion on drug metabolism & toxicology 20100801

• Fibrates: no ACCORD on their use in the treatment of dyslipidaemia.

  Current opinion in lipidology 20100801

• AMPK enhances the expression of pancreatic duodenal homeobox-1 via PPARalpha, but not PPARgamma, in rat insulinoma cell line INS-1.

  Acta pharmacologica Sinica 20100801

• World Congress on the insulin resistance syndrome, 2009: cellular mechanisms of insulin resistance.

  Diabetes care 20100801

• Are individuals with diabetes seeing better?: a long-term epidemiological perspective.

  Diabetes 20100801

• Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.

  DukeMedicine healthnews 20100801

• [The significance of fenofibrate in the therapy of atherogenic dyslipoproteinaemia].

  Vnitrni lekarstvi 20100801

• Therapeutics. Fenofibrate plus simvastatin did not prevent major CV events more than simvastatin alone in type 2 diabetes.

  Annals of internal medicine 20100720

• Reduction in risk of progression of diabetic retinopathy.

  The New England journal of medicine 20100715

• Effects of medical therapies on retinopathy progression in type 2 diabetes.

  The New England journal of medicine 20100715

• The modulatory mechanisms of fenofibrate on human primary T cells.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20100711

• Synthesis and hypolipidemic activity of novel 2-(4-(2-substituted aminothiazole-4-yl) phenoxy) acetic acid derivatives.

  European journal of medicinal chemistry 20100701

• Advancing therapy for hypercholesterolemia.

  Expert opinion on pharmacotherapy 20100701

• 2009 World Congress on the Insulin Resistance Syndrome: cardiovascular disease concepts.

  Diabetes care 20100701

• Treatment with pravastatin and fenofibrate improves atherogenic lipid profiles but not inflammatory markers in ACTG 5087.

  Journal of clinical lipidology 20100701

• Fenofibrate reduces postprandial hypertriglyceridemia in CD36 knockout mice.

  Journal of atherosclerosis and thrombosis 20100630

• The low dose combination of fenofibrate and rosiglitazone halts the progression of diabetes-induced experimental nephropathy.

  European journal of pharmacology 20100625

• [Treatments for cardiovascular risk factors and screening for coronary artery disease in type 2 diabetes mellitus].

  Revue medicale suisse 20100609

• Role of Esrrg in the fibrate-mediated regulation of lipid metabolism genes in human ApoA-I transgenic mice.

  The pharmacogenomics journal 20100601

• Targeting apoptosis in the heart of streptozotocin-induced diabetic rats.

  Journal of cardiovascular pharmacology and therapeutics 20100601

• In vitro and in vivo evaluation of fenofibrate solid dispersion prepared by hot-melt extrusion.

  Drug development and industrial pharmacy 20100601

• A comparative study of anti-inflammatory and antidyslipidemic effects of fenofibrate and statins on rheumatoid arthritis.

  Modern rheumatology 20100601

• Selective CETP inhibition and PPARalpha agonism increase HDL cholesterol and reduce LDL cholesterol in human ApoB100/human CETP transgenic mice.

  Journal of cardiovascular pharmacology and therapeutics 20100601

• Paradoxical decrease in high-density lipoprotein cholesterol with fenofibrate: a quite rare phenomenon indeed.

  Cardiovascular therapeutics 20100601

• Acyl-CoA-binding protein 2 binds lysophospholipase 2 and lysoPC to promote tolerance to cadmium-induced oxidative stress in transgenic Arabidopsis.

  The Plant journal : for cell and molecular biology 20100601

• Effect of fenofibrate therapy and ABCA1 polymorphisms on high-density lipoprotein subclasses in the Genetics of Lipid Lowering Drugs and Diet Network.

  Molecular genetics and metabolism 20100601

• Effect of fenofibrate and niacin on intrahepatic triglyceride content, very low-density lipoprotein kinetics, and insulin action in obese subjects with nonalcoholic fatty liver disease.

  The Journal of clinical endocrinology and metabolism 20100601

• Hotline update of clinical trials and registries presented at the American College of Cardiology Congress 2010: ACCORD, INVEST, NAVIGATOR, RACE II, SORT OUT III, CSP-474, DOSE, ASPIRE and more.

  Clinical research in cardiology : official journal of the German Cardiac Society 20100601

• Fenofibrate and metabolic syndrome.

  Endocrine, metabolic & immune disorders drug targets 20100601

• Update on antithrombotic therapy for stroke prevention in atrial fibrillation.

  Current treatment options in cardiovascular medicine 20100601

• Acute renal failure with the combined use of rosuvastatin and fenofibrate.

  Renal failure 20100601

• Neuropathy, retinopathy, and glucose-lowering treatments.

  Diabetes care 20100601

• Activation of PPARalpha Attenuates IFNgamma and IL-1beta-induced Cell Proliferation in Astrocytes: Involvement of IL-6 Independent Pathway.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20100601

• Effect of a Large Dose of Di (2-ethylhexyl) phthalate (DEHP) on Hepatic Peroxisome in Cynomolgus Monkeys (Macaca Fascicularis).

  Journal of toxicologic pathology 20100601

• Colloid formation by drugs in simulated intestinal fluid.

  Journal of medicinal chemistry 20100527

• Fenofibrate antagonizes Chk2 activation by inducing Wip1 expression: implications for cell proliferation and tumorigenesis.

  Life sciences 20100508

• Triglyceride-mediated pathways and coronary disease: collaborative analysis of 101 studies.

  Lancet (London, England) 20100508

• High endoplasmic reticulum activity renders multiple myeloma cells hypersensitive to mitochondrial inhibitors.

  Cancer chemotherapy and pharmacology 20100501

• Peroxisome proliferator-activated receptor ligands reduce aortic dilatation in a mouse model of aortic aneurysm.

  Atherosclerosis 20100501

• Effects of rimonabant, as monotherapy and in combination with fenofibrate or ezetimibe, on plasma adipokine levels: a pilot study.

  Angiology 20100501

• Establishment of a methodology for investigating protectants against ethanol-induced hepatotoxicity.

  Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association 20100501

• Caveolin-1 is enriched in the peroxisomal membrane of rat hepatocytes.

  Hepatology (Baltimore, Md.) 20100501

• Effect of ezetimibe on hepatic fat, inflammatory markers, and apolipoprotein B-100 kinetics in insulin-resistant obese subjects on a weight loss diet.

  Diabetes care 20100501

• Proof of concept study: does fenofibrate have a role in sleep apnoea syndrome?

  Current medical research and opinion 20100501

• The in vitro response of human retinal endothelial cells to cytokines and other chemically active agents is altered by coculture with vitreous-derived hyalocytes.

  Acta ophthalmologica 20100501

• Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial.

  Diabetes care 20100501

• Differing short-term neuroprotective effects of the fibrates fenofibrate and bezafibrate in MPTP and 6-OHDA experimental models of Parkinson's disease.

  Behavioural pharmacology 20100501

• Overexpression of Arabidopsis acyl-CoA binding protein ACBP3 promotes starvation-induced and age-dependent leaf senescence.

  The Plant cell 20100501

• Comparative analysis of fat and muscle proteins in fenofibrate-fed type II diabetic OLETF rats: the fenofibrate-dependent expression of PEBP or C11orf59 protein.

  BMB reports 20100501

• Impact of Fenofibrate on Type 2 Diabetes Patients with Features of the Metabolic Syndrome: Subgroup Analysis From FIELD.

  Current cardiology reviews 20100501

• Effects of combination lipid therapy in type 2 diabetes mellitus.

  The New England journal of medicine 20100429

• ACCORD and Risk-Factor Control in Type 2 Diabetes.

  The New England journal of medicine 20100429

• Determination of pharmaceuticals in soils and sediments by pressurized liquid extraction and liquid chromatography tandem mass spectrometry.

  Journal of chromatography. A 20100416

• PPARalpha agonist fenofibrate protects the kidney from hypertensive injury in spontaneously hypertensive rats via inhibition of oxidative stress and MAPK activity.

  Biochemical and biophysical research communications 20100409

• Discovery of an oxybenzylglycine based peroxisome proliferator activated receptor alpha selective agonist 2-((3-((2-(4-chlorophenyl)-5-methyloxazol-4-yl)methoxy)benzyl)(methoxycarbonyl)amino)acetic acid (BMS-687453).

  Journal of medicinal chemistry 20100408

• Ligand-enhanced expression and in-cell assay of human peroxisome proliferator-activated receptor alpha ligand binding domain.

  Protein expression and purification 20100401

• Regulatory role for phosphatidylcholine transfer protein/StarD2 in the metabolic response to peroxisome proliferator activated receptor alpha (PPARalpha).

  Biochimica et biophysica acta 20100401

• The prostacyclin analog beraprost sodium ameliorates characteristics of metabolic syndrome in obese Zucker (fatty) rats.

  Diabetes 20100401

• Effect of intensive compared with standard glycemia treatment strategies on mortality by baseline subgroup characteristics: the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

  Diabetes care 20100401

• Fibrate therapy in the management of dyslipidemias, alone and in combination with statins: role of delayed-release fenofibric acid.

  Expert opinion on pharmacotherapy 20100401

• Advances in the treatment of diabetic retinopathy.

  Discovery medicine 20100401

• Fenofibrate Reduces Age-related Hypercholesterolemia in Normal Rats on a Standard Diet.

  The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology 20100401

• [Recombinant cIL-18-binding protein as an antagonist to cIL-18 enhanced PBMCs secreting IFN-gamma].

  Wei sheng wu xue bao = Acta microbiologica Sinica 20100401

• [Problems with statins and the marketing of these medications].

  Revista medica de Chile 20100401

• Intrahepatic cholesterol influences progression, inhibition and reversal of non-alcoholic steatohepatitis in hyperlipidemic mice.

  FEBS letters 20100305

• PPARalpha and PPARgamma are co-expressed, functional and show positive interactions in the rat urinary bladder urothelium.

  Journal of applied toxicology : JAT 20100301

• Molecular dynamics study of the encapsulation capability of a PCL-PEO based block copolymer for hydrophobic drugs with different spatial distributions of hydrogen bond donors and acceptors.

  Biomaterials 20100301

• Management of dyslipidemia in people with type 2 diabetes mellitus.

  Reviews in endocrine & metabolic disorders 20100301

• Fenofibrate attenuates tubulointerstitial fibrosis and inflammation through suppression of nuclear factor-κB and transforming growth factor-β1/Smad3 in diabetic nephropathy.

  Experimental biology and medicine (Maywood, N.J.) 20100301

• [Establishment of a model for evaluating hypolipidemic effect in HepG2 cells].

  Wei sheng yan jiu = Journal of hygiene research 20100301

• Steroid assays in paediatric endocrinology.

  Journal of clinical research in pediatric endocrinology 20100301

• Potential health-modulating effects of isoflavones and metabolites via activation of PPAR and AhR.

  Nutrients 20100301

• Fenofibrate improves endothelial function in the brachial artery and forearm resistance arterioles of statin-treated Type 2 diabetic patients.

  Clinical science (London, England : 1979) 20100223

• Fenofibrate treatment increases human serum proprotein convertase subtilisin kexin type 9 levels.

  Journal of lipid research 20100201

• Effects of long-term fenofibrate treatment on markers of renal function in type 2 diabetes: the FIELD Helsinki substudy.

  Diabetes care 20100201

• Aspirin inhibits MMP-9 mRNA expression and release via the PPARalpha/gamma and COX-2/mPGES-1-mediated pathways in macrophages derived from THP-1 cells.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20100201

• Effects of walnut consumption on endothelial function in type 2 diabetic subjects: a randomized controlled crossover trial.

  Diabetes care 20100201

• Fenofibrate reduces systemic inflammation markers independent of its effects on lipid and glucose metabolism in patients with the metabolic syndrome.

  The Journal of clinical endocrinology and metabolism 20100201

• Proteomics analysis of cardiac muscle from rats with peroxisomal proliferator-activated receptor alpha (PPARalpha) stimulation.

  The Journal of toxicological sciences 20100201

• [HDL cholesterol reduction during rosiglitazone and fenofibrate treatment in a type 2 diabetes mellitus patient with dyslipidemia].

  The Korean journal of laboratory medicine 20100201

• Is fenofibrate a cost-saving treatment for middle-aged individuals with type 2 diabetes? A South African private-sector perspective.

  Cardiovascular journal of Africa 20100201

• Low-abundant adiponectin receptors in visceral adipose tissue of humans and rats are further reduced in diabetic animals.

  Archives of medical research 20100201

• Trace determination of pharmaceuticals and other wastewater-derived micropollutants by solid phase extraction and gas chromatography/mass spectrometry.

  Journal of chromatography. A 20100122

• Concerns about heparin therapy for hypertriglyceridemia.

  Archives of internal medicine 20100111

• Ecotoxicity assessment of lipid regulators in water and biologically treated wastewater using three aquatic organisms.

  Environmental science and pollution research international 20100101

• The role of hyperglycemia in burned patients: evidence-based studies.

  Shock (Augusta, Ga.) 20100101

• Fenofibrate improves cerebral blood flow after middle cerebral artery occlusion in mice.

  Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism 20100101

• Role of PPARs in Radiation-Induced Brain Injury.

  PPAR research 20100101

• Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  European heart journal 20100101

• Cholesteryl ester transfer protein: at the heart of the action of lipid-modulating therapy with statins, fibrates, niacin, and cholesteryl ester transfer protein inhibitors.

  European heart journal 20100101

• Residual microvascular risk in diabetes: unmet needs and future directions.

  Nature reviews. Endocrinology 20100101

• Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.

  European journal of clinical investigation 20100101

• Year two assessment of fenofibric acid and moderate-dose statin combination: a phase 3, open-label, extension study.

  Clinical drug investigation 20100101

• Regulation of oligodendrocyte progenitor cell maturation by PPARδ: effects on bone morphogenetic proteins.

  ASN neuro 20100101

• Medicinal chemistry of drugs used in diabetic cardiomyopathy.

  Current medicinal chemistry 20100101

• Evaluation of an hPXR reporter gene assay for the detection of aquatic emerging pollutants: screening of chemicals and application to water samples.

  Analytical and bioanalytical chemistry 20100101

• PPARs in Irradiation-Induced Gastrointestinal Toxicity.

  PPAR research 20100101

• Standards of medical care in diabetes--2010.

  Diabetes care 20100101

• An integrated functional genomic study of acute phenobarbital exposure in the rat.

  BMC genomics 20100101

• Paradoxical severe decrease in high-density lipoprotein cholesterol due to rosiglitazone-fenofibrate interaction.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20100101

• The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.

  BMJ (Clinical research ed.) 20100101

• A novel method to adjust efficacy estimates for uptake of other active treatments in long-term clinical trials.

  PloS one 20100101

• Effect of fenofibrate on uric acid metabolism and urate transporter 1.

  Internal medicine (Tokyo, Japan) 20100101

• Rosuvastatin-associated adverse effects and drug-drug interactions in the clinical setting of dyslipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Ramipril mitigates radiation-induced impairment of neurogenesis in the rat dentate gyrus.

  Radiation oncology (London, England) 20100101

• Role of platelets in neuroinflammation: a wide-angle perspective.

  Journal of neuroinflammation 20100101

• Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Management of hyperuricemia in gout: focus on febuxostat.

  Clinical interventions in aging 20100101

• Perturbation of lipids and glucose metabolism associated with previous 2,4-D exposure: a cross-sectional study of NHANES III data, 1988-1994.

  Environmental health : a global access science source 20100101

• Effect of glitazones on the progression of coronary artery disease in type 2 diabetes patients.

  Vascular health and risk management 20100101

• Anticancer Role of PPARgamma Agonists in Hematological Malignancies Found in the Vasculature, Marrow, and Eyes.

  PPAR research 20100101

• Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, improves hepatic microcirculatory patency and oxygen availability in a high-fat-diet-induced fatty liver in mice.

  Advances in experimental medicine and biology 20100101

• Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists induce constitutive androstane receptor (CAR) and cytochrome P450 2B in rat primary hepatocytes.

  Drug metabolism and pharmacokinetics 20100101

• Current status and future directions in lipid management: emphasizing low-density lipoproteins, high-density lipoproteins, and triglycerides as targets for therapy.

  Vascular health and risk management 20100101

• Low-density lipoprotein particle size in hepatic steatosis and metabolic syndrome.

  Diabetology & metabolic syndrome 20100101

• Metabolic and monocyte-suppressing actions of fenofibrate in patients with mixed dyslipidemia and early glucose metabolism disturbances.

  Pharmacological reports : PR 20100101

• LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.

  Preventive cardiology 20100101

• Mechanical and electrophysiological properties of the sarcolemma of muscle fibers in two murine models of muscle dystrophy: col6a1-/- and mdx.

  Journal of biomedicine & biotechnology 20100101

• Cardiovascular computed tomographic assessment of the effect of combination lipoprotein therapy on coronary arterial plaque: rationale and design of the AFRICA (Atorvastatin plus Fenofibric acid in the Reduction of Intermediate Coronary Atherosclerosis) study.

  Journal of cardiovascular computed tomography 20100101

• PPARalpha: energy combustion, hypolipidemia, inflammation and cancer.

  Nuclear receptor signaling 20100101

• Involvement of cytoskeleton in orientation of cell division in contact guided cells.

  Folia biologica 20100101

• Association and interaction of PPAR-complex gene variants with latent traits of left ventricular diastolic function.

  BMC medical genetics 20100101

• Peroxisome proliferator-activated receptor alpha and alpha/gamma agonists do not cause impairment in renal function in the rat.

  Nephron. Physiology 20100101

• Chitosan based polyelectrolyte complexes as potential carrier materials in drug delivery systems.

  Marine drugs 20100101

• Aqueous cinnamon extract (ACE-c) from the bark of Cinnamomum cassia causes apoptosis in human cervical cancer cell line (SiHa) through loss of mitochondrial membrane potential.

  BMC cancer 20100101

• Anti-obesity effect of an isoflavone fatty acid ester on obese mice induced by high fat diet and its potential mechanism.

  Lipids in health and disease 20100101

• Nutrigenomics therapy of hepatisis C virus induced-hepatosteatosis.

  BMC gastroenterology 20100101

• Vaticanol C, a resveratrol tetramer, activates PPARalpha and PPARbeta/delta in vitro and in vivo.

  Nutrition & metabolism 20100101

• How to translate therapeutic recommendations in clinical practice guidelines into rules for critiquing physician prescriptions? Methods and application to five guidelines.

  BMC medical informatics and decision making 20100101

• Modulation of LPS-mediated inflammation by fenofibrate via the TRIF-dependent TLR4 signaling pathway in vascular smooth muscle cells.

  Cellular physiology and biochemistry : international journal of experimental cellular physiology, biochemistry, and pharmacology 20100101

• Efficacy and safety of rosuvastatin and fenofibric acid combination therapy versus simvastatin monotherapy in patients with hypercholesterolemia and hypertriglyceridemia: a randomized, double-blind study.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20100101

• Effect of lipopenic and hypotensive treatment on homocysteine levels in type 2 diabetics.

  Vascular health and risk management 20100101

• Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia.

  Vascular health and risk management 20100101

• ACCORD LIPID study results strengthen guideline approach of adding fenofibrate to therapy of dyslipidaemic type 2 diabetic patients.

  Cardiovascular journal of Africa 20100101

• Influence of demographic and metabolic variables on forearm blood flow and vascular conductance in individuals without overt heart disease.

  Vascular health and risk management 20100101

• Modified intention to treat reporting in randomised controlled trials: systematic review.

  BMJ (Clinical research ed.) 20100101

• 'If it ain't broke, don't fix it': a commentary on the positive-negative results of the ACCORD Lipid study.

  Cardiovascular diabetology 20100101

• Fenofibrate in primary biliary cirrhosis: a pilot study.

  The open cardiovascular medicine journal 20100101

• ROS accumulation and IGF-IR inhibition contribute to fenofibrate/PPARalpha -mediated inhibition of glioma cell motility in vitro.

  Molecular cancer 20100101

• The efficacy and safety of insulin-sensitizing drugs in HIV-associated lipodystrophy syndrome: a meta-analysis of randomized trials.

  BMC infectious diseases 20100101

• [Acute cholestatic hepatitis probably due to fenofibrate].

  Therapie 20100101

• PPARs in the Renal Regulation of Systemic Blood Pressure.

  PPAR research 20100101

• Various Terpenoids Derived from Herbal and Dietary Plants Function as PPAR Modulators and Regulate Carbohydrate and Lipid Metabolism.

  PPAR research 20100101

• Use of statin therapy to reduce cardiovascular risk in older patients.

  Current gerontology and geriatrics research 20100101

• Preventive effects of chronic exogenous growth hormone levels on diet-induced hepatic steatosis in rats.

  Lipids in health and disease 20100101

• A subset of osteoblasts expressing high endogenous levels of PPARgamma switches fate to adipocytes in the rat calvaria cell culture model.

  PloS one 20100101

• PPAR-alpha Contributes to the Anti-Inflammatory Activity of Verbascoside in a Model of Inflammatory Bowel Disease in Mice.

  PPAR research 20100101

• Effects of Endogenous PPAR Agonist Nitro-Oleic Acid on Metabolic Syndrome in Obese Zucker Rats.

  PPAR research 20100101

• Molecular Characterization of the Onset and Progression of Colitis in Inoculated Interleukin-10 Gene-Deficient Mice: A Role for PPARalpha.

  PPAR research 20100101

• Impact of medical therapy on atheroma volume measured by different cardiovascular imaging modalities.

  Cardiology research and practice 20100101

• Fish oil for the treatment of cardiovascular disease.

  Cardiology in review 20100101

• Oxidative stress and autophagy in cardiac disease, neurological disorders, aging and cancer.

  Oxidative medicine and cellular longevity 20100101

• Metabolic syndrome, dyslipidemia, hypertension and type 2 diabetes in youth: from diagnosis to treatment.

  Diabetology & metabolic syndrome 20100101

• Management of dyslipidemias with fibrates, alone and in combination with statins: role of delayed-release fenofibric acid.

  Vascular health and risk management 20100101

• Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors.

  Cardiovascular diabetology 20100101

• Rhabdomyolysis-induced acute renal failure following fenofibrate therapy: a case report and literature review.

  Case reports in medicine 20100101

• Coactivators in PPAR-Regulated Gene Expression.

  PPAR research 20100101

• AMPK-Dependent Metabolic Regulation by PPAR Agonists.

  PPAR research 20100101

• Therapeutic Implications of PPARgamma in Cardiovascular Diseases.

  PPAR research 20100101

• Lack of association between peroxisome proliferator-activated receptors alpha and gamma2 polymorphisms and progressive liver damage in patients with non-alcoholic fatty liver disease: a case control study.

  BMC gastroenterology 20100101

• Synergism in hyperhomocysteinemia and diabetes: role of PPAR gamma and tempol.

  Cardiovascular diabetology 20100101

• [Lipid lowering, antiinflammatory, and vasoprotective effects of fenofibrate in patients with type 2 diabetes mellitus].

  Kardiologiia 20100101

• Peroxisome proliferator-activated receptors (PPARs)-independent functions of fish oil on glucose and lipid metabolism in diet-induced obese mice.

  Lipids in health and disease 20100101

• The Role of PPARα Activation in Liver and Muscle.

  PPAR research 20100101

• Vascular cellular adhesion molecule-1 (VCAM-1) expression in mice retinal vessels is affected by both hyperglycemia and hyperlipidemia.

  PloS one 20100101

• Atherogenic dyslipidemia and diabetes mellitus: what's new in the management arena?

  Vascular health and risk management 20100101

• Electrocardiographic changes with the onset of diabetes and the impact of aerobic exercise training in the Zucker Diabetic Fatty (ZDF) rat.

  Cardiovascular diabetology 20100101

• Peroxisome Proliferator-Activated Receptors Protect against Apoptosis via 14-3-3.

  PPAR research 20100101

• Role of fenofibrate alone and in combination with telmisartan on renal ischemia/reperfusion injury.

  Renal failure 20100101

• PPARα in Obesity: Sex Difference and Estrogen Involvement.

  PPAR research 20100101

• PPARs in Rhythmic Metabolic Regulation and Implications in Health and Disease.

  PPAR research 20100101

• Methods of chromatographic determination of medicines decreasing the level of cholesterol.

  Acta poloniae pharmaceutica 20100101

• Decreased fat storage by Lactobacillus paracasei is associated with increased levels of angiopoietin-like 4 protein (ANGPTL4).

  PloS one 20100101

• Role of PPARα in Hepatic Carbohydrate Metabolism.

  PPAR research 20100101

• Peroxisome proliferator-activated receptor alpha target genes.

  PPAR research 20100101

• Gene Expression Profiling in Wild-Type and PPARα-Null Mice Exposed to Perfluorooctane Sulfonate Reveals PPARα-Independent Effects.

  PPAR research 20100101

• Effects of the PPARα Agonist and Widely Used Antihyperlipidemic Drug Gemfibrozil on Hepatic Toxicity and Lipid Metabolism.

  PPAR research 20100101

• Effects of fenofibrate on lipid profiles, cholesterol ester transfer activity, and in-stent intimal hyperplasia in patients after elective coronary stenting.

  Lipids in health and disease 20100101

• Improvement on lipid metabolic disorder by 3'-deoxyadenosine in high-fat-diet-induced fatty mice.

  The American journal of Chinese medicine 20100101

• The effect of combination therapy of allicin and fenofibrate on high fat diet-induced vascular endothelium dysfunction and liver damage in rats.

  Lipids in health and disease 20100101

• Role of PPARα and Its Agonist in Renal Diseases.

  PPAR research 20100101

• Lipid control and use of lipid-regulating drugs for prevention of cardiovascular events in Chinese type 2 diabetic patients: a prospective cohort study.

  Cardiovascular diabetology 20100101

• Prevalence of lipid abnormalities before and after introduction of lipid modifying therapy among Swedish patients with dyslipidemia (PRIMULA).

  BMC public health 20100101

• Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers.

  Arzneimittel-Forschung 20100101

• Are post-treatment low-density lipoprotein subclass pattern analyses potentially misleading?

  Lipids in health and disease 20100101

• Combination therapy of statin and ezetimibe for the treatment of familial hypercholesterolemia.

  Vascular health and risk management 20100101

• Low high-density lipoprotein cholesterol: current status and future strategies for management.

  Vascular health and risk management 20100101

• Prevention of diabetic eye disease: the commonest cause of blindness in individuals younger than 65 years.

  Clinical ophthalmology (Auckland, N.Z.) 20100101

• log(TG)/HDL-C is related to both residual cardiometabolic risk and β-cell function loss in type 2 diabetes males.

  Cardiovascular diabetology 20100101

• Treatment of dyslipidemia in patients with type 2 diabetes.

  Lipids in health and disease 20100101

• Recent advances in preventing cardiovascular disorders by managing lipid levels.

  F1000 medicine reports 20100101

• Simultaneous quantitative determination of metoprolol, atorvastatin and ramipril in capsules by a validated stability-indicating RP-UPLC method.

  Scientia pharmaceutica 20100101

• High density lipoproteins-based therapies for cardiovascular disease.

  Journal of cardiovascular disease research 20100101

• Optimal management of familial hypercholesterolemia: treatment and management strategies.

  Vascular health and risk management 20100101

• Two siblings with familial chylomicronemia syndrome: disease course and effectiveness of early treatment.

  Case reports in medicine 20100101

• Regulation of Immune Responses and Autoimmune Encephalomyelitis by PPARs.

  PPAR research 20100101

• Fenofibrate treatment enhances antioxidant status and attenuates endothelial dysfunction in streptozotocin-induced diabetic rats.

  Experimental diabetes research 20100101

• WY-14643, a Potent Peroxisome Proliferator Activator Receptor-α PPAR-α Agonist Ameliorates the Inflammatory Process Associated to Experimental Periodontitis.

  PPAR research 20100101

• Hemostatic effects of fenofibrate in patients with mixed dyslipidemia and impaired fasting glucose.

  Pharmacological reports : PR 20100101

• Regulation of Proteome Maintenance Gene Expression by Activators of Peroxisome Proliferator-Activated Receptor α.

  PPAR research 20100101

• Pleiotropic effects of rosuvastatin on microvascular function in type 2 diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20100101

• The Peroxisomal 3-keto-acyl-CoA thiolase B Gene Expression Is under the Dual Control of PPARα and HNF4α in the Liver.

  PPAR research 20100101

• Pitavastatin: evidence for its place in treatment of hypercholesterolemia.

  Core evidence 20100101

• Lipid Metabolism and Cardiovascular Risk in HIV-1 Infection and HAART: Present and Future Problems.

  Cholesterol 20100101

• The Effects of Extended Release Niacin in Combination with Omega 3 Fatty Acid Supplements in the Treatment of Elevated Lipoprotein (a).

  Cholesterol 20100101

• Randomized Trial of a Pharmacist-Delivered Intervention for Improving Lipid-Lowering Medication Adherence among Patients with Coronary Heart Disease.

  Cholesterol 20100101

• Cardiovascular and smooth muscle pharmacology in the next decade.

  Frontiers in pharmacology 20100101

• New and improved strategies for the treatment of gout.

  International journal of nephrology and renovascular disease 20100101

• Drug interaction as cause of spontaneously resolving epidural spinal hematoma on warfarin therapy.

  Journal of neurosciences in rural practice 20100101

• PPARs and xenobiotic-induced adverse effects: relevance to human health.

  PPAR research 20100101

• A patient's informative mistake: niacin is very effective in correcting dyslipidaemia.

  BMJ case reports 20100101

• A review on the rationale and clinical use of concomitant rosuvastatin and fenofibrate/fenofibric acid therapy.

  Clinical pharmacology : advances and applications 20100101

• Activation of PPAR gamma induces profound multilocularization of adipocytes in adult mouse white adipose tissues.

  Experimental & molecular medicine 20091231

• Adverse effect of fenofibrate on branched-chain alpha-ketoacid dehydrogenase complex in rat's liver.

  Toxicology 20091221

• NSAID-derived gamma-secretase modulators. Part III: Membrane anchoring.

  Bioorganic & medicinal chemistry letters 20091215

• [Agonist-induced down-regulation of hepatic glucocorticoid receptor via peroxisome proliferator-activated receptor in SD rats].

  Zhonghua yi xue za zhi 20091215

• Fenofibrate simultaneously induces hepatic fatty acid oxidation, synthesis, and elongation in mice.

  The Journal of biological chemistry 20091204

• Exercise therapy in type 2 diabetes.

  Acta diabetologica 20091201

• Computer-based screening of veterans for metabolic syndrome.

  Metabolic syndrome and related disorders 20091201

• Fenofibrate causes regression of endometriotic implants: a rat model.

  Fertility and sterility 20091201

• Both substrate availability and utilisation contribute to the defence of core temperature in response to acute cold.

  Comparative biochemistry and physiology. Part A, Molecular & integrative physiology 20091201

• Rhabdomyolysis associated with fibrate therapy: review of 76 published cases and a new case report.

  European journal of clinical pharmacology 20091201

• Mining biologically-active molecules for inhibitors of fatty acid amide hydrolase (FAAH): identification of phenmedipham and amperozide as FAAH inhibitors.

  Bioorganic & medicinal chemistry letters 20091201

• Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.

  Diabetes & metabolism 20091201

• Capecitabine-induced severe hypertriglyceridaemia and diabetes: a case report and review of the literature.

  Diabetic medicine : a journal of the British Diabetic Association 20091201

• PPAR alpha and PPAR gamma coactivation rapidly induces Egr-1 in the nuclei of the dorsal and ventral urinary bladder and kidney pelvis urothelium of rats.

  Toxicologic pathology 20091201

• Efficacy and tolerability of atorvastatin/fenofibrate fixed-dose combination tablet compared with atorvastatin and fenofibrate monotherapies in patients with dyslipidemia: a 12-week, multicenter, double-blind, randomized, parallel-group study.

  Clinical therapeutics 20091201

• Lipid disorders in type 2 diabetes.

  Endocrinologia y nutricion : organo de la Sociedad Espanola de Endocrinologia y Nutricion 20091201

• No Modifying Effect of Antioxidant N-Acetyl-L-Cysteine on Fenofibrate-induced Hepatocarcinogenesis in Rats.

  Journal of toxicologic pathology 20091201

• An NSAID-like compound, FT-9, preferentially inhibits gamma-secretase cleavage of the amyloid precursor protein compared to its effect on amyloid precursor-like protein 1.

  Biochemistry 20091124

• 7-Hydroxy-benzopyran-4-one derivatives: a novel pharmacophore of peroxisome proliferator-activated receptor alpha and -gamma (PPARalpha and gamma) dual agonists.

  Journal of medicinal chemistry 20091112

• Fenofibrate and PBA prevent fatty acid-induced loss of adiponectin receptor and pAMPK in human hepatoma cells and in hepatitis C virus-induced steatosis.

  Journal of lipid research 20091101

• PPARalpha activator fenofibrate modulates angiotensin II-induced inflammatory responses in vascular smooth muscle cells via the TLR4-dependent signaling pathway.

  Biochemical pharmacology 20091101

• Serum adiponectin is decreased in patients with familial combined hyperlipidemia and normolipaemic relatives and is influenced by lipid-lowering treatment.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20091101

• Changing paradigms in the treatment of diabetic retinopathy.

  Current opinion in ophthalmology 20091101

• Regulatory effects of fenofibrate and atorvastatin on lipoprotein A-I and lipoprotein A-I:A-II kinetics in the metabolic syndrome.

  Diabetes care 20091101

• In vitro glucuronidation of fenofibric acid by human UDP-glucuronosyltransferases and liver microsomes.

  Drug metabolism and disposition: the biological fate of chemicals 20091101

• Fenofibrate enhances neovascularization in a murine ischemic hindlimb model.

  Journal of cardiovascular pharmacology 20091101

• Selective modulation of amyloid-beta peptide degradation by flurbiprofen, fenofibrate, and related compounds regulates Abeta levels.

  Journal of neurochemistry 20091101

• The PPARalpha agonist fenofibrate preserves hippocampal neurogenesis and inhibits microglial activation after whole-brain irradiation.

  International journal of radiation oncology, biology, physics 20091101

• Severe hypertriglyceridemia and recurrent pancreatitis in a girl with type Ia glycogen storage disease and type III hyperlipoproteinemia.

  American journal of medical genetics. Part A 20091101

• Triglycerides and HDL cholesterol: stars or second leads in diabetes?

  Diabetes care 20091101

• American Diabetes Association indications for statins in diabetes: is there evidence?

  Diabetes care 20091101

• A reexamination of the PPAR-alpha activation mode of action as a basis for assessing human cancer risks of environmental contaminants.

  Environmental health perspectives 20091101

• Fenofibrate reduces adiposity in pregnant and virgin rats but through different mechanisms.

  BMB reports 20091031

• [Effects of micronized fenofibrate on lipid and uric acid metabolism in patients with hyperlipidemia].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20091018

• Hepatocyte nuclear factor 1alpha plays a critical role in PCSK9 gene transcription and regulation by the natural hypocholesterolemic compound berberine.

  The Journal of biological chemistry 20091016

• Preparation of drug nanocrystals by controlled crystallization: application of a 3-way nozzle to prevent premature crystallization for large scale production.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20091008

• Effect of weight loss on HDL-apoA-II kinetics in the metabolic syndrome.

  Clinical science (London, England : 1979) 20091002

• Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution.

  Journal of pharmaceutical sciences 20091001

• Antithrombotic and antiplatelet activities of fenofibrate, a lipid-lowering drug.

  Atherosclerosis 20091001

• Naringenin prevents dyslipidemia, apolipoprotein B overproduction, and hyperinsulinemia in LDL receptor-null mice with diet-induced insulin resistance.

  Diabetes 20091001

• Dyslipidemia-induced neuropathy in mice: the role of oxLDL/LOX-1.

  Diabetes 20091001

• Structurally diverse peroxisome proliferator-activated receptor agonists induce apoptosis in human uro-epithelial cells by a receptor-independent mechanism involving store-operated calcium channels.

  Cell proliferation 20091001

• Peroxisome proliferator-activated receptor-alpha activator fenofibrate prevents high-fat diet-induced renal lipotoxicity in spontaneously hypertensive rats.

  Hypertension research : official journal of the Japanese Society of Hypertension 20091001

• Effects of fenofibrate on plasma and hepatic transaminase activities and hepatic transaminase gene expression in rats.

  The Journal of toxicological sciences 20091001

• Atorvastatin and fenofibrate increase apolipoprotein AV and decrease triglycerides by up-regulating peroxisome proliferator-activated receptor-alpha.

  British journal of pharmacology 20091001

• Effect of fibrates on lipid profiles and cardiovascular outcomes: a systematic review.

  The American journal of medicine 20091001

• Genetic mapping of targets mediating differential chemical phenotypes in Plasmodium falciparum.

  Nature chemical biology 20091001

• Acute cholestatic hepatitis induced by fenofibrate.

  Journal of clinical pharmacy and therapeutics 20091001

• How can we improve the management of vascular risk in type 2 diabetes: insights from FIELD.

  Cardiovascular drugs and therapy 20091001

• Comparative study between the effect of the peroxisome proliferator activated receptor-alpha ligands fenofibrate and n-3 polyunsaturated fatty acids on activation of 5'-AMP-activated protein kinase-alpha1 in high-fat fed rats.

  The Journal of pharmacy and pharmacology 20091001

• Contact dermatitis due to topical drugs.

  Giornale italiano di dermatologia e venereologia : organo ufficiale, Societa italiana di dermatologia e sifilografia 20091001

• A model of cardiovascular disease giving a plausible mechanism for the effect of fractionated low-dose ionizing radiation exposure.

  PLoS computational biology 20091001

• Anti-obesity effect of fish oil and fish oil-fenofibrate combination in female KK mice.

  Journal of atherosclerosis and thrombosis 20091001

• [Place of fibrates for the treatment of patients with atherogenic dyslipidemia].

  Revue medicale de Liege 20091001

• In vitro antioxidant and antihyperlipidemic activities of Bauhinia variegata Linn.

  Indian journal of pharmacology 20091001

• Probing the fibrate binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20090910

• The -1131T>C SNP of the APOA5 gene modulates response to fenofibrate treatment in patients with the metabolic syndrome: a postprandial study.

  Atherosclerosis 20090901

• Determination of fenofibric acid in human plasma by ultra performance liquid chromatography-electrospray ionization mass spectrometry: application to a bioequivalence study.

  Biomedical chromatography : BMC 20090901

• Strongly enhanced dissolution rate of fenofibrate solid dispersion tablets by incorporation of superdisintegrants.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090901

• ApoCIII-enriched LDL in type 2 diabetes displays altered lipid composition, increased susceptibility for sphingomyelinase, and increased binding to biglycan.

  Diabetes 20090901

• Fenofibrate attenuates endothelial monocyte adhesion in chronic heart failure: an in vitro study.

  European journal of clinical investigation 20090901

• Human urinary metabolomic profile of PPARalpha induced fatty acid beta-oxidation.

  Journal of proteome research 20090901

• Fenofibrate differentially regulates plasminogen activator inhibitor-1 gene expression via adenosine monophosphate-activated protein kinase-dependent induction of orphan nuclear receptor small heterodimer partner.

  Hepatology (Baltimore, Md.) 20090901

• Prescription omega-3 fatty acid as an adjunct to fenofibrate therapy in hypertriglyceridemic subjects.

  Journal of cardiovascular pharmacology 20090901

• Myopathy with statin-fibrate combination therapy: clinical considerations.

  Nature reviews. Endocrinology 20090901

• A chemical screening approach reveals that indole fluorescence is quenched by pre-fibrillar but not fibrillar amyloid-beta.

  Bioorganic & medicinal chemistry letters 20090901

• Serum concentrations and tissue expression of a novel endocrine regulator fibroblast growth factor-21 in patients with type 2 diabetes and obesity.

  Clinical endocrinology 20090901

• The effect of prescription omega-3 fatty acids on body weight after 8 to 16 weeks of treatment for very high triglyceride levels.

  Postgraduate medicine 20090901

• Correlation of non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol with apolipoprotein B during simvastatin + fenofibrate therapy in patients with combined hyperlipidemia (a subanalysis of the SAFARI trial).

  The American journal of cardiology 20090815

• Heparin treatment for severe hypertriglyceridemia in diabetic ketoacidosis.

  Archives of internal medicine 20090810

• Ordered mesoporous silica material SBA-15: a broad-spectrum formulation platform for poorly soluble drugs.

  Journal of pharmaceutical sciences 20090801

• On the mechanism for PPAR agonists to enhance ABCA1 gene expression.

  Atherosclerosis 20090801

• Changes in lipoprotein profile and urinary albumin excretion in familial LCAT deficiency with lipid lowering therapy.

  Atherosclerosis 20090801

• Differential regulation of the human versus the mouse apolipoprotein AV gene by PPARalpha. Implications for the study of pharmaceutical modifiers of hypertriglyceridemia in mice.

  Biochimica et biophysica acta 20090801

• Pleiotropic action of short-term metformin and fenofibrate treatment, combined with lifestyle intervention, in type 2 diabetic patients with mixed dyslipidemia.

  Diabetes care 20090801

• Insulin-stimulated cardiac glucose oxidation is increased in high-fat diet-induced obese mice lacking malonyl CoA decarboxylase.

  Diabetes 20090801

• Peroxisome proliferator-activated receptor alpha (PPARalpha) agonists down-regulate alpha2-macroglobulin expression by a PPARalpha-dependent mechanism.

  Biochimie 20090801

• Synthesis of novel triterpenoid (lupeol) derivatives and their in vivo antihyperglycemic and antidyslipidemic activity.

  Bioorganic & medicinal chemistry letters 20090801

• Peroxisome-proliferator-activated receptor-alpha activation protects brain capillary endothelial cells from oxygen-glucose deprivation-induced hyperpermeability in the blood-brain barrier.

  Current neurovascular research 20090801

• Fenofibrate, simvastatin and their combination in the management of dyslipidaemia in type 2 diabetic patients.

  Current medical research and opinion 20090801

• Adaptability and selectivity of human peroxisome proliferator-activated receptor (PPAR) pan agonists revealed from crystal structures.

  Acta crystallographica. Section D, Biological crystallography 20090801

• Circumventing glucocorticoid-mediated hyperinsulinemia via the activation of PPARalpha.

  Cell cycle (Georgetown, Tex.) 20090801

• Nephropathy and other topics.

  Diabetes care 20090801

• Advances in the medical treatment of diabetic retinopathy.

  Diabetes care 20090801

• Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration.

  Journal of clinical lipidology 20090801

• Discovery of a peroxisome proliferator activated receptor gamma (PPARgamma) modulator with balanced PPARalpha activity for the treatment of type 2 diabetes and dyslipidemia.

  Journal of medicinal chemistry 20090723

• Gel entrapment culture of rat hepatocytes for investigation of tetracycline-induced toxicity.

  Toxicology and applied pharmacology 20090715

• Discovery of (2R)-2-(3-{3-[(4-Methoxyphenyl)carbonyl]-2-methyl-6-(trifluoromethoxy)-1H-indol-1-yl}phenoxy)butanoic acid (MK-0533): a novel selective peroxisome proliferator-activated receptor gamma modulator for the treatment of type 2 diabetes mellitus with a reduced potential to increase plasma and extracellular fluid volume.

  Journal of medicinal chemistry 20090709

• Enhanced bioavailability of the poorly water-soluble drug fenofibrate by using liposomes containing a bile salt.

  International journal of pharmaceutics 20090706

• Estrogenic activity of pharmaceuticals in the aquatic environment.

  Environment international 20090701

• HPLC analysis of lipoproteins in culture medium of hepatoma cells: an in vitro system for screening antihyperlipidemic drugs.

  Biotechnology letters 20090701

• Peroxisome proliferator-activated receptor-alpha (PPARalpha): at the crossroads of obesity, diabetes and cardiovascular disease.

  Atherosclerosis 20090701

• Iatrogenic severe depression of high-density lipoprotein cholesterol.

  Journal of clinical pharmacology 20090701

• Elevated triglycerides correlate with progression of diabetic neuropathy.

  Diabetes 20090701

• Fibrates in the treatment of cardiovascular risk and atherogenic dyslipidaemia.

  Current opinion in cardiology 20090701

• Preparation of fenofibrate nanosuspension and study of its pharmacokinetic behavior in rats.

  Drug development and industrial pharmacy 20090701

• Nonalcoholic hepatic steatosis in Zucker diabetic rats: spontaneous evolution and effects of metformin and fenofibrate.

  Obesity (Silver Spring, Md.) 20090701

• Fenofibrate inhibits adipocyte hypertrophy and insulin resistance by activating adipose PPARalpha in high fat diet-induced obese mice.

  Experimental & molecular medicine 20090630

• Pyrrolidine dithiocarbamate, a NF-kappaB inhibitor, upregulates MMP-1 and MMP-13 in IL-1beta-stimulated rheumatoid arthritis fibroblast-like synoviocytes.

  European journal of pharmacology 20090624

• Opposing roles of peroxisome proliferator-activated receptor alpha and growth hormone in the regulation of CYP4A11 expression in a transgenic mouse model.

  The Journal of biological chemistry 20090612

• IVIVC in oral absorption for fenofibrate immediate release tablets using a dissolution/permeation system.

  Journal of pharmaceutical sciences 20090601

• Green tea extract selectively activates peroxisome proliferator-activated receptor beta/delta in cultured cardiomyocytes.

  The British journal of nutrition 20090601

• Design, synthesis and hypolipidemic activity of novel 2-(m-tolyloxy) isobutyric acid derivatives.

  European journal of medicinal chemistry 20090601

• Characterization of lipophilic drug binding to rat intestinal fatty acid binding protein.

  Molecular and cellular biochemistry 20090601

• More clinical lessons from the FIELD study.

  Cardiovascular drugs and therapy 20090601

• Effects of cevoglitazar, a dual PPARalpha/gamma agonist, on ectopic fat deposition in fatty Zucker rats.

  Diabetes, obesity & metabolism 20090601

• Manufacturing nanosized fenofibrate by salt assisted milling.

  Pharmaceutical research 20090601

• Fenofibrate metabolism in the cynomolgus monkey using ultraperformance liquid chromatography-quadrupole time-of-flight mass spectrometry-based metabolomics.

  Drug metabolism and disposition: the biological fate of chemicals 20090601

• Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.

  Arteriosclerosis, thrombosis, and vascular biology 20090601

• Fenofibrate inhibits aldosterone-induced apoptosis in adult rat ventricular myocytes via stress-activated kinase-dependent mechanisms.

  American journal of physiology. Heart and circulatory physiology 20090601

• Fenofibrate-induced muscular toxicity is associated with a metabolic shift limited to type-1 muscles in rats.

  Toxicologic pathology 20090601

• Defective peroxisomal proliferators activated receptor gamma activity due to dominant-negative mutation synergizes with hypertension to accelerate cardiac fibrosis in mice.

  European journal of heart failure 20090601

• Fluvastatin/fenofibrate vs. simvastatin/ezetimibe in patients with metabolic syndrome: different effects on LDL-profiles.

  European journal of clinical investigation 20090601

• Differentiated CaCo-2 cells as an in-vitro model to evaluate de-novo apolipoprotein A-I production in the small intestine.

  European journal of gastroenterology & hepatology 20090601

• Untargeted metabolomic profiling as an evaluative tool of fenofibrate-induced toxicology in Fischer 344 male rats.

  Toxicologic pathology 20090601

• Gout--what are the treatment options?

  Expert opinion on pharmacotherapy 20090601

• Interaction between gemfibrozil and warfarin: case report and review of the literature.

  Pharmacotherapy 20090601

• Clinical insights from the Fenofibrate Intervention and Event Lowering in Diabetes study: a community practice perspective.

  International journal of clinical practice 20090601

• Inhibition by fibrates of plasminogen activator inhibitor type-1 expression in human adipocytes and preadipocytes.

  Thrombosis and haemostasis 20090601

• Interaction of fenofibrate and fish oil in relation to lipid metabolism in mice.

  Journal of atherosclerosis and thrombosis 20090601

• Adenosine and adenosine receptors: Newer therapeutic perspective.

  Indian journal of pharmacology 20090601

• Rapid Hemodynamic Deterioration and Death due to Acute Severe Refractory Septic Shock.

  Journal of clinical medicine research 20090601

• Fenofibrate and risk of minor amputations in diabetes.

  Lancet (London, England) 20090523

• Effect of fenofibrate on amputation events in people with type 2 diabetes mellitus (FIELD study): a prespecified analysis of a randomised controlled trial.

  Lancet (London, England) 20090523

• Rosiglitazone and fenofibrate improve insulin sensitivity of pre-diabetic OLETF rats by reducing malonyl-CoA levels in the liver and skeletal muscle.

  Life sciences 20090508

• Fenofibric Acid (trilipix).

  The Medical letter on drugs and therapeutics 20090504

• Human health risk assessment for peroxisome proliferators: more than 30 years of research.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20090501

• Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study.

  Atherosclerosis 20090501

• Antiplatelet actions of statins and fibrates are mediated by PPARs.

  Arteriosclerosis, thrombosis, and vascular biology 20090501

• Management of diabetic retinopathy: could lipid-lowering be a worthwhile treatment modality?

  Eye (London, England) 20090501

• Preventing diabetic complications: a primary care perspective.

  Diabetes research and clinical practice 20090501

• A treasure of pharmacogenomic insights into postprandial lipoproteinemia and therapeutic responses to fibrate therapy: lessons from GOLDN.

  Current atherosclerosis reports 20090501

• Milky plasma, diabetes, and severe hyponatremia.

  Kidney international 20090501

• Effects of fenofibrate treatment on prothrombotic state in patients with metabolic syndrome in relation to smoking and diabetes.

  Medical science monitor : international medical journal of experimental and clinical research 20090501

• Novel action of 7-O-galloyl-D-sedoheptulose isolated from Corni Fructus as a hypertriglyceridaemic agent.

  The Journal of pharmacy and pharmacology 20090501

• Managing toxicities and optimal dosing of targeted drugs in advanced kidney cancer.

  Current oncology (Toronto, Ont.) 20090501

• Asymmetric dimethylarginine (ADMA) and endothelial dysfunction: implications for atherogenesis.

  Clinics (Sao Paulo, Brazil) 20090501

• [Inhibitory effect of fenofibrate on angiotensin II-induced toll-like receptor 4 expression, myeloperoxidase activity and expression in RAW264.7 cells].

  Yao xue xue bao = Acta pharmaceutica Sinica 20090501

• Persistently increased HDL-cholesterolemia and reduced triglyceridemia in a large lipid clinic population treated with fenofibrate for 15 years or longer.

  International journal of cardiology 20090417

• Fenofibrate-loaded PLGA microparticles: effects on ischemic stroke.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20090411

• Fenofibrate, a peroxisome proliferator-activated receptor-alpha agonist, exerts anticonvulsive properties.

  Epilepsia 20090401

• Fenofibrate reduces serum retinol-binding protein-4 by suppressing its expression in adipose tissue.

  American journal of physiology. Endocrinology and metabolism 20090401

• Bezafibrate at clinically relevant doses decreases serum/liver triglycerides via down-regulation of sterol regulatory element-binding protein-1c in mice: a novel peroxisome proliferator-activated receptor alpha-independent mechanism.

  Molecular pharmacology 20090401

• Antidiabetic action of bezafibrate in a large observational database.

  Diabetes care 20090401

• Stabilizing dispersions of hydrophobic drug molecules using cellulose ethers during anti-solvent synthesis of micro-particulates.

  Colloids and surfaces. B, Biointerfaces 20090401

• Hypertriglyceridaemia with bexarotene in cutaneous T cell lymphoma: the role of omega-3 fatty acids.

  British journal of haematology 20090401

• Rosiglitazone aggravates nonalcoholic Fatty pancreatic disease in C57BL/6 mice fed high-fat and high-sucrose diet.

  Pancreas 20090401

• Statins and fenofibrate affect skeletal muscle chloride conductance in rats by differently impairing ClC-1 channel regulation and expression.

  British journal of pharmacology 20090401

• Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.

  European journal of pharmacology 20090401

• Transcriptional modulation of the immune response by peroxisome proliferator-activated receptor-{alpha} agonists in autoimmune disease.

  Journal of immunology (Baltimore, Md. : 1950) 20090401

• New metabolites of fenofibrate in Sprague-Dawley rats by UPLC-ESI-QTOF-MS-based metabolomics coupled with LC-MS/MS.

  Xenobiotica; the fate of foreign compounds in biological systems 20090401

• Fenofibrate-induced rhabdomyolysis in a patient with chronic kidney disease: an unusual presenting feature of hypothyroidism.

  Arquivos brasileiros de endocrinologia e metabologia 20090401

• Statins and fibrate target ClC-1 - from side effects to CLC pharmacology.

  British journal of pharmacology 20090401

• Hypertriglyceridemia and its pharmacologic treatment among US adults.

  Archives of internal medicine 20090323

• Cancer biomarker AKR1B10 and carbonyl metabolism.

  Chemico-biological interactions 20090316

• Interpreting clinical trials of diabetic dyslipidaemia: new insights.

  Diabetes, obesity & metabolism 20090301

• Effects of fenofibrate treatment on cardiovascular disease risk in 9,795 individuals with type 2 diabetes and various components of the metabolic syndrome: the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.

  Diabetes care 20090301

• Effect of fenofibrate on adiponectin and inflammatory biomarkers in metabolic syndrome patients.

  Obesity (Silver Spring, Md.) 20090301

• Muscle-derived angiopoietin-like protein 4 is induced by fatty acids via peroxisome proliferator-activated receptor (PPAR)-delta and is of metabolic relevance in humans.

  Diabetes 20090301

• Chlamydia pneumoniae induces macrophage-derived foam cell formation via PPAR alpha and PPAR gamma-dependent pathways.

  Cell biology international 20090301

• A synthetic farnesoid X receptor (FXR) agonist promotes cholesterol lowering in models of dyslipidemia.

  American journal of physiology. Gastrointestinal and liver physiology 20090301

• Sleep deprivation increases oleoylethanolamide in human cerebrospinal fluid.

  Journal of neural transmission (Vienna, Austria : 1996) 20090301

• Paradoxical decreases in high-density lipoprotein cholesterol with fenofibrate: a quite common phenomenon.

  Journal of clinical pathology 20090301

• Beyond LDL cholesterol: the role of elevated triglycerides and low HDL cholesterol in residual CVD risk remaining after statin therapy.

  The American journal of managed care 20090301

• Toxicogenomic biomarkers for liver toxicity.

  Journal of toxicologic pathology 20090301

• Preparation of ultrafine fenofibrate powder by solidification process from emulsion.

  International journal of pharmaceutics 20090223

• Use of mRNA expression to detect the induction of drug metabolising enzymes in rat and human hepatocytes.

  Toxicology and applied pharmacology 20090215

• Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia.

  The American journal of cardiology 20090215

• Combination statin-fibrate therapy: safety aspects.

  Diabetes, obesity & metabolism 20090201

• Peroxisome proliferator-activated receptor-alpha contributes to the resolution of inflammation after renal ischemia/reperfusion injury.

  The Journal of pharmacology and experimental therapeutics 20090201

• BLX-1002, a novel thiazolidinedione with no PPAR affinity, stimulates AMP-activated protein kinase activity, raises cytosolic Ca2+, and enhances glucose-stimulated insulin secretion in a PI3K-dependent manner.

  American journal of physiology. Cell physiology 20090201

• Pharmacogenetic association of the APOA1/C3/A4/A5 gene cluster and lipid responses to fenofibrate: the genetics of lipid-lowering drugs and diet network study.

  Pharmacogenetics and genomics 20090201

• Impact of genetic and environmental factors on hsCRP concentrations and response to therapeutic agents.

  Clinical chemistry 20090201

• Alteration of canalicular transporters in a mouse model of total parenteral nutrition.

  Journal of pediatric gastroenterology and nutrition 20090201

• Unexpected and abnormally low HDL cholesterol levels on combination hypolipidemic therapy.

  The Journal of the Association of Physicians of India 20090201

• Activation of hepatic lipase expression by oleic acid: possible involvement of USF1.

  Nutrients 20090201

• Serum adipocyte fatty acid binding protein levels in patients with type 2 diabetes mellitus and obesity: the influence of fenofibrate treatment.

  Physiological research 20090101

• Beneficial effects of fenofibrate on plaque thrombogenicity and plaque stability in atherosclerotic rabbits.

  Cardiovascular pathology : the official journal of the Society for Cardiovascular Pathology 20090101

• Understanding the solid-state forms of fenofibrate--a spectroscopic and computational study.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20090101

• Effects and mechanisms of PPARalpha activator fenofibrate on myocardial remodelling in hypertension.

  Journal of cellular and molecular medicine 20090101

• Ameliorative effect of combination of benfotiamine and fenofibrate in diabetes-induced vascular endothelial dysfunction and nephropathy in the rat.

  Molecular and cellular biochemistry 20090101

• ABT-335, the choline salt of fenofibric acid, does not have a clinically significant pharmacokinetic interaction with rosuvastatin in humans.

  Journal of clinical pharmacology 20090101

• Comment on biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis.

  Hepatology (Baltimore, Md.) 20090101

• Oligo-arthritis and type IV hyperlipoproteinemia.

  Joint, bone, spine : revue du rhumatisme 20090101

• Proinflammatory cytokine and ligands modulate cardiac peroxisome proliferator-activated receptors.

  European journal of clinical investigation 20090101

• Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study.

  American heart journal 20090101

• The effects of Thiazolidinediones on metabolic complications and Lipodystrophy in HIV-infected patients.

  PPAR research 20090101

• Using the EQ-5D index score as a predictor of outcomes in patients with type 2 diabetes.

  Medical care 20090101

• Standards of medical care in diabetes--2009.

  Diabetes care 20090101

• Omega 3 fatty acids induce a marked reduction of apolipoprotein B48 when added to fluvastatin in patients with type 2 diabetes and mixed hyperlipidemia: a preliminary report.

  Cardiovascular diabetology 20090101

• Genome-wide association study of plasma polyunsaturated fatty acids in the InCHIANTI Study.

  PLoS genetics 20090101

• Pleiotropic effects of fenofibrate.

  Current pharmaceutical design 20090101

• Fibrates and microvascular complications in diabetes--insight from the FIELD study.

  Current pharmaceutical design 20090101

• Unraveling dynamic activities of autocrine pathways that control drug-response transcriptome networks.

  Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 20090101

• [Rosuvastatin and fenofibrate in patients with diabetes and low high density lipoprotein cholesterol: comparison of changes of lipid levels and some markers of inflammation].

  Kardiologiia 20090101

• Effect of fenofibrate on microcirculation and wound healing in healthy and diabetic mice.

  European journal of medical research 20090101

• Differences in transcriptional activation by the two allelic (L162V Polymorphic) variants of PPARα after Omega-3 fatty acids treatment.

  PPAR research 20090101

• Pan-PPAR agonist beneficial effects in overweight mice fed a high-fat high-sucrose diet.

  Nutrition (Burbank, Los Angeles County, Calif.) 20090101

• Differential protection against oxidative stress and nitric oxide overproduction in cardiovascular and pulmonary systems by propofol during endotoxemia.

  Journal of biomedical science 20090101

• Solvay addresses unmet needs in the management of hypertensive patients with cardiometabolic and lipid disorders.

  Cardiovascular journal of Africa 20090101

• Diabetic cardiomyopathy: effects of fenofibrate and metformin in an experimental model--the Zucker diabetic rat.

  Cardiovascular diabetology 20090101

• Efficacy and safety of coadministration of fenofibrate and ezetimibe compared with each as monotherapy in patients with type IIb dyslipidemia and features of the metabolic syndrome: a prospective, randomized, double-blind, three-parallel arm, multicenter, comparative study.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Different skeletal effects of the peroxisome proliferator activated receptor (PPAR)alpha agonist fenofibrate and the PPARgamma agonist pioglitazone.

  BMC endocrine disorders 20090101

• Peroxisome proliferator-activated receptors in HCV-related infection.

  PPAR research 20090101

• Analysis of PPARalpha-dependent and PPARalpha-independent transcript regulation following fenofibrate treatment of human endothelial cells.

  Angiogenesis 20090101

• PPAR and liver injury in HIV-infected patients.

  PPAR research 20090101

• MBX-102/JNJ39659100, a novel non-TZD selective partial PPAR-γ agonist lowers triglyceride independently of PPAR-α activation.

  PPAR research 20090101

• Genetic and environmental pathways to complex diseases.

  BMC systems biology 20090101

• Suggestion for linkage of chromosome 1p35.2 and 3q28 to plasma adiponectin concentrations in the GOLDN Study.

  BMC medical genetics 20090101

• Management of complex lipid abnormalities with a fixed dose combination of simvastatin and extended release niacin.

  Vascular health and risk management 20090101

• Dyslipidemia treatment of patients with diabetes mellitus in a US managed care plan: a retrospective database analysis.

  Cardiovascular diabetology 20090101

• Pharmacological Treatment of Alzheimer's Disease: Is it Progressing Adequately?

  The open neurology journal 20090101

• Mechanism of inhibitory effect of atorvastatin on resistin expression induced by tumor necrosis factor-alpha in macrophages.

  Journal of biomedical science 20090101

• Safety and efficacy of rosiglitazone in the elderly diabetic patient.

  Vascular health and risk management 20090101

• Antiretroviral effect of lovastatin on HIV-1-infected individuals without highly active antiretroviral therapy (The LIVE study): a phase-II randomized clinical trial.

  Trials 20090101

• [Fibrate-induced deterioration of renal function].

  Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia 20090101

• Effects of cardiovascular lifestyle change on lipoprotein subclass profiles defined by nuclear magnetic resonance spectroscopy.

  Lipids in health and disease 20090101

• Pleiotropic effects of statins in atrial fibrillation patients: the evidence.

  Vascular health and risk management 20090101

• Top-down lipidomics reveals ether lipid deficiency in blood plasma of hypertensive patients.

  PloS one 20090101

• Rosiglitazone prevents high glucose-induced vascular endothelial growth factor and collagen IV expression in cultured mesangial cells.

  Experimental diabetes research 20090101

• A cardiologic approach to non-insulin antidiabetic pharmacotherapy in patients with heart disease.

  Cardiovascular diabetology 20090101

• Regulation of bile acid and cholesterol metabolism by PPARs.

  PPAR research 20090101

• New options in the treatment of lipid disorders in HIV-infected patients.

  The open AIDS journal 20090101

• Actos Now for the prevention of diabetes (ACT NOW) study.

  BMC endocrine disorders 20090101

• Gout. Novel therapies for treatment of gout and hyperuricemia.

  Arthritis research & therapy 20090101

• Regulation of sulfotransferase and UDP-glucuronosyltransferase gene expression by the PPARs.

  PPAR research 20090101

• Disparities in allele frequencies and population differentiation for 101 disease-associated single nucleotide polymorphisms between Puerto Ricans and non-Hispanic whites.

  BMC genetics 20090101

• Peroxisome proliferator-activated receptor agonists: do they increase cardiovascular risk?

  PPAR research 20090101

• Comparative analysis of gene regulation by the transcription factor PPARalpha between mouse and human.

  PloS one 20090101

• [Treatment of dyslipidemia in patients with metabolic syndrome and chronic kidney disease].

  Vnitrni lekarstvi 20090101

• Antiatherosclerotic and anti-insulin resistance effects of adiponectin: basic and clinical studies.

  Progress in cardiovascular diseases 20090101

• Withdrawal of fenofibrate treatment partially abrogates preventive neuroprotection in stroke via loss of vascular protection.

  Vascular pharmacology 20090101

• Relative power and sample size analysis on gene expression profiling data.

  BMC genomics 20090101

• Postprandial lipemia in diabetic men during hypolipemic therapy.

  Polskie Archiwum Medycyny Wewnetrznej 20090101

• Early responses of insulin signaling to high-carbohydrate and high-fat overfeeding.

  Nutrition & metabolism 20090101

• Anti-inflammatory and arthritic effects of thiacremonone, a novel sulfur compound isolated from garlic via inhibition of NF-kappaB.

  Arthritis research & therapy 20090101

• Drugs associated with more suicidal ideations are also associated with more suicide attempts.

  PloS one 20090101

• Thinking beyond low-density lipoprotein cholesterol: strategies to further reduce cardiovascular risk.

  Vascular health and risk management 20090101

• TCF7L2 polymorphisms and inflammatory markers before and after treatment with fenofibrate.

  Diabetology & metabolic syndrome 20090101

• [Treatment of patients with hypertriglyceridemia].

  Terapevticheskii arkhiv 20090101

• Differential changes in serum uric acid concentrations in sibutramine promoted weight loss in diabetes: results from four weeks of the lead-in period of the SCOUT trial.

  Nutrition & metabolism 20090101

• Cardiovascular disease and intensive glucose control in type 2 diabetes mellitus: moving practice toward evidence-based strategies.

  Vascular health and risk management 20090101

• Allosteric modulation of PS1/gamma-secretase conformation correlates with amyloid beta(42/40) ratio.

  PloS one 20090101

• Fenofibric acid: in combination therapy in the treatment of mixed dyslipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20090101

• Ciprofibrate increases cholesteryl ester transfer protein gene expression and the indirect reverse cholesterol transport to the liver.

  Lipids in health and disease 20090101

• Treatment of hypertriglyceridemia and HIV: fenofibrate-induced changes in the expression of chemokine genes in circulating leukocytes.

  AIDS research and therapy 20090101

• Lipemic serum in hyperlipidemic pancreatitis.

  Cases journal 20090101

• Prediction of pharmacological and xenobiotic responses to drugs based on time course gene expression profiles.

  PloS one 20090101

• Management of dyslipidemia in children.

  Diabetology & metabolic syndrome 20090101

• Low use of statins and other coronary secondary prevention therapies in primary and secondary care in India.

  Vascular health and risk management 20090101

• Filling gaps in PPAR-alpha signaling through comparative nutrigenomics analysis.

  BMC genomics 20090101

• Fasting Upregulates PPARalpha Target Genes in Brain and Influences Pituitary Hormone Expression in a PPARalpha Dependent Manner.

  PPAR research 20090101

• Comparison of the efficacy of administering a combination of ezetimibe plus fenofibrate versus atorvastatin monotherapy in the treatment of dyslipidemia.

  Lipids in health and disease 20090101

• Adolescent type 1 Diabetes Cardio-renal Intervention Trial (AdDIT).

  BMC pediatrics 20090101

• The potential for xanthine oxidase inhibition in the prevention and treatment of cardiovascular and cerebrovascular disease.

  Cardiovascular psychiatry and neurology 20090101

• Lipogenesis in arterial wall and vascular smooth muscular cells: regulation and abnormalities in insulin-resistance.

  Cardiovascular diabetology 20090101

• Effect of atorvastatin and fenofibric acid on adipokine release from visceral and subcutaneous adipose tissue of patients with mixed dyslipidemia and normolipidemic subjects.

  Pharmacological reports : PR 20090101

• Optimising the medical management of hyperglycaemia in type 2 diabetes in the Middle East: pivotal role of metformin.

  International journal of clinical practice 20090101

• A comparative evaluation of safety and efficacy of rosuvastatin, simvastatin, and atorvastatin in patients of type 2 diabetes mellitus with dyslipidemia.

  International journal of diabetes in developing countries 20090101

• Simultaneous Estimation of Nebivolol Hydrochloride and Valsartan using RP HPLC.

  Indian journal of pharmaceutical sciences 20090101

• Porous carriers for controlled/modulated drug delivery.

  Indian journal of pharmaceutical sciences 20090101

• Febuxostat: the evidence for its use in the treatment of hyperuricemia and gout.

  Core evidence 20090101

• Raising HDL cholesterol in women.

  International journal of women's health 20090101

• Improving glycemic and cholesterol control through an integrated approach incorporating colesevelam - a clinical perspective.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Analog insulin detemir for patients with type 1 and type 2 diabetes: a review.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Peroxisome proliferator-activated receptors as stimulants of angiogenesis in cardiovascular disease and diabetes.

  Diabetes, metabolic syndrome and obesity : targets and therapy 20090101

• Reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering: a role for fenofibrate. Introduction.

  The American journal of cardiology 20081222

• Microvascular complications of diabetes mellitus: renal protection accompanies cardiovascular protection.

  The American journal of cardiology 20081222

• Fenofibrate for cardiovascular disease prevention in metabolic syndrome and type 2 diabetes mellitus.

  The American journal of cardiology 20081222

• After the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: implications for fenofibrate.

  The American journal of cardiology 20081222

• Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.

  The American journal of cardiology 20081222

• Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.

  Journal of the American College of Cardiology 20081216

• PPARalpha ligands inhibit radiation-induced microglial inflammatory responses by negatively regulating NF-kappaB and AP-1 pathways.

  Free radical biology & medicine 20081215

• Coagulanolide, a withanolide from Withania coagulans fruits and antihyperglycemic activity.

  Bioorganic & medicinal chemistry letters 20081215

• Regulatory potential for concerted modulation of Nrf2- and Nfkb1-mediated gene expression in inflammation and carcinogenesis.

  British journal of cancer 20081209

• Hypolipidaemic effects of fenofibrate and fasting in the herbivorous grass carp ( Ctenopharyngodon idella) fed a high-fat diet.

  The British journal of nutrition 20081201

• VAP II analysis of lipoprotein subclasses in mixed hyperlipidemic patients on treatment with ezetimibe/simvastatin and fenofibrate.

  Journal of lipid research 20081201

• Role of Nrf2 and oxidative stress on fenofibrate-induced hepatocarcinogenesis in rats.

  Toxicological sciences : an official journal of the Society of Toxicology 20081201

• Metabolic syndrome predicts new onset of chronic kidney disease in 5,829 patients with type 2 diabetes: a 5-year prospective analysis of the Hong Kong Diabetes Registry.

  Diabetes care 20081201

• Hepatocarcinogenic susceptibility of fenofibrate and its possible mechanism of carcinogenicity in a two-stage hepatocarcinogenesis model of rasH2 mice.

  Toxicologic pathology 20081201

• Pharmacoeconomic analysis of hypertriglyceridemia treatment at medical institutions.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20081201

• High glucose conditions induce upregulation of fractalkine and monocyte chemotactic protein-1 in human smooth muscle cells.

  Thrombosis and haemostasis 20081201

• Combination thiazolidinedione and fibrate effect on high-density lipoprotein cholesterol (HDL-C) concentration in a Veterans Affairs patient population.

  Journal of clinical lipidology 20081201

• Comparison of treatment of severe high-density lipoprotein cholesterol deficiency in men with daily atorvastatin (20 mg) versus fenofibrate (200 mg) versus extended-release niacin (2 g).

  The American journal of cardiology 20081115

• Particle diffusional layer thickness in a USP dissolution apparatus II: a combined function of particle size and paddle speed.

  Journal of pharmaceutical sciences 20081101

• Molecular characterization of peroxisome proliferator-activated receptors (PPARs) and their gene expression in the differentiating adipocytes of red sea bream Pagrus major.

  Comparative biochemistry and physiology. Part B, Biochemistry & molecular biology 20081101

• Application of molecular dynamics simulation to predict the compatability between water-insoluble drugs and self-associating poly(ethylene oxide)-b-poly(epsilon-caprolactone) block copolymers.

  Biomacromolecules 20081101

• Effect of rimonabant, micronised fenofibrate and their combination on cardiometabolic risk factors in overweight/obese patients: a pilot study.

  Expert opinion on pharmacotherapy 20081101

• Improvement of dyslipidemia, insulin sensitivity, and energy balance by a peroxisome proliferator-activated receptor alpha agonist.

  Metabolism: clinical and experimental 20081101

• LDL reduction: how low should we go and is it safe?

  Current cardiology reports 20081101

• American College of Endocrinology Pre-Diabetes Consensus Conference: part two.

  Diabetes care 20081101

• Fenofibrate: treatment of hyperlipidemia and beyond.

  Expert review of cardiovascular therapy 20081101

• Fenofibrate and pioglitazone do not ameliorate the altered vascular reactivity in aorta of isoproterenol-treated rats.

  Journal of cardiovascular pharmacology 20081101

• Fenofibrate monotherapy-induced rhabdomyolysis in a patient with type-2 diabetes.

  Indian journal of medical sciences 20081101

• Design, synthesis, and biological evaluation of novel constrained meta-substituted phenyl propanoic acids as peroxisome proliferator-activated receptor alpha and gamma dual agonists.

  Journal of medicinal chemistry 20081023

• Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.

  Journal of medicinal chemistry 20081009

• Multiple benign symmetric lipomatosis--a differential diagnosis of obesity. Is there a rationale for fibrate treatment?

  Obesity surgery 20081001

• Atorvastatin and fenofibrate have comparable effects on VLDL-apolipoprotein C-III kinetics in men with the metabolic syndrome.

  Arteriosclerosis, thrombosis, and vascular biology 20081001

• Kinetic studies of the metabolism of rapidly exchangeable apolipoproteins may leave investigators and readers with exchangeable results.

  Arteriosclerosis, thrombosis, and vascular biology 20081001

• Treatment of hyperlipidaemia with fenofibrate and related fibrates.

  Expert opinion on investigational drugs 20081001

• A novel high-throughput screening assay for putative antidiabetic agents through PPARalpha interactions.

  Journal of biomolecular screening 20081001

• Reduced high-density lipoprotein cholesterol in patients receiving rosiglitazone and fenofibrate.

  The American journal of medicine 20081001

• Activation of peroxisome proliferator-activated receptor-alpha in mice induces expression of the hepatic low-density lipoprotein receptor.

  British journal of pharmacology 20081001

• Update on the clinical utility of fenofibrate in mixed dyslipidemias: mechanisms of action and rational prescribing.

  Vascular health and risk management 20081001

• Lipid therapy utilization rates in a managed-care mixed dyslipidemia population.

  Journal of clinical lipidology 20081001

• Neuropharmacology.

  Indian journal of pharmacology 20081001

• Clinical pharmacology.

  Indian journal of pharmacology 20081001

• Autonomic nervous system and cardiovascular system.

  Indian journal of pharmacology 20081001

• Stability indicating UPLC method for simultaneous determination of atorvastatin, fenofibrate and their degradation products in tablets.

  Journal of pharmaceutical and biomedical analysis 20080910

• Peroxisome proliferator-activated receptor alpha agonist attenuates oxidized-low density lipoprotein induced immune maturation of human monocyte-derived dendritic cells.

  Chinese medical journal 20080905

• Effects of combined PPARgamma and PPARalpha agonist therapy on reverse cholesterol transport in the Zucker diabetic fatty rat.

  Diabetes, obesity & metabolism 20080901

• Possible involvement of oxidative stress in fenofibrate-induced hepatocarcinogenesis in rats.

  Archives of toxicology 20080901

• Activation of PPARalpha inhibits IGF-I-mediated growth and survival responses in medulloblastoma cell lines.

  International journal of cancer 20080901

• Combination therapy with fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, and simvastatin, a 3-hydroxy-3-methylglutaryl-coenzyme A reductase inhibitor, on experimental traumatic brain injury.

  The Journal of pharmacology and experimental therapeutics 20080901

• Effects of PPAR agonists on proliferation and differentiation in human urothelium.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20080901

• Metabolic effects of various antidiabetic and hypolipidaemic agents on a high-fat diet and multiple low-dose streptozocin (MLDS) mouse model of diabetes.

  The Journal of pharmacy and pharmacology 20080901

• Antidiabetic and hypolipidemic effects of a novel dual peroxisome proliferator-activated receptor (PPAR) alpha/gamma agonist, E3030, in db/db mice and beagle dogs.

  Journal of pharmacological sciences 20080901

• Nanocrystal technology, drug delivery and clinical applications.

  International journal of nanomedicine 20080901

• [Fenofibrate improves energy metabolism and attenuates isoproterenol induced acute myocardial ischemic injury in rats via PPAR alpha activation].

  Zhonghua xin xue guan bing za zhi 20080901

• An N-terminal fragment of mouse DGAT1 binds different acyl-CoAs with varying affinity.

  Biochemical and biophysical research communications 20080829

• Atheroprotective effect of human apolipoprotein A5 in a mouse model of mixed dyslipidemia.

  Circulation research 20080829

• Small-interference RNA-mediated knock-down of aldehyde oxidase 1 in 3T3-L1 cells impairs adipogenesis and adiponectin release.

  FEBS letters 20080820

• Role of peroxisome proliferator-activated receptor alpha activation in acute myocardial damage induced by isoproterenol in rats.

  Chinese medical journal 20080820

• PPARalpha regulates the hepatotoxic biomarker alanine aminotransferase (ALT1) gene expression in human hepatocytes.

  Toxicology and applied pharmacology 20080815

• Efficacy and safety of a potent and selective peroxisome proliferator activated receptor alpha agonist in subjects with dyslipidemia and type 2 diabetes mellitus.

  The American journal of cardiology 20080815

• Dissolution-rate enhancement of fenofibrate by adsorption onto silica using supercritical carbon dioxide.

  International journal of pharmaceutics 20080806

• Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy.

  Diabetes care 20080801

• Hemodynamic effects of fenofibrate and coenzyme Q10 in type 2 diabetic subjects with left ventricular diastolic dysfunction.

  Diabetes care 20080801

• Effects of statins on high-density lipoproteins: a potential contribution to cardiovascular benefit.

  Cardiovascular drugs and therapy 20080801

• Exposure to perfluorooctane sulfonate or fenofibrate causes PPAR-alpha dependent transcriptional responses in chicken embryo hepatocytes.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20080801

• Combination therapy for treatment or prevention of atherosclerosis.

  Hypertension (Dallas, Tex. : 1979) 20080801

• Identification of upregulators of human ATP-binding cassette transporter A1 via high-throughput screening of a synthetic and natural compound library.

  Journal of biomolecular screening 20080801

• HDL metabolism in context: looking on the bright side.

  Current opinion in lipidology 20080801

• The circulating metabolic regulator FGF21 is induced by prolonged fasting and PPARalpha activation in man.

  Cell metabolism 20080801

• A study of the pharmacokinetic interactions of the direct renin inhibitor aliskiren with metformin, pioglitazone and fenofibrate in healthy subjects.

  Current medical research and opinion 20080801

• The Relationship Between HIV Infection and Cardiovascular Disease.

  Current cardiology reviews 20080801

• Analysis of 6-month effect of orlistat administration, alone or in combination with fenofibrate, on triglyceride-rich lipoprotein metabolism in overweight and obese patients with metabolic syndrome.

  Journal of clinical lipidology 20080801

• The effects of dietary obesity on protein expressions of insulin signaling pathway in rat aorta.

  Drug discoveries & therapeutics 20080801

• Characterization of the drug binding specificity of rat liver fatty acid binding protein.

  Journal of medicinal chemistry 20080710

• Peroxisome proliferator-activated receptor alpha agonists regulate cholesterol ester transfer protein.

  Lipids 20080701

• Adiponectin receptors: expression in Zucker diabetic rats and effects of fenofibrate and metformin.

  Metabolism: clinical and experimental 20080701

• Comparison of three treatment approaches to decreasing cardiovascular disease risk in nondiabetic insulin-resistant dyslipidemic subjects.

  The American journal of cardiology 20080701

• The effect of PPAR ligands to modulate glucose metabolism alters the incorporation of metabolic precursors into proteoglycans synthesized by human vascular smooth muscle cells.

  Archives of physiology and biochemistry 20080701

• Does Tricor cause gallstones?

  Harvard heart letter : from Harvard Medical School 20080701

• Electronic structure and UV spectrum of fenofibrate in solutions.

  International journal of pharmaceutics 20080624

• Is fenofibrate a cost-saving treatment for middle-aged individuals with type II diabetes? An economic analysis of the FIELD Study.

  International journal of cardiology 20080623

• Prediction and identification of drug interactions with the human ATP-binding cassette transporter multidrug-resistance associated protein 2 (MRP2; ABCC2).

  Journal of medicinal chemistry 20080612

• [Fenofibrate in the treatment of diabetic retinopathy].

  Medicina clinica 20080607

• A novel bottom-up process to produce drug nanocrystals: controlled crystallization during freeze-drying.

  Journal of controlled release : official journal of the Controlled Release Society 20080604

• The effects of orlistat and fenofibrate, alone or in combination, on high-density lipoprotein subfractions and pre-beta1-HDL levels in obese patients with metabolic syndrome.

  Diabetes, obesity & metabolism 20080601

• Effect of powder processing on performance of fenofibrate formulations.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080601

• Fenofibrate reduces fasting and postprandial inflammatory responses among hypertriglyceridemia patients with the metabolic syndrome.

  Atherosclerosis 20080601

• Systemic and distal repercussions of liver-specific peroxisome proliferator-activated receptor-alpha control of the acute-phase response.

  Endocrinology 20080601

• Effect of peroxisome proliferator-activated receptor-alpha ligands in the interaction between adipocytes and macrophages in obese adipose tissue.

  Obesity (Silver Spring, Md.) 20080601

• Plasma PCSK9 concentrations correlate with LDL and total cholesterol in diabetic patients and are decreased by fenofibrate treatment.

  Clinical chemistry 20080601

• Fenofibrate improves endothelial function and decreases thrombin-activatable fibrinolysis inhibitor concentration in metabolic syndrome.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20080601

• Efficacy of lipid-lowering medications in patients treated with clozapine: a naturalistic study.

  Journal of clinical psychopharmacology 20080601

• Effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in patients with diabetes mellitus and mixed dyslipidemia.

  The American journal of cardiology 20080601

• Effect of fenofibrate on kidney function: a 6-week randomized crossover trial in healthy people.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20080601

• Effects of fenofibrate and ezetimibe, both as monotherapy and in coadministration, on cholesterol mass within lipoprotein subfractions and low-density lipoprotein peak particle size in patients with mixed hyperlipidemia.

  Metabolism: clinical and experimental 20080601

• Regulation of Octn2 transporter (SLC22A5) by peroxisome proliferator activated receptor alpha.

  Biological & pharmaceutical bulletin 20080601

• New evidences for C-reactive protein (CRP) deposits in the arterial intima as a cardiovascular risk factor.

  Clinical interventions in aging 20080601

• Relative safety profiles of high dose statin regimens.

  Vascular health and risk management 20080601

• The establishment of a novel non-alcoholic steatohepatitis model accompanied with obesity and insulin resistance in mice.

  Life sciences 20080507

• An automated method for the simultaneous determination of pravastatin, 3-hydroxy isomeric metabolite, pravalactone and fenofibric acid in human plasma by sensitive liquid chromatography combined with diode array and tandem mass spectrometry detection.

  Journal of chromatography. A 20080502

• A novel PPARalpha agonist ameliorates insulin resistance in dogs fed a high-fat diet.

  American journal of physiology. Endocrinology and metabolism 20080501

• The genetic architecture of fasting plasma triglyceride response to fenofibrate treatment.

  European journal of human genetics : EJHG 20080501

• Renal cytochrome P450 as a determinant of impaired natriuresis by PPAR-gamma ligands in ovariectomized obese rats.

  Obesity (Silver Spring, Md.) 20080501

• Association of common C-reactive protein (CRP) gene polymorphisms with baseline plasma CRP levels and fenofibrate response: the GOLDN study.

  Diabetes care 20080501

• Deficient renal 20-HETE release in the diabetic rat is not the result of oxidative stress.

  American journal of physiology. Heart and circulatory physiology 20080501

• Effectiveness of a fenofibrate 145-mg nanoparticle tablet formulation compared with the standard 160-mg tablet in patients with coronary heart disease and dyslipidemia.

  Pharmacotherapy 20080501

• [Fenofibrates and gynaecomastia].

  Annales de dermatologie et de venereologie 20080501

• Improvement of inflammatory responses associated with NF-kappa B pathway in kidneys from diabetic rats.

  Inflammation research : official journal of the European Histamine Research Society ... [et al.] 20080501

• Complete clinical remission of tumor-stage mycosis fungoides after acute extensive skin necroses, granulomatous reaction, and fever under treatment with bexarotene, vorinostat, and high-dose fenofibrate.

  Journal of the American Academy of Dermatology 20080501

• Inhibiting wild-type and C299S mutant AKR1B10; a homologue of aldose reductase upregulated in cancers.

  European journal of pharmacology 20080428

• A high-throughput approach towards a novel formulation of fenofibrate in omega-3 oil.

  European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences 20080423

• Peroxisome proliferator-activated receptor alpha agonist-induced down-regulation of hepatic glucocorticoid receptor expression in SD rats.

  Biochemical and biophysical research communications 20080418

• Dual mechanisms for the fibrate-mediated repression of proprotein convertase subtilisin/kexin type 9.

  The Journal of biological chemistry 20080411

• PPARalpha activators upregulate eNOS activity and inhibit cytokine-induced NF-kappaB activation through AMP-activated protein kinase activation.

  Life sciences 20080409

• Fenofibrate prevents orotic acid--induced hepatic steatosis in rats.

  Life sciences 20080409

• Fish oil and fenofibrate for the treatment of hypertriglyceridemia in HIV-infected subjects on antiretroviral therapy: results of ACTG A5186.

  Journal of acquired immune deficiency syndromes (1999) 20080401

• Early changes in arterial structure and function following statin initiation: quantification by magnetic resonance imaging.

  Atherosclerosis 20080401

• Differential effects of fibrates on the metabolic activation of 2-phenylpropionic acid in rats.

  Drug metabolism and disposition: the biological fate of chemicals 20080401

• Lipid-lowering therapy and peripheral sensory neuropathy in type 2 diabetes: the Fremantle Diabetes Study.

  Diabetologia 20080401

• Species differences in the response of liver drug-metabolizing enzymes to (S)-4-O-tolylsulfanyl-2-(4-trifluormethyl-phenoxy)-butyric acid (EMD 392949) in vivo and in vitro.

  Drug metabolism and disposition: the biological fate of chemicals 20080401

• The peroxisome: still a mysterious organelle.

  Histochemistry and cell biology 20080401

• Cytochrome P450-dependent metabolism of eicosapentaenoic acid in the nematode Caenorhabditis elegans.

  Archives of biochemistry and biophysics 20080401

• Colesevelam hydrochloride in clinical practice: a new approach in the treatment of hypercholesterolaemia.

  Current medical research and opinion 20080401

• Combination therapy in the management of mixed dyslipidaemia.

  Journal of internal medicine 20080401

• Chronic palmitate exposure inhibits AMPKalpha and decreases glucose-stimulated insulin secretion from beta-cells: modulation by fenofibrate.

  Acta pharmacologica Sinica 20080401

• [Other antihyperuricemic agents].

  Nihon rinsho. Japanese journal of clinical medicine 20080401

• Belgian expert opinion: how to reduce the residual risk in atherogenic dyslipidaemic patients: place of fibrates.

  Acta cardiologica 20080401

• Combination therapy in cholesterol reduction: focus on ezetimibe and statins.

  Vascular health and risk management 20080401

• Clinical efficacy and safety of statins in managing cardiovascular risk.

  Vascular health and risk management 20080401

• Discovery of a novel class of 1,3-dioxane-2-carboxylic acid derivatives as subtype-selective peroxisome proliferator-activated receptor alpha (PPARalpha) agonists.

  Bioorganic & medicinal chemistry letters 20080315

• Omega-(2-Naphthyloxy) amino alkanes as a novel class of anti-hyperglycemic and lipid lowering agents.

  Bioorganic & medicinal chemistry 20080301

• Differential effect of atorvastatin and fenofibrate on plasma oxidized low-density lipoprotein, inflammation markers, and cell adhesion molecules in patients with type 2 diabetes mellitus.

  Metabolism: clinical and experimental 20080301

• A pilot trial of fenofibrate for the treatment of non-alcoholic fatty liver disease.

  Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver 20080301

• Schisandrin B from Schisandra chinensis reduces hepatic lipid contents in hypercholesterolaemic mice.

  The Journal of pharmacy and pharmacology 20080301

• Fenofibrate reduces lipoprotein associated phospholipase A2 mass and oxidative lipids in hypertriglyceridemic subjects with the metabolic syndrome.

  American heart journal 20080301

• Peroxisome proliferator-activated receptor alpha activation attenuated angiotensin type 1-mediated but enhanced angiotensin type 2-mediated hemodynamic effects to angiotensin II in the rat.

  Journal of hypertension 20080301

• Fenofibrate and diabetic retinopathy.

  Lancet (London, England) 20080301

• Fenofibrate and diabetic retinopathy.

  Lancet (London, England) 20080301

• Fenofibrate and diabetic retinopathy.

  Lancet (London, England) 20080301

• The weakness of a big heart.

  Nature medicine 20080301

• Effects of fibrate drugs on expression of ABCA1 and HDL biogenesis in hepatocytes.

  Journal of cardiovascular pharmacology 20080301

• Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates.

  International journal of cardiology 20080227

• Resveratrol attenuates the expression of HMG-CoA reductase mRNA in hamsters.

  Biochemical and biophysical research communications 20080227

• Suppression of allergen-induced airway inflammation and immune response by the peroxisome proliferator-activated receptor-alpha agonist fenofibrate.

  European journal of pharmacology 20080226

• Comparison of effects of simvastatin alone versus fenofibrate alone versus simvastatin plus fenofibrate on lipoprotein subparticle profiles in diabetic patients with mixed dyslipidemia (from the Diabetes and Combined Lipid Therapy Regimen study).

  The American journal of cardiology 20080215

• Unexpected differences in dissolution behavior of tablets prepared from solid dispersions with a surfactant physically mixed or incorporated.

  International journal of pharmaceutics 20080212

• Dissolution enhancement of fenofibrate by micronization, cogrinding and spray-drying: comparison with commercial preparations.

  European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V 20080201

• Inhibitory effects of fenofibrate on apoptosis and cell proliferation in human endothelial cells in high glucose.

  Journal of molecular medicine (Berlin, Germany) 20080201

• Peroxisome proliferator-activated receptor-alpha regulates the expression of pancreatic/duodenal homeobox-1 in rat insulinoma (INS-1) cells and ameliorates glucose-induced insulin secretion impaired by palmitate.

  Endocrinology 20080201

• Fenofibrate treatment of diabetic rats reduces nitrosative stress, renal cyclooxygenase-2 expression, and enhanced renal prostaglandin release.

  The Journal of pharmacology and experimental therapeutics 20080201

• Differential effect of fenofibrate and atorvastatin on in vivo kinetics of apolipoproteins B-100 and B-48 in subjects with type 2 diabetes mellitus with marked hypertriglyceridemia.

  Metabolism: clinical and experimental 20080201

• Otophyma: a case report and review of the literature of lymphedema (elephantiasis) of the ear.

  The American Journal of dermatopathology 20080201

• Fenofibrate and rosiglitazone improve quality of lipoproteins in patients with type 2 diabetes mellitus.

  Neuro endocrinology letters 20080201

• Management of mixed dyslipidemia in patients with or at risk for cardiovascular disease: a role for combination fibrate therapy.

  Clinical therapeutics 20080201

• Does the addition of fibrates to statin therapy have a favorable risk to benefit ratio?

  Current atherosclerosis reports 20080201

• Update on the use of fibrates: focus on bezafibrate.

  Vascular health and risk management 20080201

• High density lipoprotein cholesterol: an evolving target of therapy in the management of cardiovascular disease.

  Vascular health and risk management 20080201

• The effects of physiological and pharmacological weight loss on adiponectin and leptin mRNA levels in the rat epididymal adipose tissue.

  European journal of pharmacology 20080128

• [Effects of fenofibrate on gene expression of carnitine palmitoyltransferase 1 in liver and skeletal muscle and its influence on insulin sensitivity].

  Zhonghua yi xue za zhi 20080122

• Elevated serum creatinine levels associated with fenofibrate therapy.

  American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists 20080115

• Generation of Abeta38 and Abeta42 is independently and differentially affected by familial Alzheimer disease-associated presenilin mutations and gamma-secretase modulation.

  The Journal of biological chemistry 20080111

• Effect of fenofibrate therapy on paraoxonase1 status in patients with low HDL-C levels.

  Atherosclerosis 20080101

• The PPAR alpha-humanized mouse: a model to investigate species differences in liver toxicity mediated by PPAR alpha.

  Toxicological sciences : an official journal of the Society of Toxicology 20080101

• Is there a role for fibrates in the management of dyslipidemia in the metabolic syndrome?

  Arteriosclerosis, thrombosis, and vascular biology 20080101

• Modulation of endothelial cell thrombomodulin by PPAR ligands--variation according to environment.

  Thrombosis research 20080101

• Regulation of peroxisome proliferator-activated receptor-alpha expression during lung inflammation.

  Pulmonary pharmacology & therapeutics 20080101

• Inhibition of plasminogen activator inhibitor type-1 expression in HepG2 cells by fenofibrate may be associated with Smad signaling.

  Clinica chimica acta; international journal of clinical chemistry 20080101

• Fenofibrate modulates cardiac and hepatic metabolism and increases ischemic tolerance in diet-induced obese mice.

  Journal of molecular and cellular cardiology 20080101

• Peroxisome proliferator-activated receptors--from active regulators of macrophage biology to pharmacological targets in the treatment of cardiovascular disease.

  Journal of internal medicine 20080101

• Relative safety of gemfibrozil and fenofibrate in the absence of concomitant cerivastatin use.

  The American journal of cardiology 20080101

• PPAR agonists treatment is effective in a nonalcoholic fatty liver disease animal model by modulating fatty-acid metabolic enzymes.

  Journal of gastroenterology and hepatology 20080101

• Anti-inflammatory effect of antidiabetic thiazolidinediones prevents bone resorption rather than cartilage changes in experimental polyarthritis.

  Arthritis research & therapy 20080101

• Heterozygous CAV1 frameshift mutations (MIM 601047) in patients with atypical partial lipodystrophy and hypertriglyceridemia.

  Lipids in health and disease 20080101

• Are platelets a 'forgotten' source of sepsis-induced myocardial depressing factor(s)?

  Critical care (London, England) 20080101

• Lipid profiles of patients with a transplanted heart before and after the operation.

  Transplantation proceedings 20080101

• Lipid-lowering therapy in patients with type 2 diabetes: the case for early intervention.

  Diabetes/metabolism research and reviews 20080101

• PPAR-alpha agonist fenofibrate induces renal CYP enzymes and reduces blood pressure and glomerular hypertrophy in Zucker diabetic fatty rats.

  American journal of nephrology 20080101

• Peroxisome proliferator activated receptors and lipoprotein metabolism.

  PPAR research 20080101

• Role of the peroxisome proliferator-activated receptors, adenosine monophosphate-activated kinase, and adiponectin in the ovary.

  PPAR research 20080101

• PPAR Agonists and Cardiovascular Disease in Diabetes.

  PPAR research 20080101

• The PPARalpha-PGC-1alpha Axis Controls Cardiac Energy Metabolism in Healthy and Diseased Myocardium.

  PPAR research 20080101

• The PPAR-Platelet Connection: Modulators of Inflammation and Potential Cardiovascular Effects.

  PPAR research 20080101

• Should We Use PPAR Agonists to Reduce Cardiovascular Risk?

  PPAR research 20080101

• Effect of synthetic dietary triglycerides: a novel research paradigm for nutrigenomics.

  PloS one 20080101

• PPAR-gamma, Microglial Cells, and Ocular Inflammation: New Venues for Potential Therapeutic Approaches.

  PPAR research 20080101

• Peroxisome proliferator-activated receptors: 'key' regulators of neuroinflammation after traumatic brain injury.

  PPAR research 20080101

• PPAR Genomics and Pharmacogenomics: Implications for Cardiovascular Disease.

  PPAR research 20080101

• PPAR-alpha Ligands as Potential Therapeutic Agents for Wet Age-Related Macular Degeneration.

  PPAR research 20080101

• PPARs and Female Reproduction: Evidence from Genetically Manipulated Mice.

  PPAR research 20080101

• Terminologies for text-mining; an experiment in the lipoprotein metabolism domain.

  BMC bioinformatics 20080101

• Eruptive xanthomas and acute pancreatitis in a patient with hypertriglyceridemia.

  International archives of medicine 20080101

• PPAR Ligands for Cancer Chemoprevention.

  PPAR research 20080101

• PPARalpha-mediated effects of dietary lipids on intestinal barrier gene expression.

  BMC genomics 20080101

• Anticancer Properties of PPARalpha-Effects on Cellular Metabolism and Inflammation.

  PPAR research 20080101

• Fenofibrate-induced acute renal failure due to massive rhabdomyolysis after coadministration of statin in two patients.

  Internal medicine (Tokyo, Japan) 20080101

• Synergistic Effects of PPARgamma Ligands and Retinoids in Cancer Treatment.

  PPAR research 20080101

• The SCARB1 gene is associated with lipid response to dietary and pharmacological interventions.

  Journal of human genetics 20080101

• Plasma PCSK9 levels are significantly modified by statins and fibrates in humans.

  Lipids in health and disease 20080101

• Peroxisome proliferator-activated receptors and progression of colorectal cancer.

  PPAR research 20080101

• Multiple Interactions between Peroxisome Proliferators-Activated Receptors and the Ubiquitin-Proteasome System and Implications for Cancer Pathogenesis.

  PPAR research 20080101

• Interactions between APP secretases and inflammatory mediators.

  Journal of neuroinflammation 20080101

• A Role for PPARgamma in the Regulation of Cytokines in Immune Cells and Cancer.

  PPAR research 20080101

• Structural Development Studies of Subtype-Selective Ligands for Peroxisome Proliferator-Activated Receptors (PPARs) Based on the 3,4-Disubstituted Phenylpropanoic Acid Scaffold as a Versatile Template.

  PPAR research 20080101

• Peroxisome Proliferators-Activated Receptor (PPAR) Modulators and Metabolic Disorders.

  PPAR research 20080101

• Fenofibrate set to benefit from new research on its active metabolite, fenofibric acid.

  Cardiovascular journal of Africa 20080101

• Statin induced myopathy and myalgia: time trend analysis and comparison of risk associated with statin class from 1991-2006.

  PloS one 20080101

• The Role of PPARs in Cancer.

  PPAR research 20080101

• [Rosuvastatin for the treatment of dyslipidemia in HIV-infected patients receiving highly active antiretroviral therapy. Preliminary experience].

  Enfermedades infecciosas y microbiologia clinica 20080101

• Macrophages, PPARs, and Cancer.

  PPAR research 20080101

• The Role of PPAR Ligands in Controlling Growth-Related Gene Expression and their Interaction with Lipoperoxidation Products.

  PPAR research 20080101

• Leukotriene B4-loaded microspheres: a new therapeutic strategy to modulate cell activation.

  BMC immunology 20080101

• Mitochondria, PPARs, and Cancer: Is Receptor-Independent Action of PPAR Agonists a Key?

  PPAR research 20080101

• PPAR Alpha Regulation of the Immune Response and Autoimmune Encephalomyelitis.

  PPAR research 20080101

• PPAR Ligands as Potential Modifiers of Breast Carcinoma Outcomes.

  PPAR research 20080101

• Role of peroxisome proliferator-activated receptor alpha in the control of cyclooxygenase 2 and vascular endothelial growth factor: involvement in tumor growth.

  PPAR research 20080101

• PPAR Regulation of Inflammatory Signaling in CNS Diseases.

  PPAR research 20080101

• Insulin resistance postburn: underlying mechanisms and current therapeutic strategies.

  Journal of burn care & research : official publication of the American Burn Association 20080101

• PPARalpha Ligands as Antitumorigenic and Antiangiogenic Agents.

  PPAR research 20080101

• s-ICAM-1 and s-VCAM-1 in healthy men are strongly associated with traits of the metabolic syndrome, becoming evident in the postprandial response to a lipid-rich meal.

  Lipids in health and disease 20080101

• Peroxisome proliferator-activated receptors in the modulation of the immune/inflammatory response in atherosclerosis.

  PPAR research 20080101

• PPARalpha- and DEHP-Induced Cancers.

  PPAR research 20080101

• Retrospective comparison of the effectiveness of a fenofibrate 145 mg formulation compared with the standard 160 mg tablet.

  Clinical drug investigation 20080101

• Evaluation of a new formulation of fenofibric acid, ABT-335, co-administered with statins : study design and rationale of a phase III clinical programme.

  Clinical drug investigation 20080101

• Renal and vascular mechanisms of thiazolidinedione-induced fluid retention.

  PPAR research 20080101

• Statins but not fibrates improve the atherogenic to anti-atherogenic lipoprotein particle ratio: a randomized crossover study.

  BMC clinical pharmacology 20080101

• Determination of etofibrate, fenofibrate, and atorvastatin in pharmaceutical preparations and plasma using differential pulse polarographic and square wave voltammetric techniques.

  Journal of AOAC International 20080101

• PPARalpha/gamma-Independent Effects of PPARalpha/gamma Ligands on Cysteinyl Leukotriene Production in Mast Cells.

  PPAR research 20080101

• The Role of PPARs in the Endothelium: Implications for Cancer Therapy.

  PPAR research 20080101

• Transcriptome profiling of the feeding-to-fasting transition in chicken liver.

  BMC genomics 20080101

• Improved Insulin Resistance and Lipid Metabolism by Cinnamon Extract through Activation of Peroxisome Proliferator-Activated Receptors.

  PPAR research 20080101

• PPARs Mediate Lipid Signaling in Inflammation and Cancer.

  PPAR research 20080101

• PPAR-delta in Vascular Pathophysiology.

  PPAR research 20080101

• Which dose of omega-3 fatty acids must be taken in different cases of hypertriglyceridemia?

  Romanian journal of internal medicine = Revue roumaine de medecine interne 20080101

• Rat Urinary Bladder Carcinogenesis by Dual-Acting PPARalpha + gamma Agonists.

  PPAR research 20080101

• The Role of NF-kappaB in PPARalpha-Mediated Hepatocarcinogenesis.

  PPAR research 20080101

• Peroxisome proliferator-activated receptors in diabetic nephropathy.

  PPAR research 20080101

• Development and Validation of RP-HPLC Method for Simultaneous Estimation of Atorvastatin Calcium and Fenofibrate in Tablet Dosage Forms.

  Indian journal of pharmaceutical sciences 20080101

• Use of a multidisciplinary tool to achieve target outcomes in Native American patients with diabetes: Treat-to-target.

  Journal of multidisciplinary healthcare 20080101

• 2-Methyl-2-(4-nitro-phenyl-sulfanyl)-propanoic acid.

  Acta crystallographica. Section E, Structure reports online 20080101

• Design and Evaluation of Ethyl Cellulose Based Matrix Tablets of Ibuprofen with pH Modulated Release Kinetics.

  Indian journal of pharmaceutical sciences 20080101

• Therapeutic Potential of PPARγ Activation in Stroke.

  PPAR research 20080101

• Design and synthesis of indane-ureido-thioisobutyric acids: A novel class of PPARalpha agonists.

  Bioorganic & medicinal chemistry letters 20071215

• Induction of nuclear translocation of constitutive androstane receptor by peroxisome proliferator-activated receptor alpha synthetic ligands in mouse liver.

  The Journal of biological chemistry 20071214

• Effects of fenofibrate and simvastatin on HDL-related biomarkers in low-HDL patients.

  Atherosclerosis 20071201

• Dysregulation of the expression and secretion of inflammation-related adipokines by hypoxia in human adipocytes.

  Pflugers Archiv : European journal of physiology 20071201

• Antidyslipidemic activity of polyprenol from Coccinia grandis in high-fat diet-fed hamster model.

  Phytomedicine : international journal of phytotherapy and phytopharmacology 20071201

• Fenofibrate reduces intestinal cholesterol absorption via PPARalpha-dependent modulation of NPC1L1 expression in mouse.

  Journal of lipid research 20071201

• Peroxisome proliferator-activated receptor-alpha agonist fenofibrate regulates IL-12 family cytokine expression in the CNS: relevance to multiple sclerosis.

  Journal of neurochemistry 20071201

• Fenofibrate inhibits intestinal Cl- secretion by blocking basolateral KCNQ1 K+ channels.

  American journal of physiology. Gastrointestinal and liver physiology 20071201

• Bicyclol, a synthetic dibenzocyclooctadiene derivative, decreases hepatic lipids but increases serum triglyceride level in normal and hypercholesterolaemic mice.

  The Journal of pharmacy and pharmacology 20071201

• [Impact of fenofibrate on NO and endothelial VCAM-1 expression in hyperlipidemic rats].

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20071201

• Practical guidelines for familial combined hyperlipidemia diagnosis: an up-date.

  Vascular health and risk management 20071201

• Reduction of C-reactive protein and the use of anti-hypertensives.

  Vascular health and risk management 20071201

• Rationale for multiple risk intervention: the need to move from theory to practice.

  Vascular health and risk management 20071201

• Effect of berberine on PPARalpha/delta/gamma expression in type 2 diabetic rat retinae.

  Yao xue xue bao = Acta pharmaceutica Sinica 20071201

• Efficacy and safety of ezetimibe/simvastatin co- administered with fenofibrate in mixed hyperlipidemic patients with metabolic syndrome.

  Metabolic syndrome and related disorders 20071201

• Fenofibrate for diabetic retinopathy.

  Lancet (London, England) 20071117

• Effect of fenofibrate on the need for laser treatment for diabetic retinopathy (FIELD study): a randomised controlled trial.

  Lancet (London, England) 20071117

• Cannabinoid activation of PPAR alpha; a novel neuroprotective mechanism.

  British journal of pharmacology 20071101

• Peroxisome proliferator-activated receptor alpha: friend or foe?

  Hypertension (Dallas, Tex. : 1979) 20071101

• Absence of peroxisome proliferator-activated receptor-alpha abolishes hypertension and attenuates atherosclerosis in the Tsukuba hypertensive mouse.

  Hypertension (Dallas, Tex. : 1979) 20071101

• Normalization of metabolic syndrome using fenofibrate, metformin or their combination.

  Diabetes, obesity & metabolism 20071101

• Comparison of atorvastatin versus fenofibrate in reaching lipid targets and influencing biomarkers of endothelial damage in patients with familial combined hyperlipidemia.

  Metabolism: clinical and experimental 20071101

• Hypertriglyceridemia and hepatic steatosis in senescence-accelerated mouse associate to changes in lipid-related gene expression.

  The journals of gerontology. Series A, Biological sciences and medical sciences 20071101

• A simplified method for the measurement of urinary free cortisol using LC-MS/MS.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20071015

• Fenofibrate and pioglitazone improve endothelial function and reduce arterial stiffness in obese glucose tolerant men.

  Atherosclerosis 20071001

• Risk of congenital anomalies in pregnant users of statin drugs.

  British journal of clinical pharmacology 20071001

• The application of ink-jet technology for the coating and loading of drug-eluting stents.

  Annals of biomedical engineering 20071001

• Long-term effects of fenofibrate on VLDL and HDL subspecies in participants with type 2 diabetes mellitus.

  Diabetologia 20071001

• Delta5 desaturase mRNA levels are increased by simvastatin via SREBP-1 at early stages, not via PPARalpha, in THP-1 cells.

  European journal of pharmacology 20071001

• Differential effect of hypolipidemic drugs on lipoprotein-associated phospholipase A2.

  Arteriosclerosis, thrombosis, and vascular biology 20071001

• Plasma triglycerides are not related to tissue lipids and insulin sensitivity in elderly following PPAR-alpha agonist treatment.

  Mechanisms of ageing and development 20071001

• A review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetes.

  Vascular health and risk management 20071001

• Colesevelam hydrochloride: reducing atherosclerotic coronary heart disease risk factors.

  Vascular health and risk management 20071001

• An investigation into the lipid-binding properties of alpha-, beta- and gamma-synucleins in human brain and cerebrospinal fluid.

  Brain research 20070919

• Mitochondrial impairment by PPAR agonists and statins identified via immunocaptured OXPHOS complex activities and respiration.

  Toxicology and applied pharmacology 20070915

• Is it time to stop treating dyslipidaemia with fibrates?

  The New Zealand medical journal 20070907

• Effects of fenofibrate on cardiac remodeling in aldosterone-induced hypertension.

  Hypertension (Dallas, Tex. : 1979) 20070901

• Discordance between intramuscular triglyceride and insulin sensitivity in skeletal muscle of Zucker diabetic rats after treatment with fenofibrate and rosiglitazone.

  Diabetes, obesity & metabolism 20070901

• The clinical relevance of LDL size and subclasses modulation in patients with type-2 diabetes.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20070901

• [PPAR alpha activator fenofibrate regressed left ventricular hypertrophy and increased myocardium PPAR alpha expression in spontaneously hypertensive rats].

  Zhejiang da xue xue bao. Yi xue ban = Journal of Zhejiang University. Medical sciences 20070901

• Preventing type 2 diabetes and cardiovascular disease in metabolic syndrome: the role of PPARalpha.

  Diabetes & vascular disease research 20070901

• The role of fenofibrate in clinical practice.

  Diabetes & vascular disease research 20070901

• Diabetic retinopathy: treatment and prevention.

  Diabetes & vascular disease research 20070901

• Preparation and in vivo evaluation of SMEDDS (self-microemulsifying drug delivery system) containing fenofibrate.

  The AAPS journal 20070901

• [Involvement of the foot in metabolic diseases].

  Praxis 20070822

• Design and synthesis of highly potent and selective human peroxisome proliferator-activated receptor alpha agonists.

  Bioorganic & medicinal chemistry letters 20070815

• The effect of orlistat and fenofibrate, alone or in combination, on small dense LDL and lipoprotein-associated phospholipase A2 in obese patients with metabolic syndrome.

  Atherosclerosis 20070801

• Preparation and characterization of fenofibrate-loaded PLA-PEG microspheres.

  Journal of materials science. Materials in medicine 20070801

• Atorvastatin glucuronidation is minimally and nonselectively inhibited by the fibrates gemfibrozil, fenofibrate, and fenofibric acid.

  Drug metabolism and disposition: the biological fate of chemicals 20070801

• Fenofibrate therapy ameliorates fasting and postprandial lipoproteinemia, oxidative stress, and the inflammatory response in subjects with hypertriglyceridemia and the metabolic syndrome.

  Diabetes care 20070801

• Effects of peroxisome proliferator-activated receptor (PPAR)-alpha and PPAR-gamma agonists on glucose and lipid metabolism in patients with type 2 diabetes mellitus.

  Diabetologia 20070801

• Fenofibrate increases HDL-cholesterol by reducing cholesteryl ester transfer protein expression.

  Journal of lipid research 20070801

• Influence of HDL-cholesterol-elevating drugs on the in vitro activity of the HDL receptor SR-BI.

  Journal of lipid research 20070801

• PROactive 07: pioglitazone in the treatment of type 2 diabetes: results of the PROactive study.

  Vascular health and risk management 20070801

• Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study.

  Vascular health and risk management 20070801

• Roles of oxidative stress and Akt signaling in doxorubicin cardiotoxicity.

  Biochemical and biophysical research communications 20070720

• Genome-wide analysis of PPARalpha activation in murine small intestine.

  Physiological genomics 20070718

• Long-term fenofibrate treatment impairs endothelium-dependent dilation to acetylcholine by altering the cyclooxygenase pathway.

  Cardiovascular research 20070715

• Pharmacokinetic evaluation of oral fenofibrate nanosuspensions and SLN in comparison to conventional suspensions of micronized drug.

  Advanced drug delivery reviews 20070710

• Activation of peroxisome proliferator-activated receptor-alpha prevents glycogen synthase 3beta phosphorylation and inhibits cardiac hypertrophy.

  FEBS letters 20070710

• Fenofibrate improves age-related endothelial dysfunction in rat resistance arteries.

  Atherosclerosis 20070701

• Toxic and genotoxic impact of fibrates and their photoproducts on non-target organisms.

  Environment international 20070701

• Cholesterol-like effects of selective cyclooxygenase inhibitors and fibrates on cellular membranes and amyloid-beta production.

  Molecular pharmacology 20070701

• Diabetes or peroxisome proliferator-activated receptor alpha agonist increases mitochondrial thioesterase I activity in heart.

  Journal of lipid research 20070701

• Increasing or stabilizing renal epoxyeicosatrienoic acid production attenuates abnormal renal function and hypertension in obese rats.

  American journal of physiology. Renal physiology 20070701

• New treatments for gout.

  Joint, bone, spine : revue du rhumatisme 20070701

• Neurological recovery-promoting, anti-inflammatory, and anti-oxidative effects afforded by fenofibrate, a PPAR alpha agonist, in traumatic brain injury.

  Journal of neurotrauma 20070701

• Relationship between insulin resistance and low urinary pH in patients with gout, and effects of PPARalpha agonists on urine pH.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20070701

• Hypolipidemic effects of silymarin are not mediated by the peroxisome proliferator-activated receptor alpha.

  Xenobiotica; the fate of foreign compounds in biological systems 20070701

• Fenofibrate represses interleukin-17 and interferon-gamma expression and improves colitis in interleukin-10-deficient mice.

  Gastroenterology 20070701

• Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial: design and methods.

  The American journal of cardiology 20070618

• Prevention of cardiovascular disease in persons with type 2 diabetes mellitus: current knowledge and rationale for the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

  The American journal of cardiology 20070618

• Evolution of the lipid trial protocol of the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial.

  The American journal of cardiology 20070618

• Screening method for ecotoxicological hazard assessment of 42 pharmaceuticals considering human metabolism and excretory routes.

  Environmental science & technology 20070615

• Expression of heme oxygenase-1 in human vascular cells is regulated by peroxisome proliferator-activated receptors.

  Arteriosclerosis, thrombosis, and vascular biology 20070601

• Fenofibrate effect on triglyceride and postprandial response of apolipoprotein A5 variants: the GOLDN study.

  Arteriosclerosis, thrombosis, and vascular biology 20070601

• Fenofibrate increases high molecular weight adiponectin in subjects with hypertriglyceridemia.

  Endocrine journal 20070601

• Apolipoprotein A-V genetic variation and plasma lipoprotein response to fibrates.

  Arteriosclerosis, thrombosis, and vascular biology 20070601

• Short-term therapy with atorvastatin or fenofibrate does not affect plasma ghrelin, resistin or adiponectin levels in type 2 diabetic patients with mixed hyperlipoproteinaemia.

  Acta diabetologica 20070601

• Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials.

  Expert opinion on drug metabolism & toxicology 20070601

• Hepatic fibroblast growth factor 21 is regulated by PPARalpha and is a key mediator of hepatic lipid metabolism in ketotic states.

  Cell metabolism 20070601

• Inhibition of the actions of peroxisome proliferator-activated receptor alpha on obesity by estrogen.

  Obesity (Silver Spring, Md.) 20070601

• Ezetimibe plus fenofibrate: a new combination therapy for the management of mixed hyperlipidaemia?

  Expert opinion on pharmacotherapy 20070601

• The PPARalpha activator fenofibrate slows down the progression of the left ventricular dysfunction in porcine tachycardia-induced cardiomyopathy.

  Journal of cardiovascular pharmacology 20070601

• The effects of statin and fibrate on lowering small dense LDL- cholesterol in hyperlipidemic patients with type 2 diabetes.

  Journal of atherosclerosis and thrombosis 20070601

• [Effects of activation of liver X receptor and peroxisome proliferator-activated receptor alpha on bile acid synthesis in rats].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20070601

• Investigating the mechanistic basis for hepatic toxicity induced by an experimental chemokine receptor 5 (CCR5) antagonist using a compendium of gene expression profiles.

  Toxicologic pathology 20070601

• Detection and remediation of medically urgent situations using telemedicine case management for older patients with diabetes mellitus.

  Therapeutics and clinical risk management 20070601

• Effect of fenofibrate on oxidative DNA damage and on gene expression related to cell proliferation and apoptosis in rats.

  Toxicological sciences : an official journal of the Society of Toxicology 20070501

• Preventive effects of fenofibrate on insulin resistance, hyperglycaemia, visceral fat accumulation in NIH mice induced by small-dose streptozotocin and lard.

  Pharmacological research 20070501

• Effects of peroxisome proliferator-activated receptor-alpha and -gamma agonists on 11beta-hydroxysteroid dehydrogenase type 1 in subcutaneous adipose tissue in men.

  The Journal of clinical endocrinology and metabolism 20070501

• Fenofibrate regulates retinal endothelial cell survival through the AMPK signal transduction pathway.

  Experimental eye research 20070501

• Synergistic vascular protective effects of combined low doses of PPARalpha and PPARgamma activators in angiotensin II-induced hypertension in rats.

  British journal of pharmacology 20070501

• Peroxisome proliferator-activated receptor alpha-independent actions of fenofibrate exacerbates left ventricular dilation and fibrosis in chronic pressure overload.

  Hypertension (Dallas, Tex. : 1979) 20070501

• Effects of peroxisome proliferator-activated receptor ligands in modulating tissue factor and tissue factor pathway inhibitor in acutely symptomatic carotid atheromas.

  Stroke 20070501

• Glycogen synthase 2 is a novel target gene of peroxisome proliferator-activated receptors.

  Cellular and molecular life sciences : CMLS 20070501

• Role of prescription omega-3 fatty acids in the treatment of hypertriglyceridemia.

  Pharmacotherapy 20070501

• Safety of aggressive lipid management.

  Journal of the American College of Cardiology 20070501

• Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.

  Diabetes 20070501

• Comment on: Boden et al. (2007) Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention: Diabetes 56:248-255.

  Diabetes 20070501

• Effects of hypolipemic drugs on the osteoprotegerin - sRANKL system in patients with coronary artery disease.

  Thrombosis and haemostasis 20070501

• The clinical significance of the size of low-density-lipoproteins and the modulation of subclasses by fibrates.

  Current medical research and opinion 20070501

• The Anti-Obesity Effect of the Palatinose-Based Formula Inslow is Likely due to an Increase in the Hepatic PPAR-alpha and Adipocyte PPAR-gamma Gene Expressions.

  Journal of clinical biochemistry and nutrition 20070501

• Antinociceptive and antiedematogenic activities of fenofibrate, an agonist of PPAR alpha, and pioglitazone, an agonist of PPAR gamma.

  European journal of pharmacology 20070430

• Abeta42 overproduction associated with structural changes in the catalytic pore of gamma-secretase: common effects of Pen-2 N-terminal elongation and fenofibrate.

  The Journal of biological chemistry 20070427

• Bezafibrate regulates the expression and enzyme activity of 11beta-hydroxysteroid dehydrogenase type 1 in murine adipose tissue and 3T3-L1 adipocytes.

  American journal of physiology. Endocrinology and metabolism 20070401

• Chronic activation of peroxisome proliferator-activated receptor-alpha with fenofibrate prevents alterations in cardiac metabolic phenotype without changing the onset of decompensation in pacing-induced heart failure.

  The Journal of pharmacology and experimental therapeutics 20070401

• Underlying mechanisms of pharmacology and toxicity of a novel PPAR agonist revealed using rodent and canine hepatocytes.

  Toxicological sciences : an official journal of the Society of Toxicology 20070401

• Effects of simvastatin on the development of the atrial fibrillation substrate in dogs with congestive heart failure.

  Cardiovascular research 20070401

• Role of liver X receptor, insulin and peroxisome proliferator activated receptor alpha on in vivo desaturase modulation of unsaturated fatty acid biosynthesis.

  Lipids 20070401

• Determination of fenofibric acid concentrations by HPLC after anion exchange solid-phase extraction from human serum.

  Therapeutic drug monitoring 20070401

• Simultaneous quantitative resolution of atorvastatin calcium and fenofibrate in pharmaceutical preparation by using derivative ratio spectrophotometry and chemometric calibrations.

  Analytical sciences : the international journal of the Japan Society for Analytical Chemistry 20070401

• The increase in hepatic uncoupling by fenofibrate contributes to a decrease in adipose tissue in obese rats.

  Journal of Korean medical science 20070401

• Combination therapy of low-dose atorvastatin and fenofibrate in mixed hyperlipidemia.

  Methods and findings in experimental and clinical pharmacology 20070401

• [The effect of treatment with fenofibrate on the risk profile of patients with metabolic syndrome and mixed dyslipidemia treated on an outpatient basis].

  Vnitrni lekarstvi 20070401

• Effects of a potent and selective PPAR-alpha agonist in patients with atherogenic dyslipidemia or hypercholesterolemia: two randomized controlled trials.

  JAMA 20070328

• Expert commentary: the safety of fibrates in lipid-lowering therapy.

  The American journal of cardiology 20070319

• Safety considerations with fibrate therapy.

  The American journal of cardiology 20070319

• Antihyperglycemic and antidyslipidemic agent from Aegle marmelos.

  Bioorganic & medicinal chemistry letters 20070315

• Indanylacetic acid derivatives carrying 4-thiazolyl-phenoxy tail groups, a new class of potent PPAR alpha/gamma/delta pan agonists: synthesis, structure-activity relationship, and in vivo efficacy.

  Journal of medicinal chemistry 20070308

• Lipid-lowering drugs in the MPTP mouse model of Parkinson's disease: fenofibrate has a neuroprotective effect, whereas bezafibrate and HMG-CoA reductase inhibitors do not.

  Brain research 20070302

• Risk factors for statin-associated rhabdomyolysis.

  Pharmacoepidemiology and drug safety 20070301

• Immunoselection and characterization of a human genomic PPAR binding fragment located within POTE genes.

  Biochimie 20070301

• Effects of peroxisome proliferator-activated receptor ligands, bezafibrate and fenofibrate, on adiponectin level.

  Arteriosclerosis, thrombosis, and vascular biology 20070301

• Activation of peroxisome proliferator-activated receptor-alpha by fenofibrate prevents myocardial dysfunction during endotoxemia in rats.

  Critical care medicine 20070301

• Increased plasma levels of oxysterols, in vivo markers of oxidative stress, in patients with familial combined hyperlipidemia: reduction during atorvastatin and fenofibrate therapy.

  Free radical biology & medicine 20070301

• Therapeutic effect of osthole on hyperlipidemic fatty liver in rats.

  Acta pharmacologica Sinica 20070301

• Fibrates: what have we learned in the past 40 years?

  Pharmacotherapy 20070301

• PPARalpha siRNA-treated expression profiles uncover the causal sufficiency network for compound-induced liver hypertrophy.

  PLoS computational biology 20070301

• Gynecomastia associated with fenofibrate.

  The Annals of pharmacotherapy 20070301

• Hypolipidemic mechanisms of Ananas comosus L. leaves in mice: different from fibrates but similar to statins.

  Journal of pharmacological sciences 20070301

• Sepsis-induced myocardial depression: where is the missing link?

  Critical care medicine 20070301

• Transient massive hyperlipidaemia in a type 2 diabetic subject.

  Internal and emergency medicine 20070301

• Nutritional factors associated with anaemia in pregnant women in northern Nigeria.

  Journal of health, population, and nutrition 20070301

• Effect of drugs on high-density lipoprotein.

  Journal of clinical lipidology 20070301

• Substituted 2-[(4-aminomethyl)phenoxy]-2-methylpropionic acid PPARalpha agonists. 1. Discovery of a novel series of potent HDLc raising agents.

  Journal of medicinal chemistry 20070222

• Inflammation in diabetes mellitus: role of peroxisome proliferator-activated receptor-alpha and peroxisome proliferator-activated receptor-gamma agonists.

  The American journal of cardiology 20070219

• Clinical significance of recent lipid trials on reducing risk in patients with type 2 diabetes mellitus.

  The American journal of cardiology 20070219

• Peroxisome proliferator-activated receptor alpha-independent effects of peroxisome proliferators on cysteinyl leukotriene production in mast cells.

  European journal of pharmacology 20070205

• PPAR{alpha} mediates the hypolipidemic action of fibrates by antagonizing FoxO1.

  American journal of physiology. Endocrinology and metabolism 20070201

• Factors affecting the formation of eutectic solid dispersions and their dissolution behavior.

  Journal of pharmaceutical sciences 20070201

• High glucose-boosted inflammatory responses to lipopolysaccharide are suppressed by statin.

  Journal of periodontal research 20070201

• Efficacy and safety of the coadministration of ezetimibe/simvastatin with fenofibrate in patients with mixed hyperlipidemia.

  American heart journal 20070201

• Insulin sensitivity and mitochondrial function are improved in children with burn injury during a randomized controlled trial of fenofibrate.

  Annals of surgery 20070201

• Regulation and function of collagenous repeat containing sequence of 26-kDa protein gene product 'cartonectin'.

  Obesity (Silver Spring, Md.) 20070201

• Estimating the impact of adding C-reactive protein as a criterion for lipid lowering treatment in the United States.

  Journal of general internal medicine 20070201

• Myopathy caused by a combination rosuvastatin and fenofibrate.

  The Journal of the Association of Physicians of India 20070201

• Effect of lipid-lowering and anti-hypertensive drugs on plasma homocysteine levels.

  Vascular health and risk management 20070201

• Vascular wall proteoglycan synthesis and structure as a target for the prevention of atherosclerosis.

  Vascular health and risk management 20070201

• The hypolipidaemic activity of aqueous Erica multiflora flowers extract in Triton WR-1339 induced hyperlipidaemic rats: a comparison with fenofibrate.

  Journal of ethnopharmacology 20070103

• Fenofibrate induces plaque regression in hypercholesterolemic atherosclerotic rabbits: in vivo demonstration by high-resolution MRI.

  Atherosclerosis 20070101

• PPAR agonists modulate human osteoclast formation and activity in vitro.

  Bone 20070101

• Therapeutic approach to FSGS in children.

  Pediatric nephrology (Berlin, Germany) 20070101

• Update on PPAR agonists: the clinical significance of FIELD and PROACTIVE.

  Current atherosclerosis reports 20070101

• The alteration of plasminogen activator inhibitor-1 expression by linoleic acid and fenofibrate in HepG2 cells.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20070101

• Influence of PPAR-alpha agonist fenofibrate on insulin sensitivity and selected adipose tissue-derived hormones in obese women with type 2 diabetes.

  Physiological research 20070101

• Combined use of rosiglitazone and fenofibrate in patients with type 2 diabetes: prevention of fluid retention.

  Diabetes 20070101

• Effects of fenofibrate and xuezhikang on high-fat diet-induced non-alcoholic fatty liver disease.

  Clinical and experimental pharmacology & physiology 20070101

• Fenofibrate: a review of its use in primary dyslipidaemia, the metabolic syndrome and type 2 diabetes mellitus.

  Drugs 20070101

• Intensive statin treatment or combination therapy in high-risk patients.

  Preventive cardiology 20070101

• Optimal treatment of dyslipidemia in high-risk patients: intensive statin treatment or combination therapy?

  Preventive cardiology 20070101

• Ezetimibe and fenofibrate combination therapy for mixed hyperlipidemia.

  Drugs of today (Barcelona, Spain : 1998) 20070101

• Feeding oxidized fat during pregnancy up-regulates expression of PPARalpha-responsive genes in the liver of rat fetuses.

  Lipids in health and disease 20070101

• PPARs in the Control of Uncoupling Proteins Gene Expression.

  PPAR research 20070101

• PPARs, Obesity, and Inflammation.

  PPAR research 20070101

• [The best of epidemiology and cardiovascular prevention in 2006].

  Archives des maladies du coeur et des vaisseaux 20070101

• Comparison of direct and indirect measurement of LDL-C in HIV-infected individuals: ACTG 5087.

  HIV clinical trials 20070101

• Clofibrate treatment in pigs: effects on parameters critical with respect to peroxisome proliferator-induced hepatocarcinogenesis in rodents.

  BMC pharmacology 20070101

• PPAR-alpha agonism improves whole body and muscle mitochondrial fat oxidation, but does not alter intracellular fat concentrations in burn trauma children in a randomized controlled trial.

  Nutrition & metabolism 20070101

• Which health-related quality of life score? A comparison of alternative utility measures in patients with Type 2 diabetes in the ADVANCE trial.

  Health and quality of life outcomes 20070101

• Therapeutic potential of retinoid x receptor modulators for the treatment of the metabolic syndrome.

  PPAR research 20070101

• Decrease in inflammatory cardiovascular risk markers in hyperlipidemic diabetic patients treated with fenofibrate.

  Annals of clinical and laboratory science 20070101

• [Pleiotropic effects of fibric acid derivatives (Lipanthyl-200) among patients with metabolic syndrome].

  Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology 20070101

• Ezetimibe is effective when added to maximally tolerated lipid lowering therapy in patients with HIV.

  Lipids in health and disease 20070101

• Differential vascular dysfunction in response to diets of differing macronutrient composition: a phenomenonological study.

  Nutrition & metabolism 20070101

• Ameliorative effect of combination of fenofibrate and rosiglitazone in pressure overload-induced cardiac hypertrophy in rats.

  Pharmacology 20070101

• Estimation of atorvastatin calcium and fenofibrate in tablets by derivative spectrophotometry and liquid chromatography.

  Journal of AOAC International 20070101

• FIELD study supports the value of fenofibrate in type 2 diabetes management. Good glycaemic control achieved with no weight gain.

  Cardiovascular journal of Africa 20070101

• Uric acid reduction: a new paradigm in the management of cardiovascular risk?

  Current medicinal chemistry 20070101

• Meta-analysis of primary target genes of peroxisome proliferator-activated receptors.

  Genome biology 20070101

• Successful treatment with fenofibrate of autoimmune hepatitis in a patient with rheumatoid arthritis.

  Scandinavian journal of rheumatology 20070101

• Peroxisome proliferator-activated receptors and acute lung injury.

  PPAR research 20070101

• The Role of PPARs in Lung Fibrosis.

  PPAR research 20070101

• The Effect of PPARalpha, PPARdelta, PPARgamma, and PPARpan Agonists on Body Weight, Body Mass, and Serum Lipid Profiles in Diet-Induced Obese AKR/J Mice.

  PPAR research 20070101

• [Recent treatment perspectives in lipidology].

  Revue medicale de Liege 20070101

• Aspirin and Simvastatin Combination for Cardiovascular Events Prevention Trial in Diabetes (ACCEPT-D): design of a randomized study of the efficacy of low-dose aspirin in the prevention of cardiovascular events in subjects with diabetes mellitus treated with statins.

  Trials 20070101

• 1,1-Bis(3'-indolyl)-1-(p-biphenyl)methane inhibits basal-like breast cancer growth in athymic nude mice.

  Breast cancer research : BCR 20070101

• PPARs and diabetes-associated atherosclerosis.

  Current pharmaceutical design 20070101

• PPARalpha ligands reduce PCB-induced endothelial activation: possible interactions in inflammation and atherosclerosis.

  Cardiovascular toxicology 20070101

• Are HIV positive patients resistant to statin therapy?

  Lipids in health and disease 20070101

• Acute renal failure secondary to fenofibrate monotherapy-induced rhabdomyolysis.

  Renal failure 20070101

• Peroxisome proliferator activated receptor ligands as regulators of airway inflammation and remodelling in chronic lung disease.

  PPAR research 20070101

• [Antiplatelet effects of micronized fenofibrate in subjects with dyslipidemia].

  Polskie Archiwum Medycyny Wewnetrznej 20070101

• Peroxisome proliferators-activated alpha agonist treatment ameliorates hepatic damage in rats with obstructive jaundice: an experimental study.

  BMC gastroenterology 20070101

• RAR/RXR and PPAR/RXR Signaling in Spinal Cord Injury.

  PPAR research 20070101

• Colesevelam: a review of its use in hypercholesterolemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20070101

• Reducing ocular damage in type 2 diabetes: the FIELD study shows fenofibrate benefits.

  Cardiovascular journal of Africa 20070101

• Activating effect of benzbromarone, a uricosuric drug, on peroxisome proliferator-activated receptors.

  PPAR research 20070101

• Cannabinoids: a new group of agonists of PPARs.

  PPAR research 20070101

• The Functions of PPARs in Aging and Longevity.

  PPAR research 20070101

• Effect of fenofibrate on serum and tissue sialic acid levels in short-term experimental hypercholesterolemia.

  Arzneimittel-Forschung 20070101

• Hypothyroidism is a predisposing factor for fenofibrate-induced rhabdomyolysis--patient report and literature review.

  Drug metabolism and drug interactions 20070101

• Phthalate-Induced Liver Protection against Deleterious Effects of the Th1 Response: A Potentially Serious Health Hazard.

  PPAR research 20070101

• Solubilizing properties of new surface-active agents, products of selective oxyethylation of cholic acid. Part I.

  Polimery w medycynie 20070101

• Beneficial effects of the addition of fenofibrate to statin therapy in patients with acute coronary syndrome after percutaneous coronary interventions.

  Experimental and clinical cardiology 20070101

• Pancreatitis following Olanzapine Therapy: A Report of Three Cases.

  Case reports in gastroenterology 20070101

• Hypertriglyceridemia and Recurrent Pancreatitis following Splenectomy.

  Case reports in gastroenterology 20070101

• Biochemical mechanism of insulin sensitization, lipid modulation and anti-atherogenic potential of PPAR alpha/gamma dual agonist: Ragaglitazar.

  Life sciences 20061223

• [Change in ghrelin level with the amelioration of glucose and lipid metabolic disorder in OLETF rats].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20061218

• Bifendate treatment attenuates hepatic steatosis in cholesterol/bile salt- and high-fat diet-induced hypercholesterolemia in mice.

  European journal of pharmacology 20061215

• Combination therapy with acipimox enhances the effect of growth hormone treatment on linear body growth in the normal and small-for-gestational-age rat.

  American journal of physiology. Endocrinology and metabolism 20061201

• PPARalpha activation elevates blood pressure and does not correct glucocorticoid-induced insulin resistance in humans.

  American journal of physiology. Endocrinology and metabolism 20061201

• Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.

  Contemporary clinical trials 20061201

• Rapid broad-spectrum analgesia through activation of peroxisome proliferator-activated receptor-alpha.

  The Journal of pharmacology and experimental therapeutics 20061201

• Hypolipidaemic activity of aqueous Ocimum basilicum extract in acute hyperlipidaemia induced by triton WR-1339 in rats and its antioxidant property.

  Phytotherapy research : PTR 20061201

• Effects of chronic treatment with statins and fenofibrate on rat skeletal muscle: a biochemical, histological and electrophysiological study.

  British journal of pharmacology 20061201

• Wy-14,643 and fenofibrate inhibit mitochondrial respiration in isolated rat cardiac mitochondria.

  Mitochondrion 20061201

• Should we dismiss fibrates for the treatment of diabetic dyslipidaemia?

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20061201

• Fenofibrate therapy and cardiovascular protection in diabetes: recommendations after FIELD.

  Current opinion in lipidology 20061201

• Fibrates after the FIELD study: Some answers, more questions.

  Diabetes & vascular disease research 20061201

• [PPARalpha agonist--fenofibrate inhibits LPS-induced tissue factor expression in THP-1 cells].

  Zhongguo shi yan xue ye xue za zhi 20061201

• [Effect of peroxisome proliferator-activated receptor-alpha agonist on adipokines expression in rats fed with high-fat diet].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20061201

• Effect of peroxisome proliferator-activated receptor alpha ligand fenofibrate on K(v) channels in the insulin-secreting cell line HIT-T15.

  General physiology and biophysics 20061201

• Management of hyperlipidemia with statins in the older patient.

  Clinical interventions in aging 20061201

• Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?

  British journal of clinical pharmacology 20061201

• Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro.

  Biochemical and biophysical research communications 20061124

• Inhibitory effects of micronized fenofibrate on carotid atherosclerosis in patients with essential hypertension.

  Clinical chemistry 20061101

• Human UDP-glucuronosyltransferase (UGT)1A3 enzyme conjugates chenodeoxycholic acid in the liver.

  Hepatology (Baltimore, Md.) 20061101

• Is combined treatment with fenofibrate and ezetimibe safe and efficacious in patients with mixed hyperlipidemia?

  Nature clinical practice. Cardiovascular medicine 20061101

• Micronized fenofibrate: a useful choice for the correction of dyslipidemia in metabolic syndrome and Type 2 diabetes.

  Future cardiology 20061101

• Correction to the FIELD study report.

  Lancet (London, England) 20061021

• Antipsychotic induced metabolic abnormalities: an interaction study with various PPAR modulators in mice.

  Life sciences 20061004

• Efficacy of peroxisome proliferative activated receptor (PPAR)-alpha ligands, fenofibrate, on intimal hyperplasia and constrictive remodeling after coronary angioplasty in porcine models.

  Atherosclerosis 20061001

• Fasting induces hyperlipidemia in mice overexpressing proprotein convertase subtilisin kexin type 9: lack of modulation of very-low-density lipoprotein hepatic output by the low-density lipoprotein receptor.

  Endocrinology 20061001

• Fenofibrate reduces atherogenesis in ApoE*3Leiden mice: evidence for multiple antiatherogenic effects besides lowering plasma cholesterol.

  Arteriosclerosis, thrombosis, and vascular biology 20061001

• Therapy and clinical trials.

  Current opinion in lipidology 20061001

• Fenofibrate inhibits tumor necrosis factor-alpha-induced expression of CD40 and matrix metalloproteinase in human vascular endothelial cells.

  Nan fang yi ke da xue xue bao = Journal of Southern Medical University 20061001

• Administrative claims analysis of the relationship between warfarin use and risk of hemorrhage including drug-drug and drug-disease interactions.

  Journal of managed care pharmacy : JMCP 20061001

• The transfer of a LC-UV method for the determination of fenofibrate and fenofibric acid in Lidoses: use of total error as decision criterion.

  Journal of pharmaceutical and biomedical analysis 20060911

• Effects of fenofibrate on apolipoprotein kinetics in patients with coexisting dysbetalipoproteinemia and heterozygous familial hypercholesterolemia.

  Atherosclerosis 20060901

• Peroxisome proliferator-activated receptors increase human sebum production.

  The Journal of investigative dermatology 20060901

• Relationships between changes in plasma lipid transfer proteins and apolipoprotein B-100 kinetics during fenofibrate treatment in the metabolic syndrome.

  Clinical science (London, England : 1979) 20060901

• Improvement of insulin sensitivity after peroxisome proliferator-activated receptor-alpha agonist treatment is accompanied by paradoxical increase of circulating resistin levels.

  Endocrinology 20060901

• Are the lipid-modifying effects of fibrates mediated by alterations in plasma lipid transfer activity?

  Clinical science (London, England : 1979) 20060901

• Effects of colesevelam hydrochloride (WelChol) on biomarkers of inflammation in patients with mild hypercholesterolemia.

  The American journal of cardiology 20060901

• Key issues in the role of peroxisome proliferator-activated receptor agonism and cell signaling in trichloroethylene toxicity.

  Environmental health perspectives 20060901

• Elevation of CKP induced by ezetimibe in monotherapy: report on two cases.

  Diabetes & metabolism 20060901

• The effect of apolipoprotein E polymorphism on the response to lipid-lowering treatment with atorvastatin or fenofibrate.

  Journal of cardiovascular pharmacology and therapeutics 20060901

• Metabolic syndrome: the danger signal in atherosclerosis.

  Vascular health and risk management 20060901

• Apolipoprotein modifying effects of statins and fibrate in various age groups of coronary artery disease patients.

  Journal of the Indian Medical Association 20060901

• Management of dyslipidemias in patients with diabetes and chronic kidney disease.

  Clinical journal of the American Society of Nephrology : CJASN 20060901

• Prolonged cholestasis after raloxifene and fenofibrate interaction: A case report.

  World journal of gastroenterology 20060828

• The interference of pharmaceuticals with endogenous and xenobiotic metabolizing enzymes in carp liver: an in-vitro study.

  Environmental science & technology 20060815

• Peroxisome proliferator-activated receptor alpha-independent peroxisome proliferation.

  Biochemical and biophysical research communications 20060811

• Reciprocal regulation of brain and muscle Arnt-like protein 1 and peroxisome proliferator-activated receptor alpha defines a novel positive feedback loop in the rodent liver circadian clock.

  Molecular endocrinology (Baltimore, Md.) 20060801

• Agonists of the peroxisome proliferator-activated receptor alpha induce a fiber-type-selective transcriptional response in rat skeletal muscle.

  Toxicological sciences : an official journal of the Society of Toxicology 20060801

• Reciprocal and coordinate regulation of serum amyloid A versus apolipoprotein A-I and paraoxonase-1 by inflammation in murine hepatocytes.

  Arteriosclerosis, thrombosis, and vascular biology 20060801

• Effect of ethanolic extracts of Ananas comosus L. leaves on insulin sensitivity in rats and HepG2.

  Comparative biochemistry and physiology. Toxicology & pharmacology : CBP 20060801

• Estrogenic activity of pharmaceuticals and pharmaceutical mixtures in a yeast reporter gene system.

  Reproductive toxicology (Elmsford, N.Y.) 20060801

• Attenuation of cardiac dysfunction by a PPAR-alpha agonist is associated with down-regulation of redox-regulated transcription factors.

  Journal of molecular and cellular cardiology 20060801

• Atorvastatin or fenofibrate on post-prandial lipaemia in type 2 diabetic patients with hyperlipidaemia.

  European journal of clinical investigation 20060801

• [PPAR agonists do not come up to expectations. Hope about the preventive effect in type 2 diabetes has come to nought].

  Lakartidningen 20060801

• [Lipid-lowering cardiovascular prevention in type 2-diabetes. Statins are effective according to the FIELD study].

  Lakartidningen 20060801

• The reduction of inflammatory biomarkers by statin, fibrate, and combination therapy among diabetic patients with mixed dyslipidemia: the DIACOR (Diabetes and Combined Lipid Therapy Regimen) study.

  Journal of the American College of Cardiology 20060718

• Synthetic peroxisome proliferator-activated receptor-gamma agonists restore impaired vasorelaxation via ATP-sensitive K+ channels by high glucose.

  The Journal of pharmacology and experimental therapeutics 20060701

• [Rhabdomyolysis induced by fenofibrate monotherapy].

  La Revue de medecine interne 20060701

• Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines.

  Current opinion in cardiology 20060701

• Peroxisome proliferator-activated receptor-alpha and retinoid X receptor agonists inhibit inflammatory responses of astrocytes.

  Journal of neuroimmunology 20060701

• Peroxisome proliferator-activated receptors in vascular biology-molecular mechanisms and clinical implications.

  Vascular pharmacology 20060701

• FIELD study.

  Diabetic medicine : a journal of the British Diabetic Association 20060701

• Aspirin regulates expression and function of scavenger receptor-BI in macrophages: studies in primary human macrophages and in mice.

  FASEB journal : official publication of the Federation of American Societies for Experimental Biology 20060701

• Effects of long-term fenofibrate therapy on cardiovascular events in people with type 2 diabetes mellitus.

  Current atherosclerosis reports 20060701

• Frequency of undiagnosed and untreated diabetes mellitus in patients with acute coronary syndromes.

  Expert review of cardiovascular therapy 20060701

• Dietary isoflavone supplementation modulates lipid metabolism via PPARalpha-dependent and -independent mechanisms.

  Physiological genomics 20060616

• Scavenging of reactive oxygen species by some nonsteroidal anti-inflammatory drugs and fenofibrate.

  Biopolymers 20060605

• Distinct transcriptional regulation of long-chain acyl-CoA synthetase isoforms and cytosolic thioesterase 1 in the rodent heart by fatty acids and insulin.

  American journal of physiology. Heart and circulatory physiology 20060601

• PPAR-alpha activator fenofibrate increases renal CYP-derived eicosanoid synthesis and improves endothelial dilator function in obese Zucker rats.

  American journal of physiology. Heart and circulatory physiology 20060601

• Combined therapy with PPARalpha agonist and L-carnitine rescues lipotoxic cardiomyopathy due to systemic carnitine deficiency.

  Cardiovascular research 20060601

• Aspirin and PPAR-alpha activators inhibit monocyte chemoattractant protein-1 expression induced by high glucose concentration in human endothelial cells.

  Vascular pharmacology 20060601

• Therapy and clinical trials.

  Current opinion in lipidology 20060601

• Effects of fenofibrate on lipid metabolism in adipose tissue of rats.

  Metabolism: clinical and experimental 20060601

• High doses of bifendate elevate serum and hepatic triglyceride levels in rabbits and mice: animal models of acute hypertriglyceridemia.

  Acta pharmacologica Sinica 20060601

• Effects of simvastatin on angiogenic growth factors released at the site of microvascular injury.

  Thrombosis and haemostasis 20060601

• Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver.

  Liver international : official journal of the International Association for the Study of the Liver 20060601

• The I allele of the angiotensin-converting enzyme gene polymorphism may determine an increase in homocysteine levels in fibrate-treated subjects.

  Cardiovascular drugs and therapy 20060601

• Effects of fenofibrate on atherogenic dyslipidemia in hypertriglyceridemic subjects.

  Clinical cardiology 20060601

• Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia.

  Diabetes & metabolism 20060601

• Effects of fenofibrate on C-reactive protein levels in hypertriglyceridemic patients.

  Journal of cardiovascular pharmacology 20060601

• [Effects of fenofibrate on the proliferation and apoptosis and nitric oxide synthase expression of cultured human umbilical vein endothelial cells induced by lysophosphatidylcholine].

  Zhong nan da xue xue bao. Yi xue ban = Journal of Central South University. Medical sciences 20060601

• Rosuvastatin 5 and 10 mg/d: a pilot study of the effects in hypercholesterolemic adults unable to tolerate other statins and reach LDL cholesterol goals with nonstatin lipid-lowering therapies.

  Clinical therapeutics 20060601

• New developments in clinically relevant mechanisms and treatment of hyperuricemia.

  Current rheumatology reports 20060601

• Effect of fenofibrate in combination with urate lowering agents in patients with gout.

  The Korean journal of internal medicine 20060601

• Successful treatment with rasburicase of a tophaceous gout in a patient allergic to allopurinol.

  Nature clinical practice. Rheumatology 20060601

• Long term fenofibrate did not reduce major coronary events but may reduce total CVD events in type 2 diabetes.

  Evidence-based medicine 20060601

• Fenofibrate: a novel formulation (Triglide) in the treatment of lipid disorders: a review.

  International journal of nanomedicine 20060601

• Peroxisome proliferator-activated receptor alpha activation decreases metastatic potential of melanoma cells in vitro via down-regulation of Akt.

  Clinical cancer research : an official journal of the American Association for Cancer Research 20060515

• A novel experimental model of acute hypertriglyceridemia induced by schisandrin B.

  European journal of pharmacology 20060510

• Separation of fibrate-type antihyperlipidemic drugs by capillary electrophoresis and their quantitation in pharmaceuticals.

  Journal of pharmaceutical and biomedical analysis 20060503

• Effects of chronic activation of peroxisome proliferator-activated receptor-alpha or high-fat feeding in a rat infarct model of heart failure.

  American journal of physiology. Heart and circulatory physiology 20060501

• The PPAR-alpha activator fenofibrate fails to provide myocardial protection in ischemia and reperfusion in pigs.

  American journal of physiology. Heart and circulatory physiology 20060501

• Effects of short-term fenofibrate treatment on circulating markers of inflammation and hemostasis in patients with impaired glucose tolerance.

  The Journal of clinical endocrinology and metabolism 20060501

• Microsphere-based protease assays and screening application for lethal factor and factor Xa.

  Cytometry. Part A : the journal of the International Society for Analytical Cytology 20060501

• Renoprotective effects of fenofibrate in diabetic rats are achieved by suppressing kidney plasminogen activator inhibitor-1.

  Vascular pharmacology 20060501

• Field of confusion: future prospects for fibrate therapy in cardiovascular disease.

  Current atherosclerosis reports 20060501

• The PPARalpha ligand fenofibrate: meeting multiple targets in diabetic nephropathy.

  Kidney international 20060501

• PPARalpha agonist fenofibrate improves diabetic nephropathy in db/db mice.

  Kidney international 20060501

• Statins, fenofibrate, and quinapril increase clot permeability and enhance fibrinolysis in patients with coronary artery disease.

  Journal of thrombosis and haemostasis : JTH 20060501

• Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study.

  Current medical research and opinion 20060501

• [The anti-inflammatory and antioxidants effects of micronized fenofibrate in patients with visceral obesity and dyslipidemia].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20060501

• [Effect of fenofibrate and metformin on lipotoxicity in OLETF rat kidney].

  Beijing da xue xue bao. Yi xue ban = Journal of Peking University. Health sciences 20060418

• Safety and efficacy of long-term co-administration of fenofibrate and ezetimibe in patients with mixed hyperlipidemia.

  Journal of the American College of Cardiology 20060418

• The role of fibrates in a statin world.

  Archives of internal medicine 20060410

• The FIELD study.

  Lancet (London, England) 20060408

• The FIELD study.

  Lancet (London, England) 20060408

• Early diet-induced non-alcoholic steatohepatitis in APOE2 knock-in mice and its prevention by fibrates.

  Journal of hepatology 20060401

• Peroxisome proliferator-activated receptor-alpha selective ligand reduces adiposity, improves insulin sensitivity and inhibits atherosclerosis in LDL receptor-deficient mice.

  Molecular and cellular biochemistry 20060401

• Effects of PPAR and RXR ligands in semaphorin 6B gene expression of human MCF-7 breast cancer cells.

  International journal of oncology 20060401

• Effects of fenofibrate therapy on plasma ubiquinol-10 and ubiquinone-10 levels in Japanese patients with hyperlipidemia and type 2 diabetes mellitus.

  Pharmacotherapy 20060401

• Accelerated diabetic nephropathy in mice lacking the peroxisome proliferator-activated receptor alpha.

  Diabetes 20060401

• Activation of the peroxisome proliferator-activated receptor alpha pathway potentiates interleukin-1 receptor antagonist production in cytokine-treated chondrocytes.

  Arthritis and rheumatism 20060401

• Workgroup report: Review of genomics data based on experience with mock submissions--view of the CDER Pharmacology Toxicology Nonclinical Pharmacogenomics Subcommittee.

  Environmental health perspectives 20060401

• FIELDS of dreams, fields of tears: a perspective on the fibrate trials.

  International journal of clinical practice 20060401

• [Effect of polymorphism of human intestinal fatty acid binding protein gene on the therapeutic efficacy of fenofibrate].

  Zhongguo yi xue ke xue yuan xue bao. Acta Academiae Medicinae Sinicae 20060401

• Fenofibrate can increase serum creatinine levels in renal insufficiency.

  The Journal of the Association of Physicians of India 20060401

• Fenofibrate activates AMPK and increases eNOS phosphorylation in HUVEC.

  Biochemical and biophysical research communications 20060324

• Fenofibrate, statins, and inflammation.

  Circulation research 20060317

• Fenofibrate treatment reduces circulating conjugated diene level and increases glutathione peroxidase activity.

  Pharmacological research 20060301

• Effect of fenofibrate on the level of asymmetric dimethylarginine in individuals with hypertriglyceridemia.

  European journal of clinical pharmacology 20060301

• Characterization of hypertriglyceridemia-induced erectile dysfunction.

  Urology 20060301

• Photoallergic contact dermatitis from ketoprofen in southern Sweden.

  Contact dermatitis 20060301

• [Ezetimibe with statins].

  Presse medicale (Paris, France : 1983) 20060301

• Evaluation of the potential for pharmacokinetic interaction between fenofibrate and ezetimibe: A phase I, open-label, multiple-dose, three-period crossover study in healthy subjects.

  Clinical therapeutics 20060301

• Role of surfactant and pH on dissolution properties of fenofibrate and glipizide--a technical note.

  AAPS PharmSciTech 20060301

• Fenofibrate treatment in two adults with Crigler-Najjar syndrome type II.

  The Turkish journal of gastroenterology : the official journal of Turkish Society of Gastroenterology 20060301

• Treatment of hyperlipidemia associated with Niemann-Pick disease type B by fenofibrate.

  European journal of pediatrics 20060201

• Fenofibrate and cardiovascular risk: a synopsis and commentary on (FIELD).

  Diabetic medicine : a journal of the British Diabetic Association 20060201

• Additive beneficial effects of fenofibrate combined with candesartan in the treatment of hypertriglyceridemic hypertensive patients.

  Diabetes care 20060201

• Absence of a food effect with a 145 mg nanoparticle fenofibrate tablet formulation.

  International journal of clinical pharmacology and therapeutics 20060201

• [Are pioglitazone and fenofibrate effective for the prevention of cardiovascular disease in type 2 diabetes?].

  Revue medicale suisse 20060111

• The effect of dual PPAR alpha/gamma stimulation with combination of rosiglitazone and fenofibrate on metabolic parameters in type 2 diabetic patients.

  Diabetes research and clinical practice 20060101

• Folate co-administration improves the effectiveness of fenofibrate to decrease the lipoprotein oxidation and endothelial dysfunction surrogates.

  Physiological research 20060101

• Statin/fibrate combination in patients with metabolic syndrome or diabetes: evaluating the risks of pharmacokinetic drug interactions.

  Expert opinion on drug safety 20060101

• Fibrates in combination with statins in the management of dyslipidemia.

  Journal of clinical hypertension (Greenwich, Conn.) 20060101

• Peroxisomal proliferator activated receptor-gamma deficiency in a Canadian kindred with familial partial lipodystrophy type 3 (FPLD3).

  BMC medical genetics 20060101

• PPARalpha activators may play role for the regression of ventricular hypertrophy in hypertensive and hyperlipidemic patients.

  Medical hypotheses 20060101

• Effects of a fenofibrate/losartan combination on the plasma concentration and urinary excretion of purine bases.

  International journal of clinical pharmacology and therapeutics 20060101

• [Diabetes mellitus: types 1 & 2 increasingly similar].

  Presse medicale (Paris, France : 1983) 20060101

• An open-label, crossover study of the pharmacokinetics of Insoluble Drug Delivery-MicroParticle fenofibrate in combination with atorvastatin, simvastatin, and extended-release niacin in healthy volunteers.

  Clinical therapeutics 20060101

• Flow cytometric assessment of peroxisome proliferation from frozen liver of fibrate-treated monkeys.

  International journal of toxicology 20060101

• Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism.

  Drugs of today (Barcelona, Spain : 1998) 20060101

• [The FIELD study presented and published. Unconvincing results of fenofibrates in diabetic patients].

  Vnitrni lekarstvi 20060101

• Regulatory effects of synthetic liver X receptor- and peroxisome-proliferator activated receptor agonists on sterol transport pathways in polarized cerebrovascular endothelial cells.

  The international journal of biochemistry & cell biology 20060101

• Activated protein C increases sensitivity to vasoconstriction in rabbit Escherichia coli endotoxin-induced shock.

  Critical care (London, England) 20060101

• In vitro and in vivo effects of the PPAR-alpha agonists fenofibrate and retinoic acid in endometrial cancer.

  Molecular cancer 20060101

• The effects of food on the bioavailability of fenofibrate administered orally in healthy volunteers via sustained-release capsule.

  Clinical pharmacokinetics 20060101

• Fenofibrate activates the biochemical pathways and the de novo expression of genes related to lipid handling and uncoupling protein-3 functions in liver of normal rats.

  Biochimica et biophysica acta 20060101

• Interleukin-6 -174 G/C promoter polymorphism and effects of fenofibrate and simvastatin on inflammatory markers in hypercholesterolemic patients.

  Blood coagulation & fibrinolysis : an international journal in haemostasis and thrombosis 20060101

• Inhibitory effects of fenofibrate on plasminogen activator inhibitor-1 expression in human endothelial cells.

  Journal of Huazhong University of Science and Technology. Medical sciences = Hua zhong ke ji da xue xue bao. Yi xue Ying De wen ban = Huazhong keji daxue xuebao. Yixue Yingdewen ban 20060101

• Peroxisome proliferator-activated receptor alpha (PPAR alpha) down-regulation in cystic fibrosis lymphocytes.

  Respiratory research 20060101

• C-reactive protein (CRP)-lowering agents.

  Cardiovascular drug reviews 20060101

• Atherogenic dyslipidemia in metabolic syndrome and type 2 diabetes: therapeutic options beyond statins.

  Cardiovascular diabetology 20060101

• Extralipid effects of micronized fenofibrate in dyslipidemic patients.

  Pharmacological reports : PR 20060101

• Computational strategy for discovering druggable gene networks from genome-wide RNA expression profiles.

  Pacific Symposium on Biocomputing. Pacific Symposium on Biocomputing 20060101

• Differential gene expression in mouse primary hepatocytes exposed to the peroxisome proliferator-activated receptor alpha agonists.

  BMC bioinformatics 20060101

• [Hepatitis induced by fibrates].

  Annales de biologie clinique 20060101

• Comparison of effects of fibrates in patients with hypertriglyceridemia.

  Advances in therapy 20060101

• [Fenofibrate--induced myopathy in a patient with undiagnosed hypothyroidism--case report and a review of the literature].

  Polskie Archiwum Medycyny Wewnetrznej 20060101

• Chinese red yeast rice (Monascus purpureus) for primary hyperlipidemia: a meta-analysis of randomized controlled trials.

  Chinese medicine 20060101

• [Oxidation stress, insulin resistance and endothelial dysfunction during the treatment of hyperlipidaemia].

  Casopis lekaru ceskych 20060101

• Combination of a sterol absorption inhibitor and cardiovascular agents for the treatment of dyslipidemia.

  Recent patents on cardiovascular drug discovery 20060101

• K-111: the emerging evidence for its potential in the treatment of the metabolic syndrome.

  Core evidence 20060101

• Fenofibrate reverses the decline in HDL cholesterol in mice overexpressing human phospholipid transfer protein.

  Biochimica et biophysica acta 20051230

• Fenofibrate-induced liver injury.

  World journal of gastroenterology 20051228

• Paradoxical exacerbation of combined hyperlipidemia in human apolipoprotein A-II transgenic mice treated with fenofibrate.

  Biochimica et biophysica acta 20051215

• Determination of cryptotanshinone and its metabolite in rat plasma by liquid chromatography-tandem mass spectrometry.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20051205

• Effect of fenofibrate on plasma lipoprotein composition and kinetics in patients with complete hepatic lipase deficiency.

  Arteriosclerosis, thrombosis, and vascular biology 20051201

• Role for fibrate therapy in diabetes: evidence before FIELD.

  Current opinion in lipidology 20051201

• Peroxisome proliferator-activated receptor (PPAR)alpha activation increases adiponectin receptors and reduces obesity-related inflammation in adipose tissue: comparison of activation of PPARalpha, PPARgamma, and their combination.

  Diabetes 20051201

• Potent capillary isotachophoresis (cITP) for analyzing a marker of coronary heart disease risk and electronegative low-density lipoprotein (LDL) in small dense LDL fraction.

  Circulation journal : official journal of the Japanese Circulation Society 20051201

• Effect of orlistat, micronised fenofibrate and their combination on metabolic parameters in overweight and obese patients with the metabolic syndrome: the FenOrli study.

  Current medical research and opinion 20051201

• Microvascular endothelial function in subjects with Type 2 diabetes and the effect of lipid-lowering therapy.

  Diabetic medicine : a journal of the British Diabetic Association 20051201

• Lipid-lowering properties of 6-benzoyl-2(3H)-benzothiazolone and structurally related compounds.

  Journal of enzyme inhibition and medicinal chemistry 20051201

• [Field, a randomized clinical trial of cardiovascular prevention with fenofibrate in type 2 diabetes].

  Revue medicale de Liege 20051201

• Optimal lipid modification: the rationale for combination therapy.

  Vascular health and risk management 20051201

• After FIELD: should fibrates be used to prevent cardiovascular disease in diabetes?

  Lancet (London, England) 20051126

• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  Lancet (London, England) 20051126

• Fibrates inhibit aldose reductase activity in the forward and reverse reactions.

  Biochemical pharmacology 20051125

• Reducing residual risk for patients on statin therapy: the potential role of combination therapy.

  The American journal of cardiology 20051107

• Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, exerts neuroprotective effects in traumatic brain injury.

  Neuroscience letters 20051104

• Inflammatory markers and the metabolic syndrome.

  Atherosclerosis 20051101

• Gene expression profiling of the PPAR-alpha agonist ciprofibrate in the cynomolgus monkey liver.

  Toxicological sciences : an official journal of the Society of Toxicology 20051101

• Effects of fenofibrate and insulin on the biosynthesis of unsaturated fatty acids in streptozotocin diabetic rats.

  Prostaglandins, leukotrienes, and essential fatty acids 20051101

• Ezetimibe coadministered with fenofibrate: some safety questions.

  European heart journal 20051101

• Urinary albumin levels in the normal range determine arterial wall thickness in adults with Type 2 diabetes: a FIELD substudy.

  Diabetic medicine : a journal of the British Diabetic Association 20051101

• Differential associations of statin and fibrate treatment with carotid arterial remodeling.

  American journal of hypertension 20051101

• A case of rhabdomyolysis induced acute renal failure secondary to statin-fibrate-derivative combination and occult hypothyroidism.

  Clinical nephrology 20051101

• Effect of PPAR-alpha and -gamma agonist on the expression of visfatin, adiponectin, and TNF-alpha in visceral fat of OLETF rats.

  Biochemical and biophysical research communications 20051028

• The effects of fenofibrate on metabolic and vascular changes induced by chocolate-supplemented diet in the rat.

  European journal of pharmacology 20051003

• Acute myopathy in a type 2 diabetic patient on combination therapy with metformin, fenofibrate and rosiglitazone.

  Diabetologia 20051001

• Effect of fenofibrate on lipoprotein(a) in hypertriglyceridemic patients: impact of change in triglyceride level and liver function.

  Journal of cardiovascular pharmacology 20051001

• Metabolism of repaglinide by CYP2C8 and CYP3A4 in vitro: effect of fibrates and rifampicin.

  Basic & clinical pharmacology & toxicology 20051001

• Fundamental flaws of hormesis for public health decisions.

  Environmental health perspectives 20051001

• Dissolution and solubility behavior of fenofibrate in sodium lauryl sulfate solutions.

  Drug development and industrial pharmacy 20051001

• [Drug combinations: statins and fibrates].

  Arquivos brasileiros de cardiologia 20051001

• [Hypolipidemic therapy under special conditions: acquired immune deficiency syndrome].

  Arquivos brasileiros de cardiologia 20051001

• Simultaneous determination of rosuvastatin and fenofibric acid in human plasma by LC-MS/MS with electrospray ionization: assay development, validation and application to a clinical study.

  Journal of pharmaceutical and biomedical analysis 20050915

• Isohumulones modulate blood lipid status through the activation of PPAR alpha.

  Biochimica et biophysica acta 20050905

• Regulation of adiponectin receptor 1 in human hepatocytes by agonists of nuclear receptors.

  Biochemical and biophysical research communications 20050902

• PPARalpha, but not PPARgamma, activators decrease macrophage-laden atherosclerotic lesions in a nondiabetic mouse model of mixed dyslipidemia.

  Arteriosclerosis, thrombosis, and vascular biology 20050901

• A novel thiazolidinedione MCC-555 down-regulates tumor necrosis factor-alpha-induced expression of vascular cell adhesion molecule-1 in vascular endothelial cells.

  Atherosclerosis 20050901

• Monocyte release of tumor necrosis factor-alpha and interleukin-1beta in primary type IIa and IIb dyslipidemic patients treated with statins or fibrates.

  Journal of cardiovascular pharmacology 20050901

• Pretreatment with peroxysome proliferator-activated receptor alpha agonist fenofibrate protects endothelium in rabbit Escherichia coli endotoxin-induced shock.

  Intensive care medicine 20050901

• Safety and efficacy of colesevelam hydrochloride in combination with fenofibrate for the treatment of mixed hyperlipidemia.

  Current medical research and opinion 20050901

• A randomized trial of the efficacy and safety of fenofibrate versus pravastatin in HIV-infected subjects with lipid abnormalities: AIDS Clinical Trials Group Study 5087.

  AIDS research and human retroviruses 20050901

• Actions of calcium channel blockers on vascular proteoglycan synthesis: relationship to atherosclerosis.

  Vascular health and risk management 20050901

• Vascular endothelium as a target of beraprost sodium and fenofibrate for antiatherosclerotic therapy in type 2 diabetes mellitus.

  Vascular health and risk management 20050901

• Novel 2,3-dihydrobenzofuran-2-carboxylic acids: highly potent and subtype-selective PPARalpha agonists with potent hypolipidemic activity.

  Journal of medicinal chemistry 20050825

• Administration of a PPARalpha agonist increases serum apolipoprotein A-V levels and the apolipoprotein A-V/apolipoprotein C-III ratio.

  Journal of lipid research 20050801

• Agonists for the peroxisome proliferator-activated receptor-alpha and the retinoid X receptor inhibit inflammatory responses of microglia.

  Journal of neuroscience research 20050801

• The effects of multiple doses of fenofibrate on the pharmacokinetics of pravastatin and its 3alpha-hydroxy isomeric metabolite.

  Journal of clinical pharmacology 20050801

• Increased hypercholesterolemia and atherosclerosis in mice lacking both ApoE and leptin receptor.

  Atherosclerosis 20050801

• Targeting vascular risk in patients with metabolic syndrome but without diabetes.

  Metabolism: clinical and experimental 20050801

• (2R)-2-methylchromane-2-carboxylic acids: discovery of selective PPARalpha agonists as hypolipidemic agents.

  Bioorganic & medicinal chemistry letters 20050715

• Evaluation of cytochrome P450 4 family as mediator of phospholipase D activation in aortic vascular smooth muscle cells.

  Life sciences 20050715

• Age-related decrease in expression of peroxisome proliferator-activated receptor alpha and its effects on development of dyslipidemia.

  Chinese medical journal 20050705

• Adiponectin receptor gene expression in human skeletal muscle cells is not regulated by fibrates and thiazolidinediones.

  International journal of obesity (2005) 20050701

• Differential regulation and properties of angiopoietin-like proteins 3 and 4.

  Journal of lipid research 20050701

• Fenofibrate prevents Rosiglitazone-induced body weight gain in ob/ob mice.

  International journal of obesity (2005) 20050701

• Possible role of ubiquinone in the treatment of massive hypertriglyceridemia resistant to PUFA and fibrates.

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 20050701

• Paradoxical effects of fenofibrate and nicotinic acid in apo E-deficient mice.

  Journal of cardiovascular pharmacology 20050701

• Early antithrombotic and anti-inflammatory effects of simvastatin versus fenofibrate in patients with hypercholesterolemia.

  Thrombosis and haemostasis 20050701

• Effects of fibrates on human organic anion-transporting polypeptide 1B1-, multidrug resistance protein 2- and P-glycoprotein-mediated transport.

  Xenobiotica; the fate of foreign compounds in biological systems 20050701

• Design and synthesis of alpha-aryloxyphenylacetic acid derivatives: a novel class of PPARalpha/gamma dual agonists with potent antihyperglycemic and lipid modulating activity.

  Journal of medicinal chemistry 20050630

• Fenofibrate induces a novel degradation pathway for scavenger receptor B-I independent of PDZK1.

  The Journal of biological chemistry 20050617

• Rhabdomyolysis with cardiac involvement and acute renal failure in a patient taking rosuvastatin and fenofibrate.

  Annals of internal medicine 20050607

• Fenofibric acid, an active form of fenofibrate, increases apolipoprotein A-I-mediated high-density lipoprotein biogenesis by enhancing transcription of ATP-binding cassette transporter A1 gene in a liver X receptor-dependent manner.

  Arteriosclerosis, thrombosis, and vascular biology 20050601

• A peroxisome proliferator-activated receptor alpha/gamma dual agonist with a unique in vitro profile and potent glucose and lipid effects in rodent models of type 2 diabetes and dyslipidemia.

  Molecular endocrinology (Baltimore, Md.) 20050601

• Alterations of lipids and apolipoprotein CIII in very low density lipoprotein subspecies in type 2 diabetes.

  Diabetologia 20050601

• Beneficial effects of fenofibrate to improve endothelial dysfunction and raise adiponectin levels in patients with primary hypertriglyceridemia.

  Diabetes care 20050601

• Effects of fenofibrate on inflammatory cytokines and blood pressure in patients with hypertriglyceridemia.

  Clinica chimica acta; international journal of clinical chemistry 20050601

• A case of hypothyroidism and type 2 diabetes associated with type V hyperlipoproteinemia and eruptive xanthomas.

  Journal of Korean medical science 20050601

• Learning from large cardiovascular clinical trials: classical cardiovascular risk factors.

  Diabetes research and clinical practice 20050601

• Prediction of genotoxicity of chemical compounds by statistical learning methods.

  Chemical research in toxicology 20050601

• Effect of influenza vaccine on markers of inflammation and lipid profile.

  The Journal of laboratory and clinical medicine 20050601

• Efficacy and safety profile of fenofibrate-coated microgranules 130 mg, with and without food, in patients with hypertriglyceridemia and the metabolic syndrome: an 8-week, randomized, double-blind, placebo-controlled study.

  Clinical therapeutics 20050601

• The effect of fenofibrate on serum paraoxonase activity and inflammatory markers in patients with combined hyperlipidemia.

  Kardiologia polska 20050601

• PPAR-alpha activators suppress STAT1 inflammatory signaling in lipopolysaccharide-activated rat glia.

  Neuroreport 20050531

• The benefit of fibrates in the treatment of 'bad HDL-C responders to statins'.

  International journal of cardiology 20050525

• Enhancement of oral bioavailability of poorly water-soluble drugs by poly(ethylene glycol)-block-poly(alkyl acrylate-co-methacrylic acid) self-assemblies.

  Journal of controlled release : official journal of the Controlled Release Society 20050518

• Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia.

  Journal of the American College of Cardiology 20050517

• Peroxisome proliferator-activated receptor agonists modulate heart function in transgenic mice with lipotoxic cardiomyopathy.

  The Journal of pharmacology and experimental therapeutics 20050501

• Effects of peroxisome proliferator-activated receptor alpha/delta agonists on HDL-cholesterol in vervet monkeys.

  Journal of lipid research 20050501

• Efficacy and safety of the coadministration of ezetimibe with fenofibrate in patients with mixed hyperlipidaemia.

  European heart journal 20050501

• Management of mixed hyperlipidaemia.

  European heart journal 20050501

• Individual and combined effects of peroxisome proliferator-activated receptor and {gamma} agonists, fenofibrate and rosiglitazone, on biomarkers of lipid and glucose metabolism in healthy nondiabetic volunteers.

  Journal of clinical pharmacology 20050501

• Diverse compounds mimic Alzheimer disease-causing mutations by augmenting Abeta42 production.

  Nature medicine 20050501

• Simvastatin, fenofibrate, and rhabdomyolysis.

  Diabetes care 20050501

• The beneficial effects of lipid-lowering drugs beyond lipid-lowering effects: a comparative study with pravastatin, atorvastatin, and fenofibrate in patients with type IIa and type IIb hyperlipidemia.

  Metabolism: clinical and experimental 20050501

• Spectrophotometric and liquid chromatographic determination of fenofibrate and vinpocetine and their hydrolysis products.

  Farmaco (Societa chimica italiana : 1989) 20050501

• Fenofibrate decreases asymmetric dimethylarginine level in cultured endothelial cells by inhibiting NF-kappaB activity.

  Naunyn-Schmiedeberg's archives of pharmacology 20050501

• Triglyceridemia and peroxisome proliferator-activated receptor-alpha expression are not connected in fenofibrate-treated pregnant rats.

  Molecular and cellular biochemistry 20050501

• Fenofibrate prevents the development of angiotensin II-dependent hypertension in mice.

  Hypertension (Dallas, Tex. : 1979) 20050401

• Effect of monthly atorvastatin and fenofibrate treatment on monocyte chemoattractant protein-1 release in patients with primary mixed dyslipidemia.

  Journal of cardiovascular pharmacology 20050401

• Phenotype-based treatment of dietary obesity: differential effects of fenofibrate in obesity-prone and obesity-resistant rats.

  Metabolism: clinical and experimental 20050401

• Combination of dietary phytosterols plus niacin or fenofibrate: effects on lipid profile and atherosclerosis in apo E-KO mice.

  The Journal of nutritional biochemistry 20050401

• Tryptophan-NAD+ pathway metabolites as putative biomarkers and predictors of peroxisome proliferation.

  Archives of toxicology 20050401

• The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidaemic hypertensive patients.

  International journal of clinical practice 20050401

• Dietary isohumulones, the bitter components of beer, raise plasma HDL-cholesterol levels and reduce liver cholesterol and triacylglycerol contents similar to PPARalpha activations in C57BL/6 mice.

  The British journal of nutrition 20050401

• Effects of micronized fenofibrate and vitamin E on in vitro oxidation of lipoproteins in patients with type 1 diabetes mellitus.

  Diabetes & metabolism 20050401

• Regulation of human apoA-I by gemfibrozil and fenofibrate through selective peroxisome proliferator-activated receptor alpha modulation.

  Arteriosclerosis, thrombosis, and vascular biology 20050301

• Improvement in highly active antiretroviral therapy-induced metabolic syndrome by treatment with pioglitazone but not with fenofibrate: a 2 x 2 factorial, randomized, double-blinded, placebo-controlled trial.

  Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 20050301

• Fenofibrate reduces progression to microalbuminuria over 3 years in a placebo-controlled study in type 2 diabetes: results from the Diabetes Atherosclerosis Intervention Study (DAIS).

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20050301

• Fenofibrate induces apoptotic injury in cultured human hepatocytes by inhibiting phosphorylation of Akt.

  Apoptosis : an international journal on programmed cell death 20050301

• By the way, doctor. I take Pravachol to control my cholesterol, and because of high triglycerides, my doctor wants to add TriCor. But my pharmacist warns against taking both medications. If I don't take TriCor, are there alternatives?

  Harvard health letter 20050301

• Simultaneously measuring concentrations of a model drug and a model excipient in solution using ultrasonic spectrometry.

  Journal of pharmaceutical and biomedical analysis 20050223

• Effectiveness and tolerability of simvastatin plus fenofibrate for combined hyperlipidemia (the SAFARI trial).

  The American journal of cardiology 20050215

• Hypolipidemic drugs affect monocyte IL-1beta gene expression and release in patients with IIa and IIb dyslipidemia.

  Journal of cardiovascular pharmacology 20050201

• Impaired expression of the peroxisome proliferator-activated receptor alpha during hepatitis C virus infection.

  Gastroenterology 20050201

• Fenofibric acid.

  Acta crystallographica. Section C, Crystal structure communications 20050201

• Fenofibrate-induced cirrhosis.

  Digestive diseases and sciences 20050201

• Lipid-lowering drugs and essential omega-6 and omega-3 fatty acids in patients with coronary heart disease.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20050201

• [Efficacy and safety of combination therapy with simvastatin and fenofibrate for combined hyperlipidemia].

  Zhonghua xin xue guan bing za zhi 20050201

• Decrease in serum dehydroepiandrosterone level after fenofibrate treatment in males with hyperlipidemia.

  Physiological research 20050101

• Examination of 209 drugs for inhibition of cytochrome P450 2C8.

  Journal of clinical pharmacology 20050101

• Reporting rate of rhabdomyolysis with fenofibrate + statin versus gemfibrozil + any statin.

  The American journal of cardiology 20050101

• Fenofibrate: metabolic and pleiotropic effects.

  Current vascular pharmacology 20050101

• Changes in lipids over twelve months after initiating protease inhibitor therapy among persons treated for HIV/AIDS.

  Lipids in health and disease 20050101

• Cost effectiveness of treating low HDL-cholesterol in the primary prevention of coronary heart disease.

  PharmacoEconomics 20050101

• Treatment of massive hypertriglyceridemia resistant to PUFA and fibrates: a possible role for the coenzyme Q10?

  BioFactors (Oxford, England) 20050101

• Study of the liquid chromatography retention of some fibrate-type antihyperlipidemic drugs on C18 and CN columns: application for quantitation in pharmaceutical formulations.

  Journal of AOAC International 20050101

• Ezetimibe: a review of its metabolism, pharmacokinetics and drug interactions.

  Clinical pharmacokinetics 20050101

• Inhibiting long-chain fatty acyl CoA synthetase does not increase agonist-induced release of arachidonate metabolites from human endothelial cells.

  Journal of vascular research 20050101

• Statins research unfinished saga: desirability versus feasibility.

  Cardiovascular diabetology 20050101

• Inhibition of NF-kappaB signaling by fenofibrate, a peroxisome proliferator-activated receptor-alpha ligand, presents a therapeutic strategy for rheumatoid arthritis.

  Clinical and experimental rheumatology 20050101

• Monocyte suppressing action of fenofibrate.

  Pharmacological reports : PR 20050101

• PPARalpha downregulates airway inflammation induced by lipopolysaccharide in the mouse.

  Respiratory research 20050101

• Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study: baseline characteristics and short-term effects of fenofibrate [ISRCTN64783481].

  Cardiovascular diabetology 20050101

• Transcriptional modulations by RXR agonists are only partially subordinated to PPARalpha signaling and attest additional, organ-specific, molecular cross-talks.

  Gene expression 20050101

• Dual and pan-peroxisome proliferator-activated receptors (PPAR) co-agonism: the bezafibrate lessons.

  Cardiovascular diabetology 20050101

• A new perspective in the treatment of dyslipidemia : can fenofibrate offer unique benefits in the treatment of type 2 diabetes mellitus?

  Treatments in endocrinology 20050101

• Postprandial lipemia in men with metabolic syndrome, hypertensives and healthy subjects.

  Lipids in health and disease 20050101

• Enzymatic examination of potential interaction between statins or fibrates and consumed Tricholoma equestre.

  Przeglad lekarski 20050101

• Biomarkers for early effects of carcinogenic dual-acting PPAR agonists in rat urinary bladder urothelium in vivo.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20050101

• Beyond low-density lipoprotein: addressing the atherogenic lipid triad in type 2 diabetes mellitus and the metabolic syndrome.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20050101

• Association of common variation in the PPARA gene with incident myocardial infarction in individuals with type 2 diabetes: a Go-DARTS study.

  Nuclear receptor 20050101

• [Effect of n-3 polyunsaturated fatty acids on plasma lipid, LDL lipoperoxidation, homocysteine and inflammation indicators in diabetic dyslipidemia treated with statin + fibrate combination].

  Casopis lekaru ceskych 20050101

• Effect on serum uric acid levels of drugs prescribed for indications other than treating hyperuricaemia.

  Current pharmaceutical design 20050101

• Determination of fenofibrate and gemfibrozil in pharmaceuticals by densitometric and videodensitometric thin-layer chromatography.

  Journal of AOAC International 20050101

• Gout in solid organ transplantation: a challenging clinical problem.

  Drugs 20050101

• Fibrates.

  Handbook of experimental pharmacology 20050101

• Modulation of high-density lipoprotein cholesterol metabolism and reverse cholesterol transport.

  Handbook of experimental pharmacology 20050101

• Isoxazolyl-serine-based agonists of peroxisome proliferator-activated receptor: design, synthesis, and effects on cardiomyocyte differentiation.

  Journal of the American Chemical Society 20041229

• Fenofibrate enhances CD36 mediated endocytic uptake and degradation of oxidized low density lipoprotein in adipocytes from hypercholesterolemia rabbit.

  Atherosclerosis 20041201

• Fenofibrate lowers adiposity and corrects metabolic abnormalities, but only partially restores endothelial function in dietary obese rats.

  Atherosclerosis 20041201

• Hypolipidemic drugs can change the composition of rat brain lipids.

  The Tohoku journal of experimental medicine 20041201

• Pharmacologic treatment of type 2 diabetic dyslipidemia.

  Pharmacotherapy 20041201

• Fenofibrate modifies human vascular smooth muscle proteoglycans and reduces lipoprotein binding.

  Diabetologia 20041201

• Response to micronized fenofibrate treatment is associated with the peroxisome-proliferator-activated receptors alpha G/C intron7 polymorphism in subjects with type 2 diabetes.

  Pharmacogenetics 20041201

• Effect of peroxisome proliferator-activated receptor activators on tumor necrosis factor-alpha expression in neonatal rat cardiac myocytes.

  Chinese medical sciences journal = Chung-kuo i hsueh k'o hsueh tsa chih 20041201

• Long hydrocarbon chain keto diols and diacids that favorably alter lipid disorders in vivo.

  Journal of medicinal chemistry 20041118

• PPARalpha ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats.

  Biochemical and biophysical research communications 20041112

• Rosiglitazone upregulates caveolin-1 expression in THP-1 cells through a PPAR-dependent mechanism.

  Journal of lipid research 20041101

• Comparative effects of statin and fibrate on nitric oxide bioactivity and matrix metalloproteinase in hyperlipidemia.

  International journal of cardiology 20041101

• Fenofibrate inhibits thrombogenic and fibrinolytic factors expression in adipose tissue of atherosclerotic rabbits.

  Clinica chimica acta; international journal of clinical chemistry 20041101

• Statin and fibrate treatment of combined hyperlipidemia: the effects on some novel risk factors.

  Thrombosis and haemostasis 20041101

• Current management of gout in patients unresponsive or allergic to allopurinol.

  Joint, bone, spine : revue du rhumatisme 20041101

• Efficacy and safety of 12-week treatment with fenofibrate 300 mg in Thai dyslipidemic patients.

  Journal of the Medical Association of Thailand = Chotmaihet thangphaet 20041101

• The peroxisome proliferator-activated receptor alpha activator fenofibrate inhibits endothelin-1-induced cardiac fibroblast proliferation.

  Journal of cardiovascular pharmacology 20041101

• Activation of peroxisome proliferator-activated receptor-alpha decreases endothelin-1-induced p38 mitogen-activated protein kinase activation in cardiomyocytes.

  Journal of cardiovascular pharmacology 20041101

• Peroxisome proliferator-activated receptor alpha ligands activate transcription of lectin-like oxidized low density lipoprotein receptor-1 gene through GC box motif.

  Biochemical and biophysical research communications 20041022

• Fenofibrate impairs rat mitochondrial function by inhibition of respiratory complex I.

  The Journal of pharmacology and experimental therapeutics 20041001

• Lack of effect of bezafibrate and fenofibrate on the pharmacokinetics and pharmacodynamics of repaglinide.

  British journal of clinical pharmacology 20041001

• Effects of fenofibrate on high-fat diet-induced body weight gain and adiposity in female C57BL/6J mice.

  Metabolism: clinical and experimental 20041001

• The effect of statins and fibrates on interferon-gamma and interleukin-2 release in patients with primary type II dyslipidemia.

  Atherosclerosis 20041001

• Effects of statin treatment on uric acid homeostasis in patients with primary hyperlipidemia.

  American heart journal 20041001

• Risk of adverse events with fibrates.

  The American journal of cardiology 20041001

• C-reactive protein-induced expression of CD40-CD40L and the effect of lovastatin and fenofibrate on it in human vascular endothelial cells.

  Biological & pharmaceutical bulletin 20041001

• Management of dyslipidaemia in HIV-infected patients receiving antiretroviral therapy.

  Antiviral therapy 20041001

• Comparison of fluvastatin + fenofibrate combination therapy and fluvastatin monotherapy in the treatment of combined hyperlipidemia, type 2 diabetes mellitus, and coronary heart disease: a 12-month, randomized, double-blind, controlled trial.

  Clinical therapeutics 20041001

• [An exploratory study on mechanism of PPARalpha activators-induced plasminogen activator inhibitor-1 expression in HepG-2 cells].

  Zhonghua nei ke za zhi 20041001

• Co-induction of methyltransferase Rv0560c by naphthoquinones and fibric acids suggests attenuation of isoprenoid quinone action in Mycobacterium tuberculosis.

  Canadian journal of microbiology 20041001

• Fibrates induce hepatic peroxisome and mitochondrial proliferation without overt evidence of cellular proliferation and oxidative stress in cynomolgus monkeys.

  Carcinogenesis 20040901

• Fenofibrate, troglitazone, and 15-deoxy-Delta12,14-prostaglandin J2 close KATP channels and induce insulin secretion.

  The Journal of pharmacology and experimental therapeutics 20040901

• Fenofibrate reduces tumor necrosis factor-alpha serum concentration and adipocyte secretion of hypercholesterolemic rabbits.

  Clinica chimica acta; international journal of clinical chemistry 20040901

• Simvastatin does not have a clinically significant pharmacokinetic interaction with fenofibrate in humans.

  Journal of clinical pharmacology 20040901

• Fenofibrate-associated reversible acute allograft dysfunction in 3 renal transplant recipients: biopsy evidence of tubular toxicity.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20040901

• Combination therapy with fenofibrate and rosiglitazone paradoxically lowers serum HDL cholesterol.

  Diabetes care 20040901

• A new fenofibrate formulation: results of six single-dose, clinical studies of bioavailability under fed and fasting conditions.

  Clinical therapeutics 20040901

• Alteration of 20:5n-3 and 22:6n-3 fat contents and liver peroxisomal activities in fenofibrate-treated rainbow trout.

  Lipids 20040901

• PPARalpha agonists stimulate progastrin production in human colorectal carcinoma cells.

  Regulatory peptides 20040815

• The direct peroxisome proliferator-activated receptor target fasting-induced adipose factor (FIAF/PGAR/ANGPTL4) is present in blood plasma as a truncated protein that is increased by fenofibrate treatment.

  The Journal of biological chemistry 20040813

• Analysis by liquid chromatography-electrospray ionization tandem mass spectrometry and acute toxicity evaluation for beta-blockers and lipid-regulating agents in wastewater samples.

  Journal of chromatography. A 20040813

• Peroxisome proliferator-activated receptor alpha/gamma dual agonists for the treatment of type 2 diabetes.

  Journal of medicinal chemistry 20040812

• Successful treatment with fenofibrate, a peroxisome proliferator activated receptor alpha ligand, for a patient with rheumatoid arthritis.

  Annals of the rheumatic diseases 20040801

• Effects of peroxisome proliferator activated receptors-alpha and -gamma agonists on estradiol-induced proliferation and hyperplasia formation in the mouse uterus.

  The Journal of endocrinology 20040801

• Fenofibrate increases the expression of high mobility group AT-hook 2 (HMGA2) gene and induces adipocyte differentiation of orbital fibroblasts from Graves' ophthalmopathy.

  Journal of molecular endocrinology 20040801

• Transcriptome analysis of endometrial cancer identifies peroxisome proliferator-activated receptors as potential therapeutic targets.

  Molecular cancer therapeutics 20040801

• Effect of fenofibrate on LDL-induced endothelial dysfunction in rats.

  Naunyn-Schmiedeberg's archives of pharmacology 20040801

• Pharmacodynamic and pharmacokinetic interaction between fenofibrate and ezetimibe.

  Current medical research and opinion 20040801

• The effect of fenofibrate on the levels of high sensitivity C-reactive protein in dyslipidemic obese patients.

  Endocrine research 20040801

• Effects of peroxisome proliferator-activated receptor alpha activation on pathways contributing to cholesterol homeostasis in rat hepatocytes.

  Biochimica et biophysica acta 20040705

• Visualization and quantitation of peroxisomes using fluorescent nanocrystals: treatment of rats and monkeys with fibrates and detection in the liver.

  Toxicological sciences : an official journal of the Society of Toxicology 20040701

• Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.

  American heart journal 20040701

• Peroxisome proliferator activated receptors alpha and gamma require zinc for their anti-inflammatory properties in porcine vascular endothelial cells.

  The Journal of nutrition 20040701

• Photosensitization of thymine nucleobase by benzophenone derivatives as models for photoinduced DNA damage: Paterno-Büchi vs energy and electron transfer processes.

  Chemical research in toxicology 20040701

• Inhibition of melanoma metastases by fenofibrate.

  Archives of dermatological research 20040701

• Preparation and drug loading of poly(ethylene glycol)-block-poly(epsilon-caprolactone) micelles through the evaporation of a cosolvent azeotrope.

  Pharmaceutical research 20040701

• Novel pH-sensitive supramolecular assemblies for oral delivery of poorly water soluble drugs: preparation and characterization.

  Journal of controlled release : official journal of the Controlled Release Society 20040618

• Effect of simvastatin and fenofibrate on endothelium in Type 2 diabetes.

  European journal of pharmacology 20040616

• Safety of statins: focus on clinical pharmacokinetics and drug interactions.

  Circulation 20040615

• (2R)-2-ethylchromane-2-carboxylic acids: discovery of novel PPARalpha/gamma dual agonists as antihyperglycemic and hypolipidemic agents.

  Journal of medicinal chemistry 20040603

• Evidence for anti-inflammatory activity of statins and PPARalpha activators in human C-reactive protein transgenic mice in vivo and in cultured human hepatocytes in vitro.

  Blood 20040601

• A novel selective peroxisome proliferator-activated receptor alpha agonist, 2-methyl-c-5-[4-[5-methyl-2-(4-methylphenyl)-4-oxazolyl]butyl]-1,3-dioxane-r-2-carboxylic acid (NS-220), potently decreases plasma triglyceride and glucose levels and modifies lipoprotein profiles in KK-Ay mice.

  The Journal of pharmacology and experimental therapeutics 20040601

• Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.

  Current rheumatology reports 20040601

• Effects of fenofibrate on lipoproteins, vasomotor function, and serological markers of inflammation, plaque stabilization, and hemostasis.

  Atherosclerosis 20040601

• Fenofibrate and fenofibric acid analysis by capillary electrophoresis.

  Electrophoresis 20040601

• Fenofibrate is effective in treating hypertriglyceridemia associated with HIV lipodystrophy.

  The American journal of the medical sciences 20040601

• Lipoatrophic diabetes in an elderly woman: clinical course and serum adipocytokine concentrations.

  Endocrine journal 20040601

• Fenofibrate-induced myopathy.

  Neurology India 20040601

• Comparison of combined statin-fibrate treatment to monotherapy in patients with mixed hyperlipidemia.

  Kardiologia polska 20040601

• PPARalpha activation abolishes LDL-stimulated IL-8 production via AP-1 deactivation in human aortic smooth muscle cells.

  Biochemical and biophysical research communications 20040528

• Profiling of hepatic gene expression in rats treated with fibric acid analogs.

  Mutation research 20040518

• Peroxisome proliferator-activated receptors and atherogenesis: regulators of gene expression in vascular cells.

  Circulation research 20040514

• Antidiabetic and hypolipidemic potential of DRF 2519--a dual activator of PPAR-alpha and PPAR-gamma.

  European journal of pharmacology 20040503

• Isotretinoin and fenofibrate induce adiposity with distinct effect on metabolic profile in a rat model of the insulin resistance syndrome.

  International journal of obesity and related metabolic disorders : journal of the International Association for the Study of Obesity 20040501

• Rosuvastatin and fenofibrate alone and in combination in type 2 diabetes patients with combined hyperlipidaemia.

  Diabetes research and clinical practice 20040501

• Peroxisome proliferator-activated receptor alpha agonists as therapy for autoimmune disease.

  Journal of immunology (Baltimore, Md. : 1950) 20040501

• [Pharmacological and pharmacokinetic features and clinical effects of pitavastatin (Livalo Tablet)].

  Nihon yakurigaku zasshi. Folia pharmacologica Japonica 20040501

• Fenofibrate prevents obesity and hypertriglyceridemia in low-density lipoprotein receptor-null mice.

  Metabolism: clinical and experimental 20040501

• Qualitative effect of fenofibrate and quantitative effect of atorvastatin on LDL profile in combined hyperlipidemia with dense LDL.

  Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association 20040501

• Cardiovascular drugs inhibit MMP-9 activity from human THP-1 macrophages.

  DNA and cell biology 20040501

• Fenofibrate-induced acute cholestatic hepatitis.

  Journal of the Chinese Medical Association : JCMA 20040501

• Myocardial fibrosis and diastolic dysfunction in deoxycorticosterone acetate-salt hypertensive rats is ameliorated by the peroxisome proliferator-activated receptor-alpha activator fenofibrate, partly by suppressing inflammatory responses associated with the nuclear factor-kappa-B pathway.

  Journal of the American College of Cardiology 20040421

• Global suppression of IL-6-induced acute phase response gene expression after chronic in vivo treatment with the peroxisome proliferator-activated receptor-alpha activator fenofibrate.

  The Journal of biological chemistry 20040416

• Peroxisome proliferator-activated receptor alpha agonists increase nitric oxide synthase expression in vascular endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 20040401

• Fenofibrate and losartan.

  Annals of the rheumatic diseases 20040401

• Effect of fenofibrate-mediated increase in plasma homocysteine on the progression of coronary artery disease in type 2 diabetes mellitus.

  The American journal of cardiology 20040401

• [Polymyositis induced or associated with lipid-lowering drugs: five cases].

  La Revue de medecine interne 20040401

• Clinical trials and lipid guidelines for type II diabetes.

  Journal of clinical pharmacology 20040401

• Bexarotene: a clinical review.

  Expert review of anticancer therapy 20040401

• Regulation of endothelial nitric oxide synthase by PPAR agonists: molecular and clinical perspectives.

  Arteriosclerosis, thrombosis, and vascular biology 20040401

• Fenofibrate increases the L-arginine:ADMA ratio by increase of L-arginine concentration but has no effect on ADMA concentration.

  Atherosclerosis 20040401

• Effects of micronized fenofibrate on insulin resistance in patients with metabolic syndrome.

  International journal of clinical pharmacology and therapeutics 20040401

• Peroxisomal-proliferator-activated receptor alpha activates transcription of the rat hepatic malonyl-CoA decarboxylase gene: a key regulation of malonyl-CoA level.

  The Biochemical journal 20040315

• Fenofibrate for patients with asymptomatic primary biliary cirrhosis.

  World journal of gastroenterology 20040315

• The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.

  Expert opinion on drug safety 20040301

• Reduction of palmitate-induced cardiac apoptosis by fenofibrate.

  Molecular and cellular biochemistry 20040301

• Effects of human pharmaceuticals on cytotoxicity, EROD activity and ROS production in fish hepatocytes.

  Toxicology 20040301

• Fenofibrate increases homocystinemia through a PPARalpha-mediated mechanism.

  Journal of cardiovascular pharmacology 20040301

• Effect of fenofibrate on serum inflammatory markers in patients with high triglyceride values.

  Journal of cardiovascular pharmacology and therapeutics 20040301

• Endothelin-1-induced cardiac hypertrophy is inhibited by activation of peroxisome proliferator-activated receptor-alpha partly via blockade of c-Jun NH2-terminal kinase pathway.

  Circulation 20040224

• PPARalpha activators inhibit vascular endothelial growth factor receptor-2 expression by repressing Sp1-dependent DNA binding and transactivation.

  Circulation research 20040220

• Fibrates modify the expression of key factors involved in bile-acid synthesis and biliary-lipid secretion in gallstone patients.

  European journal of clinical pharmacology 20040201

• A peroxisome proliferator-activated receptor-alpha activator induces renal CYP2C23 activity and protects from angiotensin II-induced renal injury.

  The American journal of pathology 20040201

• PPAR alpha activator fenofibrate inhibits myocardial inflammation and fibrosis in angiotensin II-infused rats.

  Journal of molecular and cellular cardiology 20040201

• Fenofibrate improves the atherogenic lipid profile and enhances LDL resistance to oxidation in HIV-positive adults.

  Atherosclerosis 20040201

• Effect of fibrates on postprandial remnant-like particles in patients with combined hyperlipidemia.

  Atherosclerosis 20040201

• Peroxisome proliferator-activated receptor alpha (PPARalpha) activators induce hepatic farnesyl diphosphate synthase gene expression in rodents.

  The Journal of steroid biochemistry and molecular biology 20040201

• Gout.

  The New England journal of medicine 20040129

• Opposite regulation of the rat and human cytosolic aspartate aminotransferase genes by fibrates.

  Biochemical pharmacology 20040115

• Influence of lipid lowering fibrates on P-glycoprotein activity in vitro.

  Biochemical pharmacology 20040115

• Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia.

  Journal of lipid research 20040101

• Electrochemical studies and square-wave voltammetric determination of fenofibrate in pharmaceutical formulations.

  Analytical and bioanalytical chemistry 20040101

• Fibrates for treatment of the metabolic syndrome.

  Current atherosclerosis reports 20040101

• Musculoskeletal features of disorders of lipid metabolism and multicentric reticulohistiocytosis.

  Current opinion in rheumatology 20040101

• Role of C-reactive protein in cardiovascular disease.

  The Annals of pharmacotherapy 20040101

• An ounce of prevention. Drugs used to treat hyperlipidemia (Part 1).

  Orthopedic nursing 20040101

• Role of fibrates in reducing coronary risk: a UK Consensus.

  Current medical research and opinion 20040101

• Molecular cloning, gene structure and expression profile of two mouse peroxisomal 3-ketoacyl-CoA thiolase genes.

  BMC biochemistry 20040101

• Rosuvastatin-induced arrest in progression of renal disease.

  Cardiology 20040101

• Homocysteine and reactive oxygen species in metabolic syndrome, type 2 diabetes mellitus, and atheroscleropathy: the pleiotropic effects of folate supplementation.

  Nutrition journal 20040101

• Medical lipid-regulating therapy: current evidence, ongoing trials and future developments.

  Drugs 20040101

• Effects of antihyperlipidemic agents on hepatic insulin sensitivity in perfused Goto-Kakizaki rat liver.

  Journal of gastroenterology 20040101

• [Systemic inflammatory process as an etiological factor in increase of atherogenic potential of plasma].

  Fiziolohichnyi zhurnal (Kiev, Ukraine : 1994) 20040101

• Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.

  Journal of human genetics 20040101

• Application of UV-derivative spectra for determination of four antihyperlipidaemic drugs in pharmaceutical formulations.

  Acta poloniae pharmaceutica 20040101

• Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20040101

• The pivotal role of cholesterol absorption inhibitors in the management of dyslipidemia.

  Lipids in health and disease 20040101

• [Fibrates: mechanism of action, effect on levels of lipids and risk of coronary events. II. Fenofibrate].

  Kardiologiia 20040101

• Effect of colesevelam HCl on single-dose fenofibrate pharmacokinetics.

  Clinical pharmacokinetics 20040101

• Fenofibrate effectively reduces remnants, and small dense LDL, and increases HDL particle number in hypertriglyceridemic men - a nuclear magnetic resonance study.

  Journal of atherosclerosis and thrombosis 20040101

• The need for a large-scale trial of fibrate therapy in diabetes: the rationale and design of the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study. [ISRCTN64783481].

  Cardiovascular diabetology 20040101

• Which is the best lipid-modifying strategy in metabolic syndrome and diabetes: fibrates, statins or both?

  Cardiovascular diabetology 20040101

• Effect of fenofibrate on uric acid metabolism in Japanese hyperlipidemic patients.

  Journal of atherosclerosis and thrombosis 20040101

• Development of a multivariate statistical model to predict peroxisome proliferation in the rat, based on urinary 1H-NMR spectral patterns.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20040101

• Interface flow process audit: using the patient's career as a tracer of quality of care and of system organisation.

  International journal of integrated care 20040101

• Efficacy, safety and tolerability of combined low-dose simvastatin-fenofibrate treatment in primary mixed hyperlipidaemia.

  Clinical drug investigation 20040101

• Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice.

  Neuroscience letters 20031211

• The peroxisome proliferator-activated receptor beta/delta agonist, GW501516, regulates the expression of genes involved in lipid catabolism and energy uncoupling in skeletal muscle cells.

  Molecular endocrinology (Baltimore, Md.) 20031201

• Effect of hypolipidemic drugs on lipoprotein-associated platelet activating factor acetylhydrolase. Implication for atherosclerosis.

  Biochemical pharmacology 20031201

• Chylomicron remnants of various sizes are lowered more effectively by fenofibrate than by atorvastatin in patients with combined hyperlipidemia.

  Atherosclerosis 20031201

• Evaluation of the therapeutic potential of PPARalpha agonists for X-linked adrenoleukodystrophy.

  Molecular genetics and metabolism 20031201

• The effect of micronised fenofibrate on paraoxonase activity in patients with coronary heart disease.

  Diabetes & metabolism 20031201

• Differential effects of peroxisome proliferator activator receptor-alpha and gamma ligands on intimal hyperplasia after balloon catheter-induced vascular injury in Zucker rats.

  Journal of cardiovascular pharmacology and therapeutics 20031201

• In vivo model for dyslipidemia with diabetes mellitus in hamster.

  Indian journal of experimental biology 20031201

• Survey of binding properties of fatty acid-binding proteins. Chromatographic methods.

  Journal of chromatography. B, Analytical technologies in the biomedical and life sciences 20031125

• Design and synthesis of a potent and selective triazolone-based peroxisome proliferator-activated receptor alpha agonist.

  Journal of medicinal chemistry 20031120

• Formalized therapeutic guideline for hyperlipidemic severe acute pancreatitis.

  World journal of gastroenterology 20031115

• Paradoxical lowering of high-density lipoprotein cholesterol level in 2 patients receiving fenofibrate and a thiazolidinedione.

  Annals of internal medicine 20031104

• Protective effects of green tea polyphenols on human HepG2 cells against oxidative damage of fenofibrate.

  Free radical biology & medicine 20031101

• Ezetimibe: a selective cholesterol absorption inhibitor.

  Pharmacotherapy 20031101

• Effect of micronized fenofibrate on vascular endothelial function in patients with hypertriglyceridemia.

  Chinese medical journal 20031101

• Peroxisome proliferator-activated receptor-alpha and receptor-gamma activators prevent cardiac fibrosis in mineralocorticoid-dependent hypertension.

  Hypertension (Dallas, Tex. : 1979) 20031001

• Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.

  British journal of pharmacology 20031001

• Effects of baseline level of triglycerides on changes in lipid levels from combined fluvastatin + fibrate (bezafibrate, fenofibrate, or gemfibrozil).

  The American journal of cardiology 20031001

• Pravastatin in hyperlipidemia secondary to HIV protease inhibitors without response to fenofibrate: a brief preliminary report.

  Nutrition (Burbank, Los Angeles County, Calif.) 20031001

• Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles.

  Atherosclerosis 20031001

• [Acute cytolytic and cholestatic hepatitis induced by fenofibrate].

  Gastroenterologie clinique et biologique 20031001

• Effects of fenofibrate on endothelial function and cell adhesion molecules during post-prandial lipemia in hypertriglyceridemia.

  Journal of clinical pharmacy and therapeutics 20031001

• Fenofibrate-induced hyperhomocysteinemia may be prevented by folate co-administration.

  European journal of clinical pharmacology 20030901

• Peroxisome proliferator activated receptor (PPAR)alpha agonists inhibit hypertrophy of neonatal rat cardiac myocytes.

  Endocrinology 20030901

• Differential influences of peroxisome proliferator-activated receptors gamma and -alpha on food intake and energy homeostasis.

  Diabetes 20030901

• Peroxisome proliferator-activated receptor (PPAR)-alpha activation prevents diabetes in OLETF rats: comparison with PPAR-gamma activation.

  Diabetes 20030901

• Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.

  Clinical pharmacology and therapeutics 20030901

• Dilazep and fenofibric acid inhibit MCP-1 mRNA expression in glycoxidized LDL-stimulated human endothelial cells.

  European journal of pharmacology 20030815

• Design, synthesis, and evaluation of substituted phenylpropanoic acid derivatives as human peroxisome proliferator activated receptor activators. Discovery of potent and human peroxisome proliferator activated receptor alpha subtype-selective activators.

  Journal of medicinal chemistry 20030814

• Novel coumarin derivatives of heterocyclic compounds as lipid-lowering agents.

  Bioorganic & medicinal chemistry letters 20030804

• The peroxisome-proliferator-activated receptor alpha agonist ciprofibrate severely aggravates hypercholesterolaemia and accelerates the development of atherosclerosis in mice lacking apolipoprotein E.

  The Biochemical journal 20030801

• Fenofibrate monotherapy induced rhabdomyolysis.

  Diabetes care 20030801

• Effect of atorvastatin and fenofibrate on autonomic tone in subjects with combined hyperlipidemia.

  The American journal of cardiology 20030801

• Lipid-lowering drugs and serum liver enzymes: the effects of body weight and baseline enzyme levels.

  Fundamental & clinical pharmacology 20030801

• Pseudo-Cushing syndrome caused by fenofibrate interference with urinary cortisol assayed by high-performance liquid chromatography.

  The Journal of clinical endocrinology and metabolism 20030801

• Comparative effects of atorvastatin, simvastatin, and fenofibrate on serum homocysteine levels in patients with primary hyperlipidemia.

  Journal of clinical pharmacology 20030801

• [Long-term hypolipidemic treatment of mixed hyperlipidemia with a combination of statins and fibrates].

  Casopis lekaru ceskych 20030801

• [Effect of peroxisome proliferator-activated receptors activators on plasminogen activator inhibitor-1 expression in HepG-2 cells].

  Zhongguo ying yong sheng li xue za zhi = Zhongguo yingyong shenglixue zazhi = Chinese journal of applied physiology 20030801

• Peroxisome proliferator-activated receptor-alpha activation as a mechanism of preventive neuroprotection induced by chronic fenofibrate treatment.

  The Journal of neuroscience : the official journal of the Society for Neuroscience 20030716

• Effects of atorvastatin, simvastatin, and fenofibrate therapy on monocyte chemoattractant protein-1 secretion in patients with hyperlipidemia.

  European journal of clinical pharmacology 20030701

• Effect of folic acid on fenofibrate-induced elevation of homocysteine and cysteine.

  American heart journal 20030701

• Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.

  Current opinion in cardiology 20030701

• Fibrates and renal function.

  Clinical nephrology 20030701

• Reducing coronary heart disease associated with type 2 diabetes: lifestyle intervention and treatment of dyslipidaemia.

  Diabetes research and clinical practice 20030701

• [Efficacy and safety of combined statin-fenofibrates therapy compared with monotherapy in patients with mixed hyperlipidemia and high risk of coronary heart disease].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030701

• Hyperuricemia and gout.

  Current rheumatology reports 20030601

• Minireview: lipid metabolism, metabolic diseases, and peroxisome proliferator-activated receptors.

  Endocrinology 20030601

• Fenofibrate and losartan.

  Annals of the rheumatic diseases 20030601

• Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.

  Annals of the rheumatic diseases 20030601

• Combination lipid-lowering therapy in diabetes.

  Current diabetes reports 20030601

• Identification of hepatic transcriptional changes in insulin-resistant rats treated with peroxisome proliferator activated receptor-alpha agonists.

  Journal of molecular endocrinology 20030601

• Effects of fenofibrate and simvastatin on plasma sICAM-1 and MCP-1 concentrations in patients with hyperlipoproteinemia.

  International journal of clinical pharmacology and therapeutics 20030601

• Serum lipid comparison in patients treated by statins or fibrates: existence of bad HDL-C responders to statins.

  Acta cardiologica 20030601

• Fibrates and their newly synthesized glycinate or glycinate-methylester derivatives: comparison of the interactions with liver cytochrome P450 dependent monooxygenase- and oxidase-functions in vitro.

  Experimental and toxicologic pathology : official journal of the Gesellschaft fur Toxikologische Pathologie 20030601

• A survey on the efficacy and tolerability of micronized fenofibrate in patients with dyslipidemia.

  Chinese medical journal 20030601

• Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model.

  Biochemical and biophysical research communications 20030530

• Apolipoprotein A5, a crucial determinant of plasma triglyceride levels, is highly responsive to peroxisome proliferator-activated receptor alpha activators.

  The Journal of biological chemistry 20030516

• [HIV-infection, HAART (highly-active antiretroviral therapy) and hyperlipidemia].

  Deutsche medizinische Wochenschrift (1946) 20030509

• Fenofibrate induces HDL-associated PAF-AH but attenuates enzyme activity associated with apoB-containing lipoproteins.

  Journal of lipid research 20030501

• Combined effect of coenzyme Q10 and fenofibrate on forearm microcirculatory function in type 2 diabetes.

  Atherosclerosis 20030501

• Differential effects of peroxisome proliferator-activated receptor activators on the mRNA levels of genes involved in lipid metabolism in primary human monocyte-derived macrophages.

  Metabolism: clinical and experimental 20030501

• [Letter to the editor by X. Roblin et al., Influence of hypolipemic treatment on homocysteinemia].

  La Revue de medecine interne 20030501

• Induction of endogenous genes by peroxisome proliferator activated receptor alpha ligands in a human kidney cell line and in vivo.

  The Journal of steroid biochemistry and molecular biology 20030501

• Urinary excretion of oxidative metabolites of bilirubin in fenofibrate-treated rats.

  The Journal of toxicological sciences 20030501

• Trans-10,cis-12 CLA increases liver and decreases adipose tissue lipids in mice: possible roles of specific lipid metabolism genes.

  Lipids 20030501

• [Pleiotropic effect of the micronized fenofibrate: the reduction of plasma chlamydia pneumoniae antibody levels in patients with coronary artery disease].

  Orvosi hetilap 20030420

• Effects of adding fenofibrate (200 mg/day) to simvastatin (10 mg/day) in patients with combined hyperlipidemia and metabolic syndrome.

  The American journal of cardiology 20030415

• Statins and fibrates for the treatment of hyperlipidaemia in HIV-infected patients receiving HAART.

  AIDS (London, England) 20030411

• Relationships between low-density lipoprotein particle size, plasma lipoproteins, and progression of coronary artery disease: the Diabetes Atherosclerosis Intervention Study (DAIS).

  Circulation 20030408

• Opposite regulation of the human paraoxonase-1 gene PON-1 by fenofibrate and statins.

  Molecular pharmacology 20030401

• Lipemia retinalis associated with branch retinal vein occlusion.

  American journal of ophthalmology 20030401

• Progression of atherosclerosis is associated with variation in the alpha1-antitrypsin gene.

  Arteriosclerosis, thrombosis, and vascular biology 20030401

• [Treatment of high blood cholesterol in patients with coronary heart disease].

  Nihon rinsho. Japanese journal of clinical medicine 20030401

• Fenofibrate inhibits angiogenesis in vitro and in vivo.

  Cellular and molecular life sciences : CMLS 20030401

• [Effect of fluvastatin and fenofibrate on reactive oxygen species generation and lipid peroxidation in patients with dyslipidemia].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401

• [Effect of fluvastatin and fenofibrate on the antioxidative barrier enzyme activity in patients with dyslipidemia].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20030401

• Properties of rapidly dissolving eutectic mixtures of poly(ethylene glycol) and fenofibrate: the eutectic microstructure.

  Journal of pharmaceutical sciences 20030301

• Differential regulation of lipoprotein kinetics by atorvastatin and fenofibrate in subjects with the metabolic syndrome.

  Diabetes 20030301

• Cell-specific toxicity of fibrates in human embryonal rhabdomyosarcoma cells.

  Naunyn-Schmiedeberg's archives of pharmacology 20030301

• Reductions in plasma cholesterol levels after fenofibrate treatment are negatively correlated with resistin expression in human adipose tissue.

  Metabolism: clinical and experimental 20030301

• Spectrum of cross-photosensitization in 18 consecutive patients with contact photoallergy to ketoprofen: associated photoallergies to non-benzophenone-containing molecules.

  Contact dermatitis 20030301

• Fenofibrate improves lipid metabolism and obesity in ovariectomized LDL receptor-null mice.

  Biochemical and biophysical research communications 20030227

• Insulin resistance and adiposity correlate with acute-phase reaction and soluble cell adhesion molecules in type 2 diabetes.

  Atherosclerosis 20030201

• Fenofibrate potentiates warfarin effects.

  The Annals of pharmacotherapy 20030201

• Fenofibrate, a ligand for PPARalpha, inhibits aromatase cytochrome P450 expression in the ovary of mouse.

  Journal of lipid research 20030201

• DRF 2655: a unique molecule that reduces body weight and ameliorates metabolic abnormalities.

  Obesity research 20030201

• Inhibition of TNF-alpha-induced RANTES expression in human hepatocyte-derived cells by fibrates, the hypolipidemic drugs.

  International immunopharmacology 20030201

• Short-term triglyceride lowering with fenofibrate improves vasodilator function in subjects with hypertriglyceridemia.

  Arteriosclerosis, thrombosis, and vascular biology 20030201

• Fenofibrate enhances urate reduction in men treated with allopurinol for hyperuricaemia and gout.

  Rheumatology (Oxford, England) 20030201

• Long-term remission from gout associated with fenofibrate therapy.

  Clinical rheumatology 20030201

• [Therapy effects of fenofibrate on alcoholic fatty liver and drug-induced fatty liver in rats].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20030201

• An open-label, randomized, three-way crossover trial of the effects of coadministration of rosuvastatin and fenofibrate on the pharmacokinetic properties of rosuvastatin and fenofibric acid in healthy male volunteers.

  Clinical therapeutics 20030201

• A chemical switch regulates fibrate specificity for peroxisome proliferator-activated receptor alpha (PPARalpha ) versus liver X receptor.

  The Journal of biological chemistry 20030124

• Design and synthesis of novel PPARalpha/gamma/delta triple activators using a known PPARalpha/gamma dual activator as structural template.

  Bioorganic & medicinal chemistry letters 20030120

• Frequency of creatine kinase elevation during treatment with fluvastatin in combination with fibrates (bezafibrate, fenofibrate, or gemfibrozil).

  The American journal of cardiology 20030115

• Micronized fenofibrate normalizes the enhanced lipidemic response to a fat load in patients with type 2 diabetes and optimal glucose control.

  Atherosclerosis 20030101

• PAPP-A, a novel marker of unstable plaque, is not influenced by hypolipidemic treatment in contrast to CRP.

  Atherosclerosis 20030101

• Comparison of micronized fenofibrate and pravastatin in patients with primary hyperlipidemia.

  Journal of cardiovascular pharmacology 20030101

• Resolution of typical lipoprotein glomerulopathy by intensive lipid-lowering therapy.

  American journal of kidney diseases : the official journal of the National Kidney Foundation 20030101

• Effect of peroxisome proliferator-activated receptor-alpha and -gamma activators on vascular remodeling in endothelin-dependent hypertension.

  Arteriosclerosis, thrombosis, and vascular biology 20030101

• Fenofibrate-induced hyperhomocysteinaemia: clinical implications and management.

  Drug safety 20030101

• Metformin, but not thiazolidinediones, inhibits plasminogen activator inhibitor-1 production in human adipose tissue in vitro.

  Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme 20030101

• Clinical pharmacokinetics of fenofibrate.

  Current medical research and opinion 20030101

• Temporal changes in cardiovascular autonomic regulation in type II diabetic patients: association with coronary risk variables and progression of coronary artery disease.

  Annals of medicine 20030101

• [Combination therapy with fluvastatin and fenofibrate in ischemic heart disease patients with combined hyperlipidemia and type 2 diabetes].

  Kardiologiia 20030101

• [Effect of combined antihypertensive and lipid lowering therapy on the level of coronary risk and tissue insulin resistance in patients with metabolic syndrome].

  Kardiologiia 20030101

• Potential urinary and plasma biomarkers of peroxisome proliferation in the rat: identification of N-methylnicotinamide and N-methyl-4-pyridone-3-carboxamide by 1H nuclear magnetic resonance and high performance liquid chromatography.

  Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals 20030101

• Bilateral lower limb hypoesthesia after radical prostatectomy in the hyperlordotic position under general anesthesia.

  Canadian journal of anaesthesia = Journal canadien d'anesthesie 20030101

• A patient with hyperlipidemia who had a gallbladder stone caused by administration of fenofibrate.

  The Kurume medical journal 20030101

• Contribution of apo CIII reduction to the greater effect of 12-week micronized fenofibrate than atorvastatin therapy on triglyceride levels and LDL size in dyslipidemic patients.

  Annals of medicine 20030101

• Left-ventricular diastolic dysfunction may be prevented by chronic treatment with PPAR-alpha or -gamma agonists in a type 2 diabetic animal model.

  Diabetes/metabolism research and reviews 20030101

• Differential effects of fenofibrate versus atorvastatin on the concentrations of E-selectin and vascular cellular adhesion molecule-1 in patients with type 2 diabetes mellitus and mixed hyperlipoproteinemia: a randomized cross-over trial.

  Cardiovascular diabetology 20030101

• Tissue-specific expression of two peroxisomal 3-ketoacyl-CoA thiolase genes in wild and PPAR alpha-null mice and induction by fenofibrate.

  Advances in experimental medicine and biology 20030101

• [Effect of antilipemic therapy on patients with diabetes mellitus and obesity].

  Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 20030101

• Quantitative real-time PCR protocol for analysis of nuclear receptor signaling pathways.

  Nuclear receptor signaling 20030101

• Fenofibrate regulates obesity and lipid metabolism with sexual dimorphism.

  Experimental & molecular medicine 20021231

• Synthetic studies of cis-4-Amino-L-proline derivatives as novel lipid lowering agents.

  Bioorganic & medicinal chemistry letters 20021216

• Effects of gemfibrozil conversion to fenofibrate on lipids in patients on statin therapy.

  The American journal of cardiology 20021215

• Cytotoxic effect of peroxisome proliferator fenofibrate on human HepG2 hepatoma cell line and relevant mechanisms.

  Toxicology and applied pharmacology 20021215

• Reduction of atherosclerosis by the peroxisome proliferator-activated receptor alpha agonist fenofibrate in mice.

  The Journal of biological chemistry 20021213

• Effect of fenofibrate on brachial artery flow-mediated dilatation in type 2 diabetes mellitus.

  The American journal of cardiology 20021201

• Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.

  Diabetes 20021201

• Comparison of gemfibrozil and fenofibrate in patients with dyslipidemic coronary heart disease.

  Pharmacotherapy 20021201

• Fibrate treatment does not modify the expression of acyl coenzyme A oxidase in human liver.

  Clinical pharmacology and therapeutics 20021201

• Pharmacoeconomic evaluation of anti-hyperlipidemic agent fenofibrate.

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20021201

• Fenofibrate in the treatment of dyslipidemia: a review of the data as they relate to the new suprabioavailable tablet formulation.

  Clinical therapeutics 20021201

• [Pleiotropic effects of micronized fenofibrate in patients with combined hyperlipidemia].

  Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego 20021201

• Effects of various fibrates on serum alkaline phosphatase activity.

  Atherosclerosis 20021101

• Effects of fibrates on metabolism of statins in human hepatocytes.

  Drug metabolism and disposition: the biological fate of chemicals 20021101

• Optimizing bexarotene therapy for cutaneous T-cell lymphoma.

  Journal of the American Academy of Dermatology 20021101

• Coenzyme Q10 improves blood pressure and glycaemic control: a controlled trial in subjects with type 2 diabetes.

  European journal of clinical nutrition 20021101

• Estrogen-induced regulation of the ATP-binding cassette transporter A1 (ABCA1) in mice: a possible mechanism of atheroprotection by estrogen.

  Molecular and cellular biochemistry 20021101

• Anastrozole ('Arimidex') blocks oestrogen synthesis both peripherally and within the breast in postmenopausal women with large operable breast cancer.

  British journal of cancer 20021021

• [Coronary heart disease prevention in type 2 diabetic patients. What is the value of fibrates?].

  MMW Fortschritte der Medizin 20021017

• Reduced IGFBP-1 is associated with thickening of the carotid wall in type 2 diabetes.

  Diabetes care 20021001

• Comparison of the effects of atorvastatin or fenofibrate on nonlipid biochemical risk factors and the LDL particle size in subjects with combined hyperlipidemia.

  American heart journal 20021001

• Efficacy and safety of fenofibrate for the treatment of hypertriglyceridemia associated with antiretroviral therapy.

  Journal of acquired immune deficiency syndromes (1999) 20021001

• [Photocontact dermatitis due to ketoprofen and photosensitization to tetrachlorosalicylanide and to Fenticlor(R)].

  Annales de dermatologie et de venereologie 20021001

• [Usefulness of examination of the cholesterol versus triglyceride ratio for lipoprotein fractions in a patient with marked hyper-triglyceridemia].

  Rinsho byori. The Japanese journal of clinical pathology 20021001

• Effects of fenofibrate on high-density lipoprotein particle size in patients with hyperlipidemia: a randomized, double-blind, placebo-controlled, multicenter, crossover study.

  Clinical therapeutics 20021001

• Insights into binding of fatty acids by fatty acid binding proteins.

  Molecular and cellular biochemistry 20021001

• Comparative effect of fenofibrate on hepatic desaturases in wild-type and peroxisome proliferator-activated receptor alpha-deficient mice.

  Lipids 20021001

• Stimulation of peroxisome proliferator-activated receptors alpha and gamma blocks HIV-1 replication and TNFalpha production in acutely infected primary blood cells, chronically infected U1 cells, and alveolar macrophages from HIV-infected subjects.

  Journal of acquired immune deficiency syndromes (1999) 20020901

• The effect of peroxisome proliferator-activated receptors alpha (PPARalpha) agonist, fenofibrate, on lipid peroxidation, total antioxidant capacity, and plasma paraoxonase 1 (PON 1) activity.

  Journal of physiology and pharmacology : an official journal of the Polish Physiological Society 20020901

• [Antilipemic agents in combined therapy].

  Orvosi hetilap 20020825

• Fenofibrate lowers abdominal and skeletal adiposity and improves insulin sensitivity in OLETF rats.

  Biochemical and biophysical research communications 20020816

• De novo expression of uncoupling protein 3 is associated to enhanced mitochondrial thioesterase-1 expression and fatty acid metabolism in liver of fenofibrate-treated rats.

  FEBS letters 20020814

• Fenofibrate induces a selective increase of protein-bound homocysteine in rodents: a PPARalpha-mediated effect.

  Biochemical and biophysical research communications 20020802

• Physical stability of amorphous pharmaceuticals: Importance of configurational thermodynamic quantities and molecular mobility.

  Journal of pharmaceutical sciences 20020801

• Fenofibrate improves insulin sensitivity in connection with intramuscular lipid content, muscle fatty acid-binding protein, and beta-oxidation in skeletal muscle.

  The Journal of endocrinology 20020801

• Fenofibrate treatment in patients with primary biliary cirrhosis.

  The American journal of gastroenterology 20020801

• Stimulation of peroxisome-proliferator-activated receptor alpha (PPAR alpha) attenuates cardiac fibrosis and endothelin-1 production in pressure-overloaded rat hearts.

  Clinical science (London, England : 1979) 20020801

• [Soluble VCAM-1].

  Nihon rinsho. Japanese journal of clinical medicine 20020801

• Fibrates suppress chenodeoxycholic acid-induced RANTES expression through inhibition of NF-kappaB activation.

  European journal of pharmacology 20020712

• Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia.

  Diabetes care 20020701

• Efficacy and tolerability of a 'suprabioavailable' formulation of fenofibrate in patients with dyslipidemia: a pooled analysis of two open-label trials.

  Clinical therapeutics 20020701

• A retrospective assessment of the effectiveness of fenofibrate 267 mg on high-density lipoprotein cholesterol levels in patients attending a lipid clinic.

  Clinical therapeutics 20020701

• A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.

  Atherosclerosis 20020601

• Effects of micronized fenofibrate versus atorvastatin in the treatment of dyslipidaemic patients with low plasma HDL-cholesterol levels: a 12-week randomized trial.

  Journal of internal medicine 20020601

• Differential effects of fenofibrate or simvastatin treatment of rats on hepatic microsomal overt and latent diacylglycerol acyltransferase activities.

  Diabetes 20020601

• Effect of apolipoprotein E, peroxisome proliferator-activated receptor alpha and lipoprotein lipase gene mutations on the ability of fenofibrate to improve lipid profiles and reach clinical guideline targets among hypertriglyceridemic patients.

  Pharmacogenetics 20020601

• Treatment of hypertriglyceridemia with fenofibrate, fatty acid composition of plasma and LDL, and their relations to parameters of lipoperoxidation of LDL.

  Annals of the New York Academy of Sciences 20020601

• [Vasculitis confined to the peripheral nervous system: atypical clinical presentation].

  La Revue de medecine interne 20020601

• Fenofibrate inhibits reactive amyloidosis in mice.

  Arthritis and rheumatism 20020601

• RU486 antagonizes the inhibitory effect of peroxisome proliferator-activated receptor alpha on interleukin-6 production in vascular endothelial cells.

  The Journal of steroid biochemistry and molecular biology 20020601

• PPAR activators inhibit endothelial cell migration by targeting Akt.

  Biochemical and biophysical research communications 20020524

• [Cross-reaction potentials of ketoprofen].

  Orvosi hetilap 20020512

• Amelioration of high fructose-induced metabolic derangements by activation of PPARalpha.

  American journal of physiology. Endocrinology and metabolism 20020501

• Upregulation of hepatic LDL transport by n-3 fatty acids in LDL receptor knockout mice.

  Journal of lipid research 20020501

• Statins and the assessment of endothelial function.

  Journal of internal medicine 20020501

• Induction of plasminogen activator inhibitor-1 in endothelial cells by basic fibroblast growth factor and its modulation by fibric acid.

  Arteriosclerosis, thrombosis, and vascular biology 20020501

• [Fibrates].

  Nihon rinsho. Japanese journal of clinical medicine 20020501

• Gateways to clinical trials.

  Methods and findings in experimental and clinical pharmacology 20020501

• Sustained ER Ca2+ depletion suppresses protein synthesis and induces activation-enhanced cell death in mast cells.

  The Journal of biological chemistry 20020419

• [Effect of fibrates on VLDL and LDL lipoprotein composition and parameters of their oxidation in hypertriglyceridemia].

  Casopis lekaru ceskych 20020412

• PPAR activators as antiinflammatory mediators in human T lymphocytes: implications for atherosclerosis and transplantation-associated arteriosclerosis.

  Circulation research 20020405

• Elevated soluble cellular adhesion molecules in subjects with low HDL-cholesterol.

  Arteriosclerosis, thrombosis, and vascular biology 20020401

• Gateways to Clinical Trials.

  Methods and findings in experimental and clinical pharmacology 20020401

• Mechanism for peroxisome proliferator-activated receptor-alpha activator-induced up-regulation of UCP2 mRNA in rodent hepatocytes.

  The Journal of biological chemistry 20020315

• Fenofibrate lowers plasma triglycerides and increases LDL particle diameter in subjects with type 2 diabetes.

  Diabetes care 20020301

• Prediction of poly(ethylene) glycol-drug eutectic compositions using an index based on the van't Hoff equation.

  Pharmaceutical research 20020301

• A laser flash photolysis study of fenofibric acid in aqueous buffered media: unexpected triplet state inversion in a derivative of 4-alkoxybenzophenone.

  Photochemistry and photobiology 20020301

• Fish oil feeding alters liver gene expressions to defend against PPARalpha activation and ROS production.

  American journal of physiology. Gastrointestinal and liver physiology 20020201

• Pharmacological analysis of wild-type alpha, gamma and delta subtypes of the human peroxisome proliferator-activated receptor.

  Naunyn-Schmiedeberg's archives of pharmacology 20020201

• Pancreatitis associated with simvastatin plus fenofibrate.

  The Annals of pharmacotherapy 20020201

• [Studies on the risk factors for fenofibrate-induced elevation of liver function tests].

  Yakugaku zasshi : Journal of the Pharmaceutical Society of Japan 20020201

• Microarray analysis of gene expression changes in mouse liver induced by peroxisome proliferator- activated receptor alpha agonists.

  Biochemical and biophysical research communications 20020125

• PPARalpha and PPARdelta activators inhibit cytokine-induced nuclear translocation of NF-kappaB and expression of VCAM-1 in EAhy926 endothelial cells.

  European journal of pharmacology 20020125

• A pharmacoepidemiological assessment of the effect of statins and fibrates on fibrinogen concentration.

  Atherosclerosis 20020101

• Effect of fenofibrate on Chlamydia pneumoniae antibody levels in patients with coronary artery disease.

  The American journal of cardiology 20020101

• Opposite metabolic response to fenofibrate treatment in pregnant and virgin rats.

  Journal of lipid research 20020101

• Dual regulation of mouse Delta(5)- and Delta(6)-desaturase gene expression by SREBP-1 and PPARalpha.

  Journal of lipid research 20020101

• Both cerivastatin and fenofibrate improve arterial vasoreactivity in patients with combined hyperlipidaemia.

  Journal of internal medicine 20020101

• Use of fibrates in the management of hyperlipidemia in HIV-infected patients receiving HAART.

  Infection 20020101

• [Effect of phenofibrate treatment on endothelial dysfunction in patients with history of myocardial infarction in young age].

  Terapevticheskii arkhiv 20020101

• Activation of the peroxisome proliferator-activated receptor alpha protects against myocardial ischaemic injury and improves endothelial vasodilatation.

  BMC pharmacology 20020101

• Fenofibrate of gemfibrozil for treatment of types IIa and IIb primary hyperlipoproteinemia: a randomized, double-blind, crossover study.

  Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists 20020101

• Randomised crossover studies of the bioequivalence of two fenofibrate formulations after administration of a single oral dose in healthy volunteers.

  Arzneimittel-Forschung 20020101

• The effects of the addition of micronised fenofibrate on uric acid metabolism in patients receiving indapamide.

  Current medical research and opinion 20020101

• [Results of a French nationwide survey of cutaneous side effects of ketoprofen gel reported between September 1996 and August 2000].

  Therapie 20020101

• Combined treatment with fibrates and small doses of atorvastatin in patients with mixed hyperlipidemia.

  Current medical research and opinion 20020101

• A 'bad responder' to statins.

  Cardiology 20020101

• Micronised fenofibrate: an updated review of its clinical efficacy in the management of dyslipidaemia.

  Drugs 20020101

• Fenofibrate, a peroxisome proliferator-activated receptor alpha activator, suppresses experimental autoimmune myocarditis by stimulating the interleukin-10 pathway in rats.

  Journal of atherosclerosis and thrombosis 20020101

• Effects of fibrates on serum metabolic parameters.

  Current medical research and opinion 20020101

• Fenofibrate increases creatininemia by increasing metabolic production of creatinine.

  Nephron 20020101

• Ezetimibe: the first in a novel class of selective cholesterol-absorption inhibitors.

  Heart disease (Hagerstown, Md.) 20020101

• Update on fenofibrate.

  Cardiovascular drug reviews 20020101

• Rosuvastatin: a highly effective new HMG-CoA reductase inhibitor.

  Cardiovascular drug reviews 20020101

• Management of protease inhibitor-associated hyperlipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Micronized fenofibrate in dyslipidemia: a focus on plasma high-density lipoprotein cholesterol (HDL-C) levels.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Management of co-existing diabetes mellitus and dyslipidemia: defining the role of thiazolidinediones.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20020101

• Increasing high-density lipoprotein cholesterol: an update on fenofibrate.

  The American journal of cardiology 20011220

• Treating lipid abnormalities in patients with type 2 diabetes mellitus.

  The American journal of cardiology 20011220

• The transcription of the peroxisome proliferator-activated receptor alpha gene is regulated by protein kinase C.

  Toxicology letters 20011215

• Effects of fibrates on plasma prothrombotic activity in patients with type IIb dyslipidemia.

  International journal of clinical pharmacology and therapeutics 20011201

• [Different serum lipid adjustment drugs for the treatment of hyperlipidemic fatty liver].

  Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology 20011201

• Peroxisome proliferator-activated receptor a ligands increase lectin-like oxidized low density lipoprotein receptor-1 expression in vascular endothelial cells.

  Annals of the New York Academy of Sciences 20011201

• Lipid-lowering trials in diabetes.

  Current opinion in lipidology 20011201

• Serum uric acid levels: a useful but not absolute marker of compliance with fenofibrate treatment.

  Fundamental & clinical pharmacology 20011201

• Hyperlipidemia related to the use of HIV-protease inhibitors: natural history and results of treatment with fenofibrate.

  The Brazilian journal of infectious diseases : an official publication of the Brazilian Society of Infectious Diseases 20011201

• Effects of fenofibrate and gemfibrozil on plasma homocysteine.

  Lancet (London, England) 20011124

• Effects of fenofibrate and gemfibrozil on plasma homocysteine.

  Lancet (London, England) 20011124

• Both fenofibrate and atorvastatin improve vascular reactivity in combined hyperlipidaemia (fenofibrate versus atorvastatin trial--FAT).

  Cardiovascular research 20011101

• Comparison of DNA damage photoinduced by ketoprofen, fenofibric acid and benzophenone via electron and energy transfer.

  Photochemistry and photobiology 20011101

• Regulation of lipid metabolism and gene expression by fenofibrate in hamsters.

  Biochimica et biophysica acta 20011031

• [Pleiotrophic effect of anti-hyperlipemic agents].

  Nihon Naika Gakkai zasshi. The Journal of the Japanese Society of Internal Medicine 20011010

• Functional analysis of the transcriptional activity of the mouse phospholipid transfer protein gene.

  Biochemical and biophysical research communications 20011005

• Fenofibrate: a new treatment for hyperuricaemia and gout?

  Annals of the rheumatic diseases 20011001

• Effects of fenofibrate on lipid parameters in obese rhesus monkeys.

  Journal of lipid research 20011001

• Variation at position 162 of peroxisome proliferator-activated receptor alpha does not influence the effect of fibrates on cholesterol or triacylglycerol concentrations in hyperlipidaemic subjects.

  Pharmacogenetics 20011001

• Effect of fenofibrate on plasma concentration and urinary excretion of purine bases and oxypurinol.

  The Journal of rheumatology 20011001

• [Photoaggravated contact allergy and contact photoallergy caused by ketoprofen: 19 cases].

  Annales de dermatologie et de venereologie 20011001

• High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists.

  European journal of pharmacology 20010921

• Vitamin supplementation can markedly reduce the homocysteine elevation induced by fenofibrate.

  Atherosclerosis 20010901

• Impact of postprandial hypertriglyceridemia on vascular responses in patients with coronary artery disease: effects of ACE inhibitors and fibrates.

  Atherosclerosis 20010901

• Folate supplementation prevents plasma homocysteine increase after fenofibrate therapy.

  Nutrition (Burbank, Los Angeles County, Calif.) 20010901

• Fenofibrate-Induced elevation in serum creatinine.

  Pharmacotherapy 20010901

• Cerivastatin and gemfibrozil-associated rhabdomyolysis.

  The Annals of pharmacotherapy 20010901

• [Acute hepatitis and drug dermatitis due to fenofibrate (Secalip)].

  Annales de medecine interne 20010901

• PPARalpha and GR differentially down-regulate the expression of nuclear factor-kappaB-responsive genes in vascular endothelial cells.

  Endocrinology 20010801

• Peroxisome proliferator-activated receptor subtype-specific regulation of hepatic and peripheral gene expression in the Zucker diabetic fatty rat.

  Metabolism: clinical and experimental 20010801

• [Milestone in the treatment of diabetic dyslipidemia: the DAIS Study].

  Orvosi hetilap 20010722

• Atorvastatin versus micronized fenofibrate in the treatment of patients with mixed hyperlipoproteinemia.

  The American journal of cardiology 20010715

• Induction of the phospholipid transfer protein gene accounts for the high density lipoprotein enlargement in mice treated with fenofibrate.

  The Journal of biological chemistry 20010713

• Effects of fenofibrate and gemfibrozil on plasma homocysteine.

  Lancet (London, England) 20010707

• Fibrate-induced increase in blood urea and creatinine.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010701

• Fenofibrate and warfarin interaction.

  Pharmacotherapy 20010701

• [Peroxisome proliferator-activated receptors (PPARs) in the vessel wall: new regulators of gene expression in vascular cells].

  Zeitschrift fur Kardiologie 20010701

• Statin-induced inhibition of the Rho-signaling pathway activates PPARalpha and induces HDL apoA-I.

  The Journal of clinical investigation 20010601

• Fibrate treatment can increase serum creatinine levels.

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20010601

• Effect of fenofibrate on fatty liver in rats treated with alcohol.

  Alcoholism, clinical and experimental research 20010601

• Fibrate induction of the adrenoleukodystrophy-related gene (ABCD2): promoter analysis and role of the peroxisome proliferator-activated receptor PPARalpha.

  European journal of biochemistry 20010601

• Modulation of C-reactive protein-mediated monocyte chemoattractant protein-1 induction in human endothelial cells by anti-atherosclerosis drugs.

  Circulation 20010529

• Choice of lipid-regulating drugs.

  The Medical letter on drugs and therapeutics 20010528

• Plasma vascular endothelial growth factor and its receptor Flt-1 in patients with hyperlipidemia and atherosclerosis and the effects of fluvastatin or fenofibrate.

  The American journal of cardiology 20010515

• Fenofibrate in hyperlipidaemia secondary to HIV protease inhibitors. Fenofibrate and HIV protease inhibitor.

  Nutrition (Burbank, Los Angeles County, Calif.) 20010501

• Fenofibrate raises plasma homocysteine levels in the fasted and fed states.

  Atherosclerosis 20010401

• LpAI in HDL subfractions: serum levels in men and women with coronary heart disease and changes under hypolipemic therapy.

  Clinica chimica acta; international journal of clinical chemistry 20010401

• Homocysteine elevation with fibrates: is it a class effect?

  The Israel Medical Association journal : IMAJ 20010401

• Statins enhance arachidonic acid synthesis in hypercholesterolemic patients.

  Nutrition, metabolism, and cardiovascular diseases : NMCD 20010401

• Phospholipid composition of high-density lipoproteins reflects lipolysis of triglyceride-rich lipoproteins during hyperlipidemia.

  Bulletin of experimental biology and medicine 20010401

• [Allergies to ketoprofen gels].

  Presse medicale (Paris, France : 1983) 20010331

• [On the article by Dr. R. Ceska, et al: Fenofibrat Pharmavit SR 250 in patients with mixed hyperlipoproteinemia].

  Casopis lekaru ceskych 20010329

• Effect of fenofibrate on progression of coronary-artery disease in type 2 diabetes: the Diabetes Atherosclerosis Intervention Study, a randomised study.

  Lancet (London, England) 20010324

• Preferential reduction of very low density lipoprotein-1 particle number by fenofibrate in type IIB hyperlipidemia: consequences for lipid accumulation in human monocyte-derived macrophages.

  Atherosclerosis 20010301

• Role of fibrates and HMG-CoA reductase inhibitors in gallstone formation: epidemiological study in an unselected population.

  Digestive diseases and sciences 20010301

• [Fenofibrate].

  Nihon rinsho. Japanese journal of clinical medicine 20010301

• Fenofibrate prevents and reduces body weight gain and adiposity in diet-induced obese rats.

  FEBS letters 20010223

• Peroxisome proliferator-activated receptor alpha is not rate-limiting for the lipoprotein-lowering action of fish oil.

  The Journal of biological chemistry 20010216

• Oxidized low-density lipoprotein and peroxisome-proliferator-activated receptor alpha down-regulate platelet-activating-factor receptor expression in human macrophages.

  The Biochemical journal 20010215

• Comparative effects of cerivastatin and fenofibrate on the atherogenic lipoprotein phenotype in proteinuric renal disease.

  Journal of the American Society of Nephrology : JASN 20010201

• A potent PPARalpha agonist stimulates mitochondrial fatty acid beta-oxidation in liver and skeletal muscle.

  American journal of physiology. Endocrinology and metabolism 20010201

• Homocysteine and lipid lowering agents. A comparison between atorvastatin and fenofibrate in patients with mixed hyperlipidemia.

  Atherosclerosis 20010201

• Benefits of micronised Fenofibrate in type 2 diabetes mellitus subjects with good glycemic control.

  Atherosclerosis 20010201

• Rare side-effects of fenofibrate.

  Diabetes & metabolism 20010201

• Rat adrenoleukodystrophy-related (ALDR) gene: full-length cDNA sequence and new insight in expression.

  Biochimica et biophysica acta 20010126

• PPARalpha agonists inhibit tissue factor expression in human monocytes and macrophages.

  Circulation 20010116

• Abundant expression of uncoupling protein-2 in the small intestine: up-regulation by dietary fish oil and fibrates.

  Biochimica et biophysica acta 20010115

• The role of fibric acids in atherosclerosis.

  Current atherosclerosis reports 20010101

• Effects of atorvastatin versus fenofibrate on lipoprotein profiles, low-density lipoprotein subfraction distribution, and hemorheologic parameters in type 2 diabetes mellitus with mixed hyperlipoproteinemia.

  The American journal of cardiology 20010101

• Deterioration in renal function associated with fibrate therapy.

  Clinical nephrology 20010101

• Rapid and simple method for detection of fenofibric acid in human serum by high-performance liquid chromatography.

  Die Pharmazie 20010101

• Apoprotein c-III and E-containing lipoparticles are markedly increased in HIV-infected patients treated with protease inhibitors: association with the development of lipodystrophy.

  The Journal of clinical endocrinology and metabolism 20010101

• [New concepts on the mechanism of action of fibrates and therapeutic prospectives in atherosclerosis].

  Bulletin de l'Academie nationale de medecine 20010101

• [Effects of hypolipidemic therapy on the endothelial dysfunction in patients with myocardial infarction at young age].

  Terapevticheskii arkhiv 20010101

• Fibrates and homocysteine.

  Nutrition (Burbank, Los Angeles County, Calif.) 20010101

• Advances in lipid-lowering therapy in atherosclerosis.

  Advances in experimental medicine and biology 20010101

• [Fibrate influence on lipids and insulin resistance in patients with metabolic syndrome].

  Przeglad lekarski 20010101

• Effects of zopiclone on blood glucose level, serum lipid concentration and clot lysis time in normoglycemic and normolipidemic rats.

  Acta physiologica Hungarica 20010101

• Drug treatment of combined hyperlipidemia.

  American journal of cardiovascular drugs : drugs, devices, and other interventions 20010101

• Fibrate-induced increase in blood urea and creatinine: is gemfibrozil the only innocuous agent?

  Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 20001201

• Activation of human peroxisome proliferator-activated receptor (PPAR) subtypes by pioglitazone.

  Biochemical and biophysical research communications 20001130

• Fenofibrate and rosiglitazone lower serum triglycerides with opposing effects on body weight.

  Biochemical and biophysical research communications 20000510

• The PPARs: from orphan receptors to drug discovery.

  Journal of medicinal chemistry 20000224

• Rhabdomyolysis and acute renal failure after changing statin-fibrate combinations.

  Cardiology 20000101

• Expression of peroxisomal proliferator-activated receptors and retinoid X receptors in the kidney.

  The American journal of physiology 19991201

• A ureido-thioisobutyric acid (GW9578) is a subtype-selective PPARalpha agonist with potent lipid-lowering activity.

  Journal of medicinal chemistry 19990923

• Effects of fibrate compounds on expression of plasminogen activator inhibitor-1 by cultured endothelial cells.

  Arteriosclerosis, thrombosis, and vascular biology 19990601

• Fibrates suppress fibrinogen gene expression in rodents via activation of the peroxisome proliferator-activated receptor-alpha.

  Blood 19990501

• Severe toxic neuropathy due to fibrates.

  Journal of neurology, neurosurgery, and psychiatry 19990301

• Fibrate-modulated expression of fibrinogen, plasminogen activator inhibitor-1 and apolipoprotein A-I in cultured cynomolgus monkey hepatocytes -- role of the peroxisome proliferator-activated receptor-alpha.

  Thrombosis and haemostasis 19981201

• Clinical pharmacokinetics of fibric acid derivatives (fibrates).

  Clinical pharmacokinetics 19980201

• Interaction between fenofibrate and warfarin.

  The Annals of pharmacotherapy 19980101

• [Hypothyroidism and muscular toxicity from fenofibrate, report of a case revealed by polymyositis].

  La Tunisie medicale 19970201

• A head-to-head comparison of the cost effectiveness of HMG-CoA reductase inhibitors and fibrates in different types of primary hyperlipidemia.

  Cardiovascular drugs and therapy 19970101

• [Painful acute liver involvement related to ingestion of fenofibrate].

  Gastroenterologie clinique et biologique 19960101

• Hypolipidemic activity of select fibrates correlates to changes in hepatic apolipoprotein C-III expression: a potential physiologic basis for their mode of action.

  Journal of lipid research 19951201

• Currently available hypolipidaemic drugs and future therapeutic developments.

  Bailliere's clinical endocrinology and metabolism 19951001

• Regulation of rat liver apolipoprotein A-I, apolipoprotein A-II and acyl-coenzyme A oxidase gene expression by fibrates and dietary fatty acids.

  European journal of biochemistry 19950815

• Negative regulation of the human apolipoprotein A-I promoter by fibrates can be attenuated by the interaction of the peroxisome proliferator-activated receptor with its response element.

  The Journal of biological chemistry 19941209

• [Chronic lesion of the interlobular bile ducts induced by fenofibrate].

  Gastroenterologie clinique et biologique 19940101

• Effects of fenofibrate on angiographically examined coronary atherosclerosis and left ventricular function in hypercholesterolemic patients.

  Atherosclerosis 19930125

• [Chronic active cirrhogenic hepatitis induced by fenofibrate].

  Gastroenterologie clinique et biologique 19930101

• Mechanism of action of fibrates.

  Postgraduate medical journal 19930101

• [Myopathy caused by fenofibrate].

  Medicina clinica 19911116

• [Fenofibrate induced polymyositis].

  La Revue de medecine interne 19910101

• Effects of gemfibrozil and other fibric acid derivatives on blood lipids and lipoproteins.

  Journal of clinical pharmacology 19910101

• [Muscular toxicity caused by fenofibrate].

  Presse medicale (Paris, France : 1983) 19890520

• Treatment of heterozygous familial hypercholesterolemia with lipid-lowering drugs.

  Arteriosclerosis (Dallas, Tex.) 19890101

• Biliary lipid secretion in patients with heterozygous familial hypercholesterolemia and combined hyperlipidemia. Influence of bezafibrate and fenofibrate.

  Journal of lipid research 19860701

• [Clofibrate hepatitis. A case report].

  Minerva medica 19860507

• [Hepatitis caused by fenofibrate].

  Cahiers d'anesthesiologie 19860501

• Effects of fenofibrate on biliary lipids and bile acid pool size in patients with type IV hyperlipoproteinemia.

  Atherosclerosis 19850501

• Drug-induced hepatitis associated with anticytoplasmic organelle autoantibodies.

  Hepatology (Baltimore, Md.) 19850101

• [Muscular toxicity due to fenofibrate. Apropos of a case].

  Revue du rhumatisme et des maladies osteo-articulaires 19820201

• Antiviral activity of antilipidemic compounds on herpes simplex virus type 1.

  Antimicrobial agents and chemotherapy 19800801

• [Drug-induced hepatitis due to fenofibrate].

  Therapie 19800101

• Analysis of skin grafts across the MSA-barrier in mice pretreated with sera from specifically or syngeeically grafted donors.

  Folia biologica 19750101